

CITATION REPORT

List of articles citing

The effect of spironolactone on morbidity and mortality in patients with severe heart failure.
Randomized Aldactone Evaluation Study Investigators

DOI: 10.1056/nejm199909023411001

New England Journal of Medicine, 1999, 341, 709-17.

Source: <https://exaly.com/paper-pdf/30661844/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2241	Heart Failure. 31-37		
2240	Aldosterone and spironolactone in heart failure. <i>New England Journal of Medicine</i> , 1999 , 341, 753-5	59.2	92
2239	Chronic Heart Failure. 1999 , 1, 231-242		3
2238	Candesartan was at least as effective as enalapril and, in combination, may be more beneficial than either drug alone. 1999 , 3, 107		
2237	Aldosterone antagonism in heart failure. 1999 , 354, 789-90		7
2236	HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunctionpharmacological approaches. 1999 , 5, 357-382		261
2235	Spironolactone for heart failure. 1999 , 1, 1		
2234	Chapter 7. Advances in the understanding and treatment of congestive heart failure (HF). 2000 , 35, 63-72		
2233	A Rapid Access Heart Failure Clinic provides a prompt diagnosis and appropriate management of new heart failure presenting in the community. 2000 , 2, 423-9		34
2232	Cardiac complications of end-stage renal disease. 2000 , 7, 210-9		7
2231	Effect of beta-blocker on left ventricular function and natriuretic peptides in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitor. 2000 , 64, 365-9		51
2230	Drug Therapy of Heart Failure in the Elderly. 2000 , 30, 274-278		0
2229	Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: analysis of individual patient data from studies of left ventricular dysfunction. 2000 , 321, 1113-6		17
2228	Bibliography. Current world literature. Cardiac failure. 2000 , 15, B95-136		
2227	Bibliography. Current world literature. Pediatrics. 2000 , 15, B151-74		
2226	Current World Literature. 2000 , 9, 555-590		
2225	Treatment of Edematous Disorders with Diuretics. 2000 , 319, 25-37		6

2224	Cardiac transplantation: the final therapeutic option for the treatment of heart failure. 2000 , 15, 178-82	16
2223	Eplerenone, a new mineralocorticoid antagonist: in vitro and in vivo studies. 2000 , 7, 138-142	6
2222	Update on recent clinical trials in congestive heart failure. 2000 , 15, 293-303	11
2221	Prevention of sudden cardiac death: management considerations. 2000 , 15, 304-8	2
2220	The Euro Heart Failure Survey of the EUROHEART survey programme. A survey on the quality of care among patients with heart failure in Europe. The Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Medicines Evaluation Group Centre for Health Economics University of York. 2000 , 2, 123-32	100
2219	Combination therapy with carvedilol and amiodarone in patients with severe heart failure. 2000 , 2, 71-9	32
2218	Heart failure: we need more trials in typical patients. 2000 , 21, 699-700	29
2217	Renal implications of the renin-angiotensin-aldosterone system blockade in heart failure. 2000 , 18, 1545-51	17
2216	Reduction of hospital days by biventricular pacing. 2000 , 2, 399-406	40
2215	Design and methodology of the CAPRICORN trial - a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction. 2000 , 2, 325-32	46
2214	Catabolism in chronic heart failure. 2000 , 21, 521-32	104
2213	Effect of receiving a heart transplant: analysis of a national cohort entered on to a waiting list, stratified by heart failure severity. Comparative Outcome and Clinical Profiles in Transplantation (COCBIT) Study Group. 2000 , 321, 540-5	124
2212	Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. 2000 , 57, 1408-11	152
2211	Therapy of heart failure. 2000 , 57, 1418-25	30
2210	Debate: Do all patients with heart failure require automatic implantable defibrillators for the prevention of sudden death?. 2000 , 1, 95-97	2
2209	When will the ACE-inhibitors be declared obsolete?. 2000 , 14, 79-81	0
2208	Recent advances in the management of chronic heart failure. 2000 , 30, 475-82	2
2207	Spironolactone and agranulocytosis. 2000 , 30, 515	0

2206	Pathophysiology of aldosterone and its antagonists. 2000 , 14, 549-52	4
2205	Heart Failure and Cardiac Resynchronization Therapies: U.S. Experience in the Year 2000. 2000 , 5, 188-194	10
2204	Systolic heart failure: practical implementation of standard guidelines. 2000 , 3, 1-12	2
2203	Management of advanced heart failure. 2000 , 3, 25-35	5
2202	Management of the patient with congestive heart failure using outpatient, home, and palliative care. 2000 , 43, 259-74	33
2201	Spironolactone in heart failure--a revived role for an old drug. 2000 , 16, 403-4	2
2200	Adverse cardiovascular drug interactions. 2000 , 25, 621-76	9
2199	Heart-hitting tales of salt and destruction. 2000 , 136, 7-13	8
2198	Acid-base and endocrine effects of aldosterone and angiotensin II inhibition in metabolic acidosis in human patients. 2000 , 136, 379-89	54
2197	Spironolactone in the management of congestive heart failure. 2000 , 15, 145-8	
2196	Aldosterone, a new appreciation of its role in heart failure. 2000 , 20, 1107-15	7
2195	The role of the renin-angiotensin-aldosterone system in the management of heart failure. 2000 , 20, 368S-378S	5
2194	Practical issues in the treatment of patients with heart failure. 2000 , 20, 385S-391S	1
2193	HEART FAILURE SOCIETY OF AMERICA (HFSA) PRACTICE GUIDELINES. 2000 , 20, 495-522	24
2192	Advances in the treatment of congestive heart failure: new approaches for an old disease. 2000 , 20, 787-804	22
2191	The role of angiotensin receptor blockers in heart failure. 2000 , 6, 103-109	
2190	Difficult cases in heart failure: beneficial effects of aldosterone blockade in heart failure. 2000 , 6, 115-117	
2189	Ventricular remodeling and the renin angiotensin aldosterone system. 2000 , 6, 187-192	11

2188	The AHF SCENE II Preceptorship Program: rationale and design of an educational program to optimize management of advanced heart failure. 2000 , 6, 319-324	1
2187	Update in internal medicine. 2000 , 31, 329-52	
2186	Myocyte contractile dysfunction with hypertrophy and failure: relevance to cardiac surgery. 2000 , 119, 388-400	9
2185	Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins. 2000 , 85, 973-6	30
2184	Inverse relation between aldosterone and venous capacitance in chronically treated congestive heart failure. 2000 , 85, 977-80	7
2183	Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. 2000 , 85, 1207-11	102
2182	Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure. 2000 , 86, 649-53	40
2181	Meta-analysis of effect of beta-blocker therapy on mortality in patients with New York Heart Association class IV chronic congestive heart failure. 2000 , 86, 886-9	25
2180	Profiling risk from arrhythmic or hemodynamic death. 2000 , 86, 126K-132K	9
2179	Treatment of hypertension with valsartan combined with spironolactone. 2000 , 32, 161-3	
2178	Postinfarction left ventricular remodeling: a pathophysiological and therapeutic review. 2000 , 14, 243-52	21
2177	The control of adrenergic function in heart failure: therapeutic intervention. 2000 , 5, 101-14	30
2176	Antiarrhythmic Impact of Anti-Ischemic, Anti-Failure and Other Cardiovascular Strategies. 2000 , 4, 194-205	2
2175	Use of myocardial perfusion imaging to assess viability. 2000 , 7, 72-80	3
2174	Can we prevent congestive heart failure? Excerpts from a symposium. 2000 , 23, IV1-3	
2173	Overview of the relationship between ischemia and congestive heart failure. 2000 , 23, IV4-8	25
2172	New and emerging pharmacologic strategies in the management of chronic heart failure. 2000 , 23, 724-30	7
2171	Chagas' heart disease. 2000 , 23, 883-9	221

2170	Effect of heart failure program on cardiovascular drug utilization and dosage in patients with chronic heart failure. 2000 , 23, 909-14	20
2169	Beta-blockers and spironolactone in heart failure. 2000 , 2, 87-9	1
2168	The myocardial matrix and the development and progression of ventricular remodeling. 2000 , 2, 112-9	29
2167	Management of heart failure. 2000 , 2, 221-4	1
2166	Spironolactone in congestive heart failure. 2000 , 2, 451-6	35
2165	The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure. 2000 , 2, 378-83	11
2164	Free radical production and angiotensin. 2000 , 2, 167-73	106
2163	[Current status of therapy of chronic heart failure]. 2000 , 41, 137-44	
2162	[Angiotensin-II-receptor antagonists for cardiac insufficiency]. 2000 , 41, 917-24	
2161	Aldosterone and myocardial fibrosis in heart failure. 2000 , 25, 299-306	98
2160	Cost of treating heart failure in an Irish teaching hospital. 2000 , 169, 241-4	7
2159	Chronic cardiac failure in children due to dilated cardiomyopathy: diagnostic approach, pathophysiology and management. 2000 , 159, 803-10	9
2158	The management of heart failure--an overview. 2000 , 95 Suppl 1, I3-7	10
2157	ACE inhibitors in heart failure: an update. 2000 , 95 Suppl 1, I8-14	9
2156	Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients. 2000 , 23, 25-31	30
2155	Divalent cation transport by the distal nephron: insights from Bartter's and Gitelman's syndromes. 2000 , 279, F616-25	79
2154	CANINE DILATED CARDIOMYOPATHY. 2000 , 230-237	
2153	Reviewers List. 2000 , 160, 3503	

2152	Stimulation of unitary T-type Ca(2+) channel currents by calmodulin-dependent protein kinase II. 2000 , 279, C1694-703	46
2151	Management of Adult Heart Failure: Bolus versus Continuous Infusion Loop Diuretics, A Review of the Literature. 2000 , 35, 832-836	2
2150	Importance of neuroendocrine activation in chronic heart failure. Impact on treatment strategies. 2000 , 2, 229-33	20
2149	[Antiarrhythmic therapy in patients with heart failure]. 2000 , 57, 324-32	2
2148	The problem of ventricular dysrhythmias and sudden death mortality in heart failure: the impact of current therapy. 2000 , 93, 56-69	6
2147	New therapies for heart failure: is thalidomide the answer?. 2000 , 93, 305-11	24
2146	[Diuretic therapy in congestive heart failure--new views on spironolactone therapy]. 2000 , 57, 374-9	1
2145	Combined Alteplase and Eptifibatide Lead to Death and Coma in Two Incidents More on Sleep Attacks with Pramipexole More on Avoiding Thrombocytopenia Caused by Heparin Flushes Morbidity from Non-Potassium-Sparing Diuretics. 2000 , 35, 239-241	
2144	Evaluating quality of care for patients with heart failure. 2000 , 101, E122-40	101
2143	Radiopharmaceuticals for nuclear endocrinology at the University of Michigan. 2000 , 15, 305-18	4
2142	Why we need new strategies in CHF management. 2000 , 1 Suppl 1, 12-6	0
2141	The HF epidemic: the need for new treatment strategies. 2000 , 1, S32-4	
2140	Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES. 2000 , 102, 2325-8	42
2139	Is there a cirrhotic cardiomyopathy?. 2000 , 95, 3026-8	24
2138	Clinical trials in cardiovascular medicine: are we looking for statistical significance or clinical relevance?. 2000 , 84, 129-33	2
2137	AT(1) receptor antagonists-beyond blood pressure control: possible place in heart failure treatment. 2000 , 84 Suppl 1, i42-5: discussion i50	3
2136	Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure. 2000 , 36, 523-30	36
2135	Drug treatment of heart failure--do nursing-home residents deserve better?. 2000 , 18, 226-31	13

2134	Home-based intervention: the next step in treatment of chronic heart failure?. 2000 , 21, 1807-9		15
2133	Is more better? About dose levels of ACE inhibitors in chronic heart failure. 2000 , 21, 1902-3		1
2132	The electrocardiogram in heart failure. 2000 , 29, 203-6		12
2131	Spironolactone for heart failure: spiraling out of control. 2000 , 118, 1522-3		1
2130	Acute exacerbation of chronic bronchitis: what is the clinical significance of pathogenic bacteria in sputum cultures?. 2000 , 118, 1523-5		1
2129	Effects of the mineralocorticoid fludrocortisone on fibrinolytic function in healthy subjects. 2000 , 1, 357-60		2
2128	Spironolactone in patients with heart failure. <i>New England Journal of Medicine</i> , 2000 , 342, 132; author reply 133-4	59.2	17
2127	ACE inhibition in cardiovascular disease. <i>New England Journal of Medicine</i> , 2000 , 342, 201-2	59.2	67
2126	Primary hyperaldosteronism without suppressed renin due to secondary hypertensive kidney damage. 2000 , 85, 3266-70		35
2125	beta-blockers in heart failure: recently completed and ongoing clinical trials. 2000 , 9, 415-28		1
2124	Steroidogenic enzyme gene expression in the human heart. 2000 , 85, 2519-25		129
2123	Testosterone: a natural tonic for the failing heart?. 2000 , 93, 689-94		32
2122	Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. 2000 , 85, 336-44		138
2121	Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension. 2000 , 85, 3313-8		66
2120	Pharmacotherapy following myocardial infarction--a review of current treatment practices. 2000 , 1, 1105-16		4
2119	Reversal of heart failure remodeling in women. 2000 , 9, 513-9		1
2118	Epidemiology, aetiology, and prognosis of heart failure. 2000 , 83, 596-602		528
2117	Distinguishing mechanisms from markers of cardiac contractile dysfunction: more than 1 way to skin the cat of heart failure. 2000 , 101, 738-9		2

2116	Progress in heart failure Management? Lessons from the real world. 2000 , 102, 1076-8	82
2115	Essential hypertension : part II: treatment. 2000 , 101, 446-53	51
2114	Surgical alternatives to mechanical support. 2000 , 15, 379-86	
2113	Hypertensive heart disease. A complex syndrome or a hypertensive 'cardiomyopathy'?. 2000 , 21, 1653-65	84
2112	Why biventricular pacing might be of value in refractory heart failure?. 2000 , 84, 125-6	8
2111	Neurohumoral blockade in CHF management. 2000 , 1 Suppl 1, 24-30	17
2110	Spironolactone in the treatment of congestive heart failure. 2000 , 34, 1336-40	5
2109	Cardiomyopathy. Diagnosis and management of dilated cardiomyopathy. 2000 , 84, 106-12	119
2108	Hyperaldosteronemia in rabbits inhibits the cardiac sarcolemmal Na(+)-K(+) pump. 2000 , 86, 37-42	56
2107	Ongoing Clinical trials with angiotensin II receptor antagonists in chronic heart failure and myocardial infarction. 2000 , 1, 131-6	1
2106	Apoptosis in Cardiovascular Aging Research: Future Directions. 2000 , 9, 263-264	8
2105	Induction of cardiac fibrosis by aldosterone. 2000 , 32, 865-79	200
2104	Different regulation of cardiac and renal corticosteroid receptors in aldosterone-salt treated rats: effect of hypertension and glucocorticoids. 2000 , 32, 1249-63	20
2103	Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study. 2000 , 139, 624-31	53
2102	Spironolactone and congestive heart-failure. 2000 , 355, 1369-70	19
2101	Early uptake of research findings after fast-track publication. 2000 , 355, 579-80	13
2100	The cardiac renin-angiotensin system: novel signaling mechanisms related to cardiac growth and function. 2000 , 91, 1-11	81
2099	Clinical trials, treatment guidelines and real life. 2000 , 73, 205-7	5

2098	Left ventricular remodelling and dysfunction. Can the process be prevented?. 2000 , 72, 143-50	22
2097	Tissue-specific corticosteroidogenesis in the rat. 2000 , 165, 221-4	26
2096	Applied physiology: understanding cardiac failure. 2000 , 10, 284-288	
2095	At The Bedside with Professor Karl Swedberg. 2000 , 4, 57-58	
2094	Subgroups time to change the question?. 2000 , 4, 79-81	
2093	Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure. 2000 , 140, 361-6	37
2092	A pilot experience with permanent biventricular pacing to treat advanced heart failure. 2000 , 140, 862-70	107
2091	Aldosterone and the heart. 2000 , 11, 224-6	71
2090	Heart failure: future treatment approaches. 2000 , 13, 74S-78S	2
2089	Plasma renin activity in the emergency department and its independent association with acute myocardial infarction. 2000 , 13, 855-63	27
2088	Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. 2000 , 355, 1126-30	1111
2087	Dressing heart-failure patients on Savile Row--tailored treatment?. 2000 , 355, 2012-3	14
2086	[Spironolactone in heart failure]. 2000 , 25, 281	2
2085	[And spironolactone in the treatment of heart failure?]. 2000 , 25, 281-2	1
2084	Interventional therapy in heart failure management. 2000 , 16, 549-66	3
2083	Diuretic therapy in elderly heart failure patients with and without left ventricular systolic dysfunction. 2000 , 16, 289-300	16
2082	Losartan: a review of its use, with special focus on elderly patients. 2000 , 16, 227-50	34
2081	Elderly heart failure patients with drug-induced serious hyperkalemia. 2000 , 12, 315-9	5

2080	Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. 2000 , 141, 3871-8	387
2079	[Prevention of sudden death in patients awaiting heart transplantation]. 2000 , 53, 736-45	1
2078	Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. 2000 , 102, 2700-6	750
2077	Healthcare costs of patients with heart failure treated with torasemide or furosemide. 2000 , 17, 429-40	42
2076	Congestive heart failure: fifty years of progress. 2000 , 102, IV14-23	257
2075	Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. 2000 , 101, 594-7	450
2074	Drug therapy of heart failure caused by systolic dysfunction in the elderly. 2000 , 16, 513-34	2
2073	Heart failure with normal systolic function. 2000 , 16, 489-512	28
2072	The COHERE Registry: hype or hope?. 2000 , 6, 272-5	14
2071	Heart failure complicating acute myocardial infarction. 2000 , 16, 535-48	3
2070	Surviving heart failure: Robert L. Frye lecture. 2000 , 75, 111-8	8
2069	Respuesta de los autores. 2000 , 25, 283-284	78
2068	La insuficiencia cardíaca congestiva en atención primaria (y II).. 2000 , 26, 66-76	2
2067	[Decrease in mortality on spironolactone being added to the conventional treatment of heart failure]. 2000 , 25, 282-4	
2066	Management of heart failure. 2000 , 27, 651-75;vi	2
2065	[Results of the RALES trial: good news for patients with heart failure and ... for health administrations]. 2000 , 114, 545-50	0
2064	El tratamiento de la insuficiencia cardíaca. 2000 , 200, 551-562	3
2063	What does atlas really tell us about High-Dose angiotensin-converting enzyme inhibition in heart failure?. 2000 , 6, 165-168	6

2062	Lisinopril: a review of its use in congestive heart failure. 2000 , 59, 1149-67	24
2061	Reply. 2000 , 36, 305	
2060	Coenzyme Q10 as an adjunctive therapy in patients with congestive heart failure. 2000 , 36, 304-5	5
2059	Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure. 2000 , 36, 838-44	68
2058	Chronic heart failure in the community: missed diagnosis and missed opportunities. 2001 , 7, 232-8	27
2057	A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. <i>New England Journal of Medicine</i> , 2001 , 345, 1667-75	59.2 2420
2056	Pathophysiology of sodium and water retention in heart failure. 2001 , 96, 122-31	50
2055	Effect of aldosterone on collagen steady state levels in primary and subcultured rat hepatic stellate cells. 2001 , 34, 230-8	14
2054	Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. 2001 , 37, 1228-33	285
2053	Smoking cessation in heart failure: it is never too late. 2001 , 37, 1683-4	23
2052	Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. 2001 , 37, 1677-82	126
2051	Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. 2001 , 37, 1820-6	148
2050	Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. 2001 , 37, 1808-12	103
2049	Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. 2001 , 37, 1800-7	124
2048	Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. 2001 , 38, 955-62	558
2047	Temporal decline in defibrillation thresholds with an active pectoral lead system. 2001 , 38, 1150-5	14
2046	Should an abnormal serum potassium concentration be considered a correctable cause of cardiac arrest?. 2001 , 38, 1224-5	15
2045	Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction. 2001 , 38, 1375-82	60

2044 Absolute, not relative, changes are important when interpreting trial data. **2001**, 38, 2132-3

2043 Improved endothelial function with metformin in type 2 diabetes mellitus: Reply. **2001**, 38, 2131-2132 6

2042 Absolute, not relative, changes are important when interpreting trial data: Reply. **2001**, 38, 2132-2133 4

2041 Aldosterone in congestive heart failure. *New England Journal of Medicine*, **2001**, 345, 1689-97 59.2 568

2040 Pharmacological differences among angiotensin II receptor antagonists. **2001**, 2, 13-8 9

2039 [Thrombogenic and endothelial damage markers in patients with ischemic systolic impairment]. **2001**, 54, 1155-60 2

2038 Espironolactona e insuficiencia cardíaca. **2001**, 8, 48-52

2037 Polypharmacy of heart failure. Creating a rational pharmacotherapeutic protocol. **2001**, 19, 583-96, viii 12

2036 Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure. **2001**, 19, 195-202, v 15

2035 Clinical implications of physiological changes in the aging heart. **2001**, 18, 263-76 104

2034 Beyond the usual strategies for blood pressure reduction: therapeutic considerations and combination therapies. **2001**, 3, 346-53 12

2033 Primary aldosteronism: a practical approach to diagnosis and treatment. **2001**, 3, 189-95 14

2032 Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. **2001**, 110, 438-41 196

2031 Medical therapy or coronary artery bypass graft surgery for chronic stable angina: an update using decision analysis. **2001**, 111, 89-95 18

2030 Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone. **2001**, 111, 587 13

2029 Prognosis determination in heart failure. **2001**, 110 Suppl 7A, 14S-36S 80

2028 Pathophysiology of chronic heart failure. **2001**, 110 Suppl 7A, 37S-46S 177

2027 Medical management of mild-to-moderate heart failure before the advent of beta blockers. **2001**, 110 Suppl 7A, 47S-62S 2

2026	The role of endothelins and their receptors in heart failure. 2001 , 43, 111-26	89
2025	Spironolactone and captopril attenuates isoproterenol-induced cardiac remodelling in rats. 2001 , 44, 311-5	25
2024	Aldosterone inhibition and heart failure: too good to be true?. 2001 , 141, 1-2	36
2023	ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. 2001 , 141, 800-7	34
2022	Comparing methods to identify general internal medicine clinic patients with chronic heart failure. 2001 , 142, 1003-9	15
2021	Congestive heart failure in pediatric patients. 2001 , 142, 923-8	73
2020	Women and heart failure. 2001 , 30, 87-97	26
2019	Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. 2001 , 37, 677-88	117
2018	Cardiac mechanotransduction: from sensing to disease and treatment. 2001 , 22, 254-60	52
2017	The combination ace-inhibitors plus canreonate in patients with anterior myocardial infarction: safety and tolerability study. 2001 , 77, 119-27; discussion 128-9	5
2016	Will aldosterone blockade in acute myocardial infarction be useful?. 2001 , 77, 128-129	2
2015	Heart Failure at the extremes of life: Chalk and Cheese?. 2001 , 78, 230-231	3
2014	The underreporting of results and possible mechanisms of 'negative' drug trials in patients with chronic heart failure. 2001 , 80, 19-27	36
2013	Exciting new drugs on the horizon Eplerenone, a selective aldosterone receptor antagonist (SARA). 2001 , 80, 1-4	8
2012	Angiotensin-converting enzyme inhibitors. 2001 , 56, 13-75	44
2011	Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. 2001 , 1, 190-6	75
2010	New and emerging pharmacological strategies in the management of chronic heart failure. 2001 , 1, 126-33	6
2009	ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. 2001 , 14, 241-7	105

2008	Clinical pearl #1: diuretic- induced-K ⁺ depletion may be hazardous: the miracle of low-dose spironolactone. 2001 , 14, 86-89	1
2007	Aldosterone esters and the heart. 2001 , 14, 200S-205S	8
2006	Management of hypertensive crises: the scientific basis for treatment decisions. 2001 , 14, 1154-67	68
2005	Pathophysiological effects of aldosterone in cardiovascular tissues. 2001 , 12, 308-14	178
2004	Elevations in antidiuretic hormone and aldosterone as possible causes of fluid retention in the Maze procedure. 2001 , 72, 58-64	12
2003	A novel combination therapy to reverse end-stage heart failure. 2001 , 33, 2762-4	22
2002	Pacing for heart failure. 2001 , 357, 1277-83	13
2001	Cardiomyopathies: from genetics to the prospect of treatment. 2001 , 358, 1627-37	138
2000	Perioperative cardiac complications. 2001 , 85, 1151-69, vi	13
1999	[Evidence based medical treatment of heart failure]. 2001 , 54, 715-34	6
1998	Otros aspectos del tratamiento de la insuficiencia cardíaca. Trasplante cardíaco. Asistencia circulatoria. 2001 , 8, 2021-2029	
1997	The pathophysiologic basis for the treatment of cirrhotic ascites. 2001 , 5, 819-32	7
1996	Tratamiento de la insuficiencia cardíaca crónica. 2001 , 8, 2010-2020	
1995	A clinician's perspective on clinical trials. 2001 , 7, 1-3	12
1994	The looming polypharmacy crisis in the management of patients with heart failure. Potential solutions. 2001 , 19, 541-5	8
1993	Observation unit management of heart failure. 2001 , 19, 209-32	36
1992	Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. 2001 , 104, 137-9	182
1991	[Management of dilated cardiomyopathy]. 2001 , 201, 466-8	

1990	Hormonal therapy in dermatology. 2001 , 19, 169-78, ix	16
1989	Step care therapy for hypertension in diabetic patients. 2001 , 76, 1266-74	8
1988	Older and more complicated heart failure patients: an increasing challenge to the health care system!. 2001 , 5, 121-125	1
1987	Chronic illnesses and the end of life. 2001 , 28, 339-47	4
1986	To anticoagulate or not to anticoagulate patients with cardiomyopathy. 2001 , 19, 605-15	6
1985	The dilemma of late-stage heart failure. Rationale for chronic parenteral inotropic support. 2001 , 19, 627-36	5
1984	Análisis coste-beneficio del uso de espironolactona en el tratamiento de la insuficiencia cardíaca crónica. 2001 , 54, 175-180	0
1983	[New pharmacological agents in heart failure]. 2001 , 54, 624-34	1
1982	Brain natriuretic peptide-guided therapy for heart failure. 2001 , 33, 422-7	25
1981	Torsemide: a pharmacoeconomic review of its use in chronic heart failure. 2001 , 19, 679-703	15
1980	Mechanisms underlying ventricular arrhythmias in idiopathic dilated cardiomyopathy: implications for management. 2001 , 1, 105-18	10
1979	Carvedilol versus other beta-blockers in heart failure. 2001 , 10, 971-80	5
1978	Effect of carvedilol on survival in severe chronic heart failure. <i>New England Journal of Medicine</i> , 2001 , 344, 1651-8	59.2 2438
1977	Altered potassium balance and aldosterone secretion in a mouse model of human congenital long QT syndrome. 2001 , 98, 8792-7	55
1976	Nephrotoxicity in the elderly due to co-prescription of ACE inhibitors and NSAIDs. 2001 , 94, 657-8	5
1975	New Strategies for Improving Heart Failure Management. 2001 , 94, 166-174	1
1974	Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management. 2001 , 77, 4-10	105
1973	Different effects of calcium antagonist and beta-blocker therapy on left-ventricular diastolic function in ischemic heart disease. A direct comparison of the impact of mibefradil and atenolol. 2001 , 96, 65-71	

1972	Guidelines for the management of hypertension for general practitioners. 2001 , 24, 613-34	109
1971	EARTH: EndothelinA Receptor Antagonist Trial in Heart Failure. 2001 , 1, 294-298	3
1970	Do cardiologists at a university hospital adopt the guidelines for the treatment of heart failure?. 2001 , 77, 30-6	2
1969	Effects of spironolactone and fasinopril on the spontaneous and chronic ventricular arrhythmias in a rat model of myocardial infarction. 2001 , 96, 85-93	8
1968	Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. 2001 , 281, H2241-51	118
1967	Geriatric medicine. 2001 , 322, 86-89	7
1966	Nontraditional aspects of aldosterone physiology. 2001 , 281, E1122-7	32
1965	Aldosterone as a determinant of cardiovascular and renal dysfunction. 2001 , 94, 378-83	45
1964	Repetitive stunning, hibernation, and heart failure: contribution of PET to establishing a link. 2001 , 280, H929-36	29
1963	Guidelines for management of patients with chronic heart failure in Australia. 2001 , 174, 459-66	37
1962	Slowing the progression of CHF. Drug therapy to correct neurohormonal abnormalities. 2001 , 109, 36-8, 41-5	1
1961	Enabling clinical governance: a primary care audit of prescribing for heart failure in central Auckland, New Zealand. 2001 , 6, 175-182	
1960	Heart failure in older people: the epidemic we had to have. 2001 , 174, 432-3	6
1959	The kidney in congestive heart failure: renal adverse event rate of treatment. 2001 , 38, 99-107	6
1958	Optimizing treatment for chronic congestive heart failure in children. 2001 , 29, S237-40	13
1957	Managing patients with heart failure. 2001 , 101, 34-40	3
1956	Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. 2001 , 19, 829-42	63
1955	Clinical therapeutic conference: congestive heart failure therapy. 2001 , 8, 65-72	1

1954	Heart failure: pathophysiologic mechanisms. 2001 , 101, 26-33	8
1953	Treatment of heart failure: state of the art and prospectives. 2001 , 38 Suppl 2, S59-63	7
1952	Mineralocorticoid target genes. 2001 , 8, 118-123	12
1951	Heart, aging, and hypertension. 2001 , 16, 336-41	32
1950	Aldosterone in renal disease. 2001 , 10, 105-10	35
1949	A mineralocorticoid receptor mutation causing human hypertension. 2001 , 10, 661-5	13
1948	A review of the medical treatment of primary aldosteronism. 2001 , 19, 353-61	138
1947	Clinical trials update: Highlights of the Scientific Sessions of Heart Failure 2001, a meeting of the Working Group on Heart Failure of the European Society of Cardiology. CONTAK-CD, CHRISTMAS, OPTIME-CHF. 2001 , 3, 491-4	46
1946	The role of continuous positive airway pressure in the treatment of congestive heart failure. 2001 , 120, 1675-85	59
1945	Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. 2001 , 3, 495-502	41
1944	Risk stratification in middle-aged patients with congestive heart failure: prospective comparison of the Heart Failure Survival Score (HFSS) and a simplified two-variable model. 2001 , 3, 577-85	55
1943	Diuretics for heart failure. 2001 ,	1
1942	Flow-mediated dilatation following wrist and upper arm occlusion in humans: the contribution of nitric oxide. 2001 , 101, 629-635	229
1941	Flow-mediated dilatation following wrist and upper arm occlusion in humans: the contribution of nitric oxide. 2001 , 101, 629	72
1940	[Torasemide (LUPRAC): a review of its pharmacological and clinical profile]. 2001 , 118, 97-105	5
1939	The oxidative stress hypothesis of congestive heart failure: radical thoughts. 2001 , 120, 2035-46	116
1938	Diuretics. 2001 , 246-252	
1937	Clinical trials update: highlights of the scientific sessions of the American Heart Association year 2000: Val HeFT, COPERNICUS, MERIT, CIBIS-II, BEST, AMIOVIRT, V-MAC, BREATHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle myoblast transfer for heart failure. 2001 , 3, 117-24	24

1936 . **2001**, 3, 883-911

1935 Reducing the cost of frequent hospital admissions for congestive heart failure: a randomized trial of a home telecare intervention. **2001**, 39, 1234-45 243

1934 Management of Congestive Heart Failure. **2001**, 4, 161-170

1933 Reversal of endothelial dysfunction in humans. **2001**, 12, 463-73 13

1932 High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients. **2001**, 24, 99-104 24

1931 Current world literature. **2001**, 14, 93-125

1930 Of phospholamban, mice, and humans with heart failure. **2001**, 103, 787-8 9

1929 Current World Literature. **2001**, 10, 271-293

1928 [Update 2001. Myocarditis--cardiomyopathy]. **2001**, 96, 608-25 18

1927 [Pharmacotherapy after cardiac infarction]. **2001**, 42, 699-712 1

1926 The role of endothelin receptor antagonists in the treatment of chronic heart failure. **2001**, 3, 232-40 3

1925 Implications of recent heart failure trials for patients with hypertension. **2001**, 3, 504-10 7

1924 Aldosterone antagonists in the treatment of hypertension and target organ damage. **2001**, 3, 240-8 19

1923 Role of central mineralocorticoid receptors in cardiovascular disease. **2001**, 3, 263-9 17

1922 The effect of antihypertensive drugs on vascular compliance. **2001**, 3, 297-304 27

1921 Dilated Cardiomyopathy. **2001**, 3, 451-462 1

1920 Diabetic Cardiomyopathy. **2001**, 3, 481-492 29

1919 [Guidelines for the treatment of chronic heart failure. Issued by the Executive Committee of the German Society of Cardiology--Heart and Circulation Research, compiled on behalf of the Commission of Clinical Cardiology in cooperation with Pharmaceutic Commission of the German Physicians' Association]. **2001**, 90, 218-37 47

1918	Het effect van spironolacton op morbiditeit en mortaliteit bij patiënten met ernstig hartfalen. 2001 , 39, 137-138	
1917	De behandeling van decompensatio cordis: toevoeging van spironolacton. 2001 , 39, 141-142	
1916	Experience collecting interim data on mortality: an example from the RALES study. 2001 , 2, 59-62	9
1915	Cytokines as new treatment targets in chronic heart failure. 2001 , 2, 271-277	34
1914	Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure. 2001 , 51, 35-43	13
1913	Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives. 2001 , 21, 661-72	95
1912	Beta-blocker treatment in heart failure. 2001 , 15, 95-109	26
1911	Individualized treatment of heart failure. 2001 , 31, 138-41	6
1910	Sudden death in heart failure associated with reduced left ventricular function: substrates, mechanisms, and evidence-based management, Part II. 2001 , 24, 1002-22	8
1909	New perspectives on the role of aldosterone excess in cardiovascular disease. 2001 , 28, 783-91	50
1908	Mineralocorticoids and cardiac fibrosis: the decade in review. 2001 , 28, 1002-6	62
1907	Dobutamine as bridge to angiotensin-converting enzyme inhibitor-nitrate therapy in endstage heart failure. 2001 , 24, 231-6	11
1906	Carvedilol in the failing heart. 2001 , 24, 757-66	11
1905	Global improvement in left ventricular performance observed with cardiac contractility modulation is the result of changes in regional contractility. 2001 , 6, 35-44	3
1904	The challenge of prediction and prevention of sudden cardiac death in congestive heart failure. 2001 , 5, 5-8	3
1903	Heart failure therapy at the turn of the century. 2001 , 6, 7-14	12
1902	Electric currents applied during the refractory period can modulate cardiac contractility in vitro and in vivo. 2001 , 6, 27-34	43
1901	The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. 2001 , 15, 79-87	248

1900	Hormones, drugs, remodeling and outcome in heart failure and after myocardial infarction. 2001 , 15, 9-10	3
1899	Hemodynamic effects of bosentan in patients with chronic heart failure. 2001 , 6, 325-34	9
1898	Aldosterone and myocardial infarction--are aldosterone antagonists needed to prevent remodelling or does ACE inhibition suffice?. 2001 , 15, 297-8	1
1897	ACE-inhibition plus mineralocorticoid antagonism versus ACE-inhibition alone in patients with anterior myocardial infarction. 2001 , 15, 309-14	5
1896	Apoptosis in cardiac disease--what is it--how does it occur. 2001 , 15, 507-23	26
1895	Hypotension after first-dose ACE inhibitor administration in heart failure--should doctors stop worrying?. 2001 , 15, 475-7	2
1894	Neurohormones, cytokines and programmed cell death in heart failure: a new paradigm for the remodeling heart. 2001 , 15, 529-37	3
1893	Recombinant human GHRH(1-44)NH2: clinical utility and therapeutic development program. 2001 , 14, 137-41	3
1892	The chain of survival. 2001 , 37, S5-16	19
1891	Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. 2001 , 133, 687-94	161
1890	Cardiovascular monitoring and therapy for HIV-infected patients. 2001 , 946, 236-73	14
1889	Effects of aldosterone on transient outward K ⁺ current density in rat ventricular myocytes. 2001 , 537, 151-60	82
1888	Heart failure in 2001: a prophecy revisited. 2001 , 87, 1383-6	5
1887	Indications for multisite pacing in patients with heart failure. 2001 , 88, 688-90	6
1886	Electrical and structural remodeling of the failing ventricle. 2001 , 92, 213-30	79
1885	[Heart insufficiency in the elderly]. 2001 , 50, 426-33	2
1884	[Prognostic factors of chronic heart insufficiency]. 2001 , 50, 21-9	
1883	[Medical treatment of chronic heart insufficiency]. 2001 , 50, 30-7	0

1882	[Drug prospects in the treatment of heart insufficiency]. 2001 , 50, 38-49	1
1881	What is the optimal medical management of ischemic heart failure?. 2001 , 43, 433-55	19
1880	Coronary artery surgery for ischemic heart failure: risks, benefits, and the importance of assessment of myocardial viability. 2001 , 43, 373-86	13
1879	Statistical significance versus clinical relevance in cardiovascular medicine. 2001 , 44, 155-67	11
1878	Management of heart failure. 2001 , 12, 273-280	
1877	My defibrillator fired: what to do?. 2001 , 10, 76-81	
1876	Crossovers between functional and proliferative signaling: key to understanding the pathophysiology and management of heart failure. 2001 , 5, 125-31	2
1875	Difficult cases in heart failure: Raison d'être behind ACE inhibitors and AT1 receptor combinations in chronic heart failure: chemical nuances or clinical significance?. 2001 , 7, 101-104	
1874	Pharmacotherapy in congestive heart failure: Hyperkalemia in congestive heart failure. 2001 , 7, 97-100	3
1873	Optimal use of spironolactone for treatment of heart failure. 2001 , 7, 315-318	1
1872	Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis. 2001 , 21, 1389-402	15
1871	Guidelines for the diagnosis and treatment of chronic heart failure. 2001 , 22, 1527-60	1001
1870	Combined therapy with an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor in heart failure. 2001 , 35, 242-8	13
1869	Task Force on Sudden Cardiac Death of the European Society of Cardiology. 2001 , 22, 1374-450	520
1868	Arterial pressure, left ventricular mass, and aldosterone in essential hypertension. 2001 , 37, 845-50	97
1867	The Syndrome of Cardiac Cachexia. 2001 , 93-103	
1866	What is the optimal medical management of ischaemic heart failure?. 2001 , 59, 135-58	5
1865	ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. 2001 , 37, 1444-9	99

1864	New competition in the realm of renin-angiotensin axis inhibition; the angiotensin II receptor antagonists in congestive heart failure. 2001 , 35, 71-84	12
1863	Endothelin 1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11beta-hydroxysteroid dehydrogenase inhibition: role of nitric oxide. 2001 , 103, 3129-35	46
1862	Electrical storm presages nonsudden death: the antiarrhythmics versus implantable defibrillators (AVID) trial. 2001 , 103, 2066-71	276
1861	Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. 2001 , 38, 1227-32	106
1860	Influence of aldosterone vs. endothelin receptor antagonism on renovascular function in liquorice-induced hypertension. 2001 , 16, 2146-51	16
1859	Digitalis for treatment of congestive heart failure in patients in sinus rhythm. 2001 , CD002901	3
1858	Effects of canrenone on aorta and right ventricle of the rat. 2001 , 37, 540-7	10
1857	Perspectives on n-3 PUFAs: primary prevention, antiarrhythmic effects, congestive heart failure. 2001 , 3, D106-D109	4
1856	Specialty-related differences in the epidemiology, clinical profile, management and outcome of patients hospitalized for heart failure; the OSCUR study. Outcome dello Scompenso Cardiaco in relazione all'Utilizzo delle Risorse. 2001 , 22, 596-604	88
1855	Clinical events leading to the progression of heart failure: insights from a national database of hospital discharges. 2001 , 22, 153-64	60
1854	Trends in hospitalization for heart failure in Scotland, 1990-1996. An epidemic that has reached its peak?. 2001 , 22, 209-17	151
1853	Endothelin antagonists for chronic heart failure: do they have a role?. 2001 , 22, 1772-84	22
1852	Failing ageing hearts. 2001 , 22, 1978-90	24
1851	A novel strategy to maximize the efficacy of left ventricular assist devices as a bridge to recovery. 2001 , 22, 534-40	127
1850	The Denolin lecture. Congestive heart failure: a half century perspective. 2001 , 22, 825-36	33
1849	The endothelin-type-A receptor in dilated cardiomyopathy: another key player?. 2001 , 22, 1849-51	1
1848	Refractory heart failure - drugs and devices. 2001 , 22, 2227-30	7
1847	Serum aldosterone changes during hyperinsulinemia are correlated to body mass index and insulin sensitivity in patients with essential hypertension. 2001 , 19, 107-12	15

1846	The endothelin-aldosterone axis and cardiovascular diseases. 2001 , 38 Suppl 2, S49-52		21
1845	Treatment of congestive heart failure: guidelines for the primary care physician and the heart failure specialist. 2001 , 161, 342-52		47
1844	Myocardial fibrosis in DOCA-salt hypertensive rats: effect of endothelin ET(A) receptor antagonism. 2001 , 103, 319-24		132
1843	Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. <i>New England Journal of Medicine</i> , 2001 , 344, 873-80	59.2	2212
1842	Trastuzumab and breast cancer. <i>New England Journal of Medicine</i> , 2001 , 345, 995-6	59.2	117
1841	Fortnightly review: Beneficial effects of potassium. 2001 , 323, 497-501		131
1840	Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). 2001 , 86, 3568-73		145
1839	Serious adverse events experienced by patients with chronic heart failure taking spironolactone. 2001 , 85, E8		51
1838	Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. 2001 , 37, 801-5		73
1837	Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. 2001 , 29, 13-21		122
1836	How many medicines do patients with heart failure need?. 2001 , 103, 1611-2		10
1835	Economics of chronic heart failure. 2001 , 3, 283-91		254
1834	Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. 2001 , 104, 1985-91		248
1833	Heart failure in the 21st century: a cardiogeriatric syndrome. 2001 , 56, M88-96		127
1832	Interaction of rapid nongenomic cardiovascular aldosterone effects with the adrenergic system. 2001 , 86, 761-7		45
1831	Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. 2001 , 161, 1849-56		646
1830	The Year in Review: Cardiology. 2001 , 14, 18-40		
1829	Preventable deaths and injuries during magnetic resonance imaging. <i>New England Journal of Medicine</i> , 2001 , 345, 1000-1	59.2	22

1828	Diagnosis and management of primary aldosteronism. 2001 , 2, 156-69		132
1827	Regulation of cardiac collagen: angiotensin and cross-talk with local growth factors. 2001 , 37, 841-4		69
1826	Mediators of chronic heart failure: how drugs work. 2001 , 35, 1066-74		2
1825	Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor. 2001 , 276, 38911-20		88
1824	K(+) depletion and the progression of hypertensive disease or heart failure. The pathogenic role of diuretic-induced aldosterone secretion. 2001 , 37, 806-10		25
1823	Manipulation of the renin-angiotensin system. 2001 , 104, E14-8		62
1822	Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. 2001 , 37, 787-93		182
1821	Aldosterone production is activated in failing ventricle in humans. 2001 , 103, 72-7		293
1820	Essential hypertension: the heart and hypertension. 2001 , 86, 467-75		24
1819	Heart failure in an elderly population. 2001 , 11, 311-321		
1818	Aborted sudden cardiac death: a clinical perspective. 2001 , 77, 363-70		4
1817	Transplantation of liver grafts from living donors into adults. <i>New England Journal of Medicine</i> , 2001 , 345, 923-4	59.2	11
1816	Serratia liquefaciens infections at a hemodialysis center. <i>New England Journal of Medicine</i> , 2001 , 345, 921-2; author reply 922-3	59.2	2
1815	MHC class I molecules and progression to AIDS. <i>New England Journal of Medicine</i> , 2001 , 345, 924-5	59.2	1
1814	Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. <i>New England Journal of Medicine</i> , 2001 , 345, 925-6	59.2	195
1813	Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. <i>New England Journal of Medicine</i> , 2001 , 345, 926	59.2	49
1812	Effects of beta-blocker therapy in severe chronic heart failure. <i>New England Journal of Medicine</i> , 2001 , 345, 998-9	59.2	4
1811	A long-term survivor with the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. <i>New England Journal of Medicine</i> , 2001 , 345, 999-1000	59.2	22

1810	Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. <i>New England Journal of Medicine</i> , 2001 , 345, 1000	59.2	131
1809	Cardiac steroidogenesis in the normal and failing heart. 2001 , 86, 5121-6		109
1808	Factors derived from adrenals are required for activation of cardiac gene expression in angiotensin II-induced hypertension. 2001 , 142, 4256-63		18
1807	A critical evaluation of the NICE guidelines for post-myocardial infarction prophylaxis. National Institute for Clinical Excellence. 2001 , 2, 2079-84		2
1806	Reawakening of interest in aldosterone and aldosterone antagonists: implications for treatment of cardiovascular disease. 2001 , 10, 166-9		
1805	Cardiac architecture: Gothic versus Romanesque. A cardiologist's view. 2001 , 13, 417-30		7
1804	Outcomes after aortic valve replacement in patients with severe aortic regurgitation and markedly reduced left ventricular function. 2002 , 106, 2687-93		195
1803	Impact numbers in health policy decisions. 2002 , 56, 600-5		18
1802	Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. 2002 , 106, 1055-7		82
1801	Halting the progression of chronic nephropathy. 2002 , 13 Suppl 3, S190-5		38
1800	Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. 2002 , 105, 677-9		71
1799	A lifetime of prevention: the case of heart failure. 2002 , 106, 2997-8		26
1798	Heart failure in frail elderly patients: diagnostic difficulties, co-morbidities, polypharmacy and treatment dilemmas. 2002 , 4, 91-8		142
1797	Cardiac-resynchronization therapy for heart failure. <i>New England Journal of Medicine</i> , 2002 , 346, 1902-5	59.2	63
1796	New therapeutics for chronic heart failure. 2002 , 53, 59-74		54
1795	Ligand-selective potentiation of rat mineralocorticoid receptor activation function 1 by a CBP-containing histone acetyltransferase complex. 2002 , 22, 3698-706		89
1794	Activation of mitogen-activated protein kinase (mitogen-activated protein kinase/extracellular signal-regulated kinase) cascade by aldosterone. 2002 , 13, 3042-54		41
1793	Imbalance of catabolic and anabolic pathways in chronic heart failure. 2002 , 46, 3-10		8

- 1792 Red pepper and functional dyspepsia. *New England Journal of Medicine*, **2002**, 346, 947-8 59.2 27
- 1791 Angiotensin-Converting Enzyme Inhibitors in Congestive Heart Failure: Practice versus Guidelines. **2002**, 18, 229-240 1
- 1790 Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes. **2002**, 99, 7160-5 83
- 1789 The human steroid hydroxylases CYP1B1 and CYP11B2. **2002**, 383, 1537-51 69
- 1788 Medical management of advanced heart failure. **2002**, 287, 628-40 294
- 1787 Myocardial remodelling: pharmacological targets. **2002**, 11, 661-74 8
- 1786 Metalloproteinase in myocardial adaptation and maladaptation. **2002**, 7, 241-6 15
- 1785 Diuretics in the treatment of patients who present congestive heart failure and hypertension. **2002**, 16 Suppl 1, S104-13 8
- 1784 Broadening the real world of health care: what we can do for heart failure patients. **2002**, 23, 425; author reply 425 1
- 1783 Alterations in oxygen consumption and sympathetic nervous activity in heart failure: independent or associated mechanisms?. **2002**, 23, 764-6
- 1782 Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. **2002**, 87, 448-52 69
- 1781 What do Cochrane reviews tell us about anti-thrombotic therapy in heart failure with sinus rhythm?. **2002**, 95, 419-21 2
- 1780 Comment on Dr Canaud's editorial. **2002**, 17, 2034-5
- 1779 Mineralocorticoid receptor malfunction: further insights from rare forms of hypertension. **2002**, 17, 539-42 4
- 1778 Cumulative effect of complete left bundle-branch block and chronic atrial fibrillation on 1-year mortality and hospitalization in patients with congestive heart failure. A report from the Italian network on congestive heart failure (in-CHF database). **2002**, 23, 1692-8 50
- 1777 Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. **2002**, 23, 1780-7 294
- 1776 Vasopressin antagonists in CHF: ready for clinical trials?. **2002**, 54, 13-5 10
- 1775 Aldactone therapy in a peritoneal dialysis patient with decreased left ventricular function. **2002**, 17, 2035-6 14

1774	Spironolactone and ACE inhibition in chronic renal failure. <i>New England Journal of Medicine</i> , 2002 , 346, 456-7	59.2	4
1773	Legalized physician-assisted suicide in Oregon, 2001. <i>New England Journal of Medicine</i> , 2002 , 346, 450-2	59.2	20
1772	Deep-brain stimulation in Parkinson's disease. <i>New England Journal of Medicine</i> , 2002 , 346, 452-3	59.2	10
1771	Selective postoperative inhibition of gastrointestinal opioid receptors. <i>New England Journal of Medicine</i> , 2002 , 346, 455	59.2	2
1770	Withholding proven treatment in research. <i>New England Journal of Medicine</i> , 2002 , 346, 455-6	59.2	
1769	Tranexamic acid in hereditary hemorrhagic telangiectasia. <i>New England Journal of Medicine</i> , 2002 , 346, 457	59.2	3
1768	Prevention of venous thromboembolism with fondaparinux. <i>New England Journal of Medicine</i> , 2002 , 346, 940-2; author reply 940-2	59.2	4
1767	Estrogen-replacement therapy after ischemic stroke. <i>New England Journal of Medicine</i> , 2002 , 346, 942-3; author reply 942-3	59.2	3
1766	Recognition and management of anthrax. <i>New England Journal of Medicine</i> , 2002 , 346, 943-5; author reply 943-5	59.2	9
1765	Cutaneous anthrax infection. <i>New England Journal of Medicine</i> , 2002 , 346, 945-6; author reply 945-6	59.2	1
1764	Sudden death due to cardiac arrhythmias. <i>New England Journal of Medicine</i> , 2002 , 346, 946-7; author reply 945-7	59.2	3
1763	Left ventricular assist device. <i>New England Journal of Medicine</i> , 2002 , 346, 1023-5; author reply 1023-5	59.2	3
1762	Aldosterone. 2002 , 26, 8-20		94
1761	C-reactive protein as a predictor of improvement and readmission in heart failure. 2002 , 4, 331-6		164
1760	Expression of aldosterone synthase gene in failing human heart: quantitative analysis using modified real-time polymerase chain reaction. 2002 , 87, 3936-40		83
1759	Pharmacotherapy of chronic heart failure: current status and future aspects. 2002 , 4, 181-187		2
1758	How to best to counteract the enemies? By blocking neurohormonal activation. 2002 , 4, G45-G50		1
1757	[Cardiac resynchronization therapy by biventricular pacing. How many patients with left ventricular dysfunction are eligible?]. 2002 , 127, 2259-63		2

1756	Klinische Aspekte der Hyperkalifñie. 2002 , 27, 43-46	1
1755	[Chronic heart failure--treatment]. 2002 , 127, 1139-44	6
1754	Heart failure in older people: causes, diagnosis and treatment. 2002 , 31, 29-36	27
1753	Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. 2002 , 106, 2967-72	176
1752	B-type natriuretic peptide and acute coronary syndromes. <i>New England Journal of Medicine</i> , 2002 , 346, 453-5	59.2 5
1751	Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. 2002 , 40, 23-7	186
1750	Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure. 2002 , 88, 475-80	32
1749	B-type natriuretic peptide in the diagnosis of cardiac disease in elderly day hospital patients. 2002 , 31, 295-301	23
1748	Spironolactone improves angiotensin-induced vascular changes and oxidative stress. 2002 , 40, 504-10	347
1747	Mineralocorticoid and angiotensin receptor antagonism during hyperaldosteronemia. 2002 , 40, 124-9	17
1746	Effect of a standardized nurse case-management telephone intervention on resource use in patients with chronic heart failure. 2002 , 162, 705-12	323
1745	Contemporary medical options for treating patients with heart failure. 2002 , 105, 2244-6	15
1744	Images in cardiology: Spontaneous right coronary artery dissection. 2002 , 88, 130	2
1743	Surrogate end points in heart failure. 2002 , 36, 479-88	9
1742	Carvedilol prospective randomized cumulative survival (COPERNICUS) trial: carvedilol as the sun and center of the beta-blocker world?. 2002 , 106, 2164-6	21
1741	Women, heart failure, and heart failure therapies. 2002 , 105, 1526-8	25
1740	Evidence-based medicine in practice. 2002 , 7, 68-69	1
1739	Effect of number of medications on cardiovascular therapy adherence. 2002 , 36, 1532-9	78

1738	Local renin-angiotensin systems and their interactions with extra-adrenal corticosteroid production. 2002 , 3, 214-21	26
1737	Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. 2002 , 40, 28-33	100
1736	Prevalence of myocardial viability assessed by single photon emission computed tomography in patients with chronic ischaemic left ventricular dysfunction. 2002 , 88, 125-30	25
1735	Eplerenone--a novel selective aldosterone blocker. 2002 , 36, 1567-76	34
1734	Current limitations in treatment of heart failure: new avenues and treatment options. 2002 , 13, S53-6	5
1733	Optimal stimulation of the left ventricle. 2002 , 13, S57-62	21
1732	Outcome studies with device therapy in patients with heart failure. 2002 , 13, S73-91	30
1731	Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. 2002 , 324, 1498	151
1730	Sodium transporter abundance profiling in kidney: effect of spironolactone. 2002 , 283, F923-33	72
1729	Combined primary aldosteronism and Cushing's syndrome due to a single adrenocortical adenoma complicated by Hashimoto's thyroiditis. 2002 , 41, 967-71	14
1728	Aldosterone induces a vascular inflammatory phenotype in the rat heart. 2002 , 283, H1802-10	487
1727	New ideas about aldosterone signaling in epithelia. 2002 , 282, F559-76	124
1726	Treatment paradigms in heart failure. 2002 , 63, 80-7	1
1725	Evidence-based medicine in practice. 2002 , 136, A11-2	2
1724	The multifaceted phenotype of the knockout mouse for the KCNE1 potassium channel gene. 2002 , 282, R639-48	50
1723	Cardiac resynchronization therapy in advanced heart failure the multicenter InSync clinical study. 2002 , 4, 311-20	201
1722	End-stage heart failure: which options?. 2002 , 4, D122-D130	
1721	A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. 2002 , 144, 834-9	148

1720	The current cost of heart failure to the National Health Service in the UK. 2002 , 4, 361-71	378
1719	Dietary prevention of sudden cardiac death. 2002 , 23, 277-85	17
1718	Selecting patients for heart transplantation: which patients are too well for transplant?. 2002 , 17, 137-44	21
1717	Long-term renal consequences of hypertension for normal and diseased kidneys. 2002 , 11, 73-80	77
1716	Systemic and regional hemodynamic and cardiac remodeling effects of candesartan in dilated cardiomyopathic hamsters with advanced congestive heart failure. 2002 , 40, 189-200	3
1715	Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension. 2002 , 20, 745-51	33
1714	Combined effects of metoprolol and spironolactone in dilated cardiomyopathic hamsters. 2002 , 40, 543-53	6
1713	Nesiritide: review of clinical pharmacology and role in heart failure management. 2002 , 4, 199-203	13
1712	Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency. 2002 , 95, 39-41, table of contents	12
1711	Aldosterone as a mediator in cardiovascular injury. 2002 , 10, 97-107	120
1710	Candidate selection for heart transplantation in the 21st Century. 2002 , 7, 221-225	2
1709	Influence of progressive renal dysfunction in chronic heart failure. 2002 , 4, 125-30	21
1708	Neurohumoral prediction of left-ventricular morphologic response to beta-blockade with metoprolol in chronic left-ventricular systolic heart failure. 2002 , 4, 635-46	12
1707	Evidence-based drug therapy for chronic heart failure. 2002 , 4, D66-D72	
1706	Polypharmacy in chronic heart failure: practical issues regarding the use of angiotensin-converting enzyme inhibitors, beta-blockers and other drugs. 2002 , 4, D111-D116	
1705	Improving care for patients with chronic heart failure in the community: the importance of a disease management program. 2002 , 122, 906-12	58
1704	Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. 2002 , 102, 381-386	56
1703	Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. 2002 , 103, 425-31	182

1702	Chronic effects of an endothelin-converting enzyme inhibitor on cardiorenal and hormonal function in heart failure. 2002 , 103 Suppl 48, 254S-257S	6
1701	Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. 2002 , 102, 381	34
1700	Torsemide in chronic heart failure: results of the TORIC study. 2002 , 4, 507-13	169
1699	Recent advances in the treatment of heart failure. 2002 , 66, 117-21	17
1698	Proliferative signaling and disease progression in heart failure. 2002 , 66, 225-31	19
1697	The Frederiksberg Heart Failure Study: Rationale, Design and Methodology, with Special Emphasis on the Sampling Procedure for the Study Population and Its Comparison to the Background Population. 2002 , 2, 167-174	10
1696	Management of chronic heart failure. 2002 , 325, 422-5	43
1695	Recovery of cardiac autonomic responsiveness with low-intensity physical training in patients with chronic heart failure. 2002 , 4, 159-66	49
1694	End-stage heart failure: which options?. 2002 , 4, D122-D130	1
1693	Diuretics. 2002 , 250-256	
1692	Prevalence of left ventricular systolic dysfunction and heart failure in high risk patients: community based epidemiological study. 2002 , 325, 1156	38
1691	Renin angiotensin aldosterone and adrenergic modulation in chronic heart failure: contemporary concepts. 2002 , 324, 267-75	7
1690	Prevention of heart failure. 2002 , 17, 512-7	5
1689	Central effects of mineralocorticoids on blood pressure: new answers, new questions. 2002 , 20, 1715-6	2
1688	How do heart failure patients die?. 2002 , 4, D59-D65	3
1687	Effects of long-term enalapril and losartan therapy of heart failure on cardiovascular aldosterone. 2002 , 25, 463-8	14
1686	Congestive heart failure: what should be the initial therapy and why?. 2002 , 2, 1-6	21
1685	Aldosterone-induced inflammation in the rat heart : role of oxidative stress. 2002 , 161, 1773-81	511

1684	Eplerenone: a new aldosterone receptor antagonist--are the FDA's restrictions appropriate?. 2002 , 4, 441-5	26
1683	Molecular mechanisms of myocardial remodeling. The role of aldosterone. 2002 , 34, 1577-84	141
1682	Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat. 2002 , 34, 1655-65	59
1681	Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure. 2002 , 39, 70-8	70
1680	Neurohormonal blockade in chronic heart failure. How much is enough? Can there be too much?. 2002 , 39, 79-82	22
1679	The prevalence of treatable left ventricular systolic dysfunction in patients who present with noncardiac vascular episodes: a case-control study. 2002 , 39, 219-24	26
1678	Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. 2002 , 39, 351-8	97
1677	Retiming the failing heart: principles and current clinical status of cardiac resynchronization. 2002 , 39, 194-201	359
1676	Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. 2002 , 39, 1151-8	1012
1675	Long-term benefits of biventricular pacing in congestive heart failure: results from the MULTISITE STimulation in cardiomyopathy (MUSTIC) study. 2002 , 40, 111-8	721
1674	Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. 2002 , 40, 304-10	136
1673	Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. 2002 , 40, 1596-601	157
1672	Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. 2002 , 40, 1801-8	157
1671	Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease. 2002 , 46, 203-12	20
1670	Aldosterone stimulates angiotensin-converting enzyme expression and activity in rat neonatal cardiac myocytes. 2002 , 8, 167-74	20
1669	Effect of cardiac resynchronization therapy on ventricular remodeling. 2002 , 8, S549-55	15
1668	Acupuncture inhibits sympathetic activation during mental stress in advanced heart failure patients. 2002 , 8, 399-406	71
1667	Do diuretics and aldosterone receptor antagonists improve ventricular remodeling?. 2002 , 8, S491-3	6

1666	Effects of metoprolol CR/XL on mortality and hospitalizations in patients with heart failure and history of hypertension. 2002 , 8, 8-14	18
1665	Impaired endothelium-mediated vasodilation in heart failure: clinical evidence and the potential for therapy. 2002 , 8, 15-20	33
1664	Comment--Val-HeFT and angiotensin-receptor blockers in perspective: A tale of the blind man and the elephant. 2002 , 8, 56-8	7
1663	Treatment of heart failure in patients with diabetes mellitus. 2002 , 62, 285-307	5
1662	Cefditoren Pivoxil. 2002 , 62, 337-338	1
1661	Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders. 2002 , 62, 339-85	13
1660	Rationale for the use of aldosterone antagonists in congestive heart failure. 2002 , 62, 723-31	43
1659	Angiotensin II receptor antagonists in chronic heart failure: where do they fit?. 2002 , 62, 1433-40	4
1658	Optimising the use of beta-blockers in older patients with heart failure. 2002 , 19, 671-84	4
1657	Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. 2002 , 91, 1103-13	413
1656	Congestive heart failure. 2002 , 165, 4-8	33
1655	Long-term trends in the incidence of and survival with heart failure. <i>New England Journal of Medicine</i> , 2002 , 347, 1397-402	59.2 1597
1654	La insuficiencia cardíaca en los servicios de medicina interna (estudio SEMI-IC). 2002 , 118, 605-610	39
1653	Severe heart failure in the elderly: potential benefits of high-dose and continuous infusion diuretics. 2002 , 19, 249-56	8
1652	Manejo de la insuficiencia cardíaca en el anciano ¿Quién y dónde? Visión del especialista. 2002 , 37, 13-19	
1651	[Cardiac resynchronisation therapy in congestive heart failure. Current concept, results and prospects]. 2002 , 119, 785-94	1
1650	[Aldosterone blockade in heart failure. So much for so little]. 2002 , 118, 779-81	2
1649	Pharmacoeconomic considerations in assessing and selecting congestive heart failure therapies. 2002 , 20, 963-77	5

1648	Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure?. 2002 , 4, 771-8	19
1647	Cardiac resynchronization therapy in patients with chronic heart failure: pathophysiology and current experience. 2002 , 2, 219-26	5
1646	Racial differences in responses to drug treatment: implications for pharmacotherapy of heart failure. 2002 , 2, 389-99	24
1645	Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. 2002 , 30, 1344-51	49
1644	Cellular mechanisms for the treatment of chronic heart failure: the nitric oxide- and adenosine-dependent pathways. 2002 , 7, 99-110	5
1643	Effects of angiotensin receptor blockade on haemodynamics and gene expression after myocardial infarction. 2002 , 3, 239-49	4
1642	How to survive the survival plots. 2002 , 360, 954	10
1641	Nongenomic effects of aldosterone: cellular aspects and clinical implications. 2002 , 67, 493-8	48
1640	Clinical predictors of outcome in patients with heart failure and neurohormonal blockade: referral for transplantation from heart failure units without heart transplantation programs. 2002 , 34, 3227-9	
1639	Investigation and Treatment of Heart Failure. 2002 , 30, 98-103	
1638	What's new in Heart failure. 2002 , 30, 1-4	
1637	Long-term outcome and the use of revascularization in patients with heart failure, suspected ischemic heart disease, and large reversible myocardial perfusion defects. 2002 , 143, 904-9	17
1636	Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. 2002 , 143, 923-9	84
1635	QRS duration and mortality in patients with congestive heart failure. 2002 , 143, 1085-91	317
1634	Diuretic resistance predicts mortality in patients with advanced heart failure. 2002 , 144, 31-8	271
1633	An integrated approach to diagnosis and therapeutic management of patients with systolic heart failure in the Copenhagen metropolitan area. 2002 , 144, E2	34
1632	Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: The Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. 2002 , 144, 597-607	
1631	Tezosentan in patients with acute heart failure and acute coronary syndromes: Design of the Randomized Intravenous Tezosentan Study (RITZ-4). 2002 , 144, 583-588	1

1630	Aldosterone: cardiovascular assault. 2002 , 144, S2-7	68
1629	Clinical implications of aldosterone blockade. 2002 , 144, S12-8	26
1628	New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone. 2002 , 144, S8-11	32
1627	The role of spironolactone in the treatment of patients with refractory hypertension. 2002 , 15, 333-9	172
1626	Insights from Laragh's review course: the role of the renin-angiotensin system in blood pressure regulation. 2002 , 15, 653-4	5
1625	PAI-1 in human hypertension: relation to hypertensive groups. 2002 , 15, 683-90	31
1624	Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. 2002 , 15, 709-16	293
1623	Additive effect of drospirenone/17-beta-estradiol in hypertensive postmenopausal women receiving enalapril. 2002 , 15, 816-22	44
1622	Évolution du facteur natriurétique de type B après resynchronisation biventriculaire chez les patients présentant une insuffisance cardiaque sévère. 2002 , 17, 382-386	
1621	Current treatment and future directions in heart failure. 2002 , 2, 148-53	4
1620	Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells. 2002 , 81, 173-9	75
1619	Non-genomic aldosterone action: from the cell membrane to human physiology. 2002 , 83, 167-71	25
1618	BNP in hormone-guided treatment of heart failure. 2002 , 13, 151-5	36
1617	Endothelial dysfunction in chronic heart failure: clinical and therapeutic implications. 2002 , 13, 233-239	17
1616	[Study of drug prescribing in patients older than 65 in Languedoc-Roussillon]. 2002 , 23, 745-50	1
1615	Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. 2002 , 82, 149-58	149
1614	Use of ejection fraction (or lack thereof), morbidity/mortality and heart failure drug trials: a review. 2002 , 84, 119-32	11
1613	The syndrome of cardiac cachexia. 2002 , 85, 51-66	219

1612	Spironolactone increases integrin beta3 gene expression in kidney and heart muscle cells. 2002 , 194, 175-82	6
1611	Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: The Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. 2002 , 144, 597-607	120
1610	[Medical care of patients with heart failure: clinical characteristics, determinants of prognosis and follow-up in primary care]. 2002 , 29, 531-7; discussion 537-9	0
1609	[Aldosterone antagonists in the treatment of heart failure]. 2002 , 119, 333-5	
1608	Prevention of cardiovascular diseases. Coronary artery disease, congestive heart failure, and stroke. 2002 , 18, 463-83, vii	9
1607	Clinical pharmacology of antihypertensive drugs. 2002 , 20, 265-80	7
1606	Manejo de la insuficiencia cardíaca del viejo. ¿Quié y dónde? Visión del geriatra. 2002 , 37, 5-12	
1605	Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4). 2002 , 144, 583-8	17
1604	Ventricular instability and sudden death in patients with heart failure: lessons from clinical trials. 2002 , 4, D31-D42	
1603	Présentation. 2002 , 186, 15-17	
1602	Digoxin Assays: Frequent, Substantial, and Potentially Dangerous Interference by Spironolactone, Canrenone, and Other Steroids. 2002 , 48, 507-516	70
1601	Cardiac Damage Prevention by Eplerenone: Comparison With Low Sodium Diet or Potassium Loading. 2002 , 39, 614-618	111
1600	Therapeutic options and heart failure survival score predictability in an academic heart failure center: an analysis of 120 consecutive patients during a 1-year period. 2002 , 4, 207-14	3
1599	Effect of spironolactone on impaired fibrinolysis of hypertensive patients. 2002 , 25, 260-4	12
1598	Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. 2002 , 25, 837-42	50
1597	Is Heart Rate Reduction Beneficial to Patients with Chronic Congestive Heart Failure?. 2002 , 2, 135-141	
1596	The potential benefits of aldosterone antagonism in Type 2 diabetes mellitus. 2002 , 3, 150-5	4
1595	Altered communication between L-type calcium channels and ryanodine receptors in heart failure. 2002 , 7, e263-75	32

1594	Influence of plasma aldosterone on left ventricular geometry and diastolic function in treated essential hypertension. 2002 , 25, 49-56	29
1593	Heart failure as an inflammatory condition: potential role for androgens as immune modulators. 2002 , 4, 673-80	29
1592	Altered communication between l-type calcium channels and ryanodine receptors in heart failure. 2002 , 7, e263-275	12
1591	Polypharmacy in chronic heart failure: practical issues regarding the use of angiotensin-converting enzyme inhibitors, beta-blockers and other drugs. 2002 , 4, D111-D116	4
1590	Neurohormonal modulation in chronic heart failure. 2002 , 4, D3-D11	12
1589	Ventricular instability and sudden death in patients with heart failure: lessons from clinical trials. 2002 , 4, D31-D42	0
1588	How do heart failure patients die?. 2002 , 4, D59-D65	15
1587	Evidence-based drug therapy for chronic heart failure. 2002 , 4, D66-D72	1
1586	Syndrome of inappropriate antidiuretic hormone-induced hyponatremia associated with amiodarone. 2002 , 22, 649-51	19
1585	Benefits of prophylactic continuous infusion of furosemide after the maze procedure for atrial fibrillation. 2002 , 123, 232-6	11
1584	Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. 2002 , 89, 403-7	64
1583	QRS duration variability in patients with heart failure. 2002 , 90, 335-7	23
1582	Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade. 2002 , 90, 662-3	23
1581	Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease. 2002 , 90, 663-5	40
1580	Relation of the total ejection isovolume index to symptoms in aortic stenosis. 2002 , 90, 665-8	2
1579	Myocardial changes after spironolactone in spontaneous hypertensive rats. A laser scanning confocal microscopy study. 2002 , 6, 49-57	8
1578	Balancing diuretic therapy in heart failure: loop diuretics, thiazides, and aldosterone antagonists. 2002 , 8, 307-12	15
1577	Oxidative stress and endothelial dysfunction in heart failure. 2002 , 8, 165-72	44

1576	Carvedilol: a nonselective beta blocking agent with antioxidant properties. 2002 , 8, 173-7, 190	30
1575	Immune and neurohormonal pathways in chronic heart failure. 2002 , 8, 23-8, 48	23
1574	Future challenges in quality improvement in heart failure. 2002 , 8, 342-5	2
1573	Pharmacotherapy in congestive heart failure: diuretic resistance and strategies to overcome resistance in patients with congestive heart failure. 2002 , 8, 80-5	34
1572	Management of advanced heart failure. 2002 , 4, 42-52	3
1571	Atypical dose-route-dependent food effects of eplerenone in the dog: presence of food effects following intravenous dosing and lack of food effects of following oral dosing. 2002 , 91, 607-14	2
1570	Interconversion pharmacokinetics of eplerenone, a selective aldosterone blocker, and its lactone-ring open form. 2002 , 91, 1383-9	3
1569	Prevention of Left Ventricular Remodeling After Myocardial Infarction. 2002 , 4, 97-108	6
1568	Endocrine Heart Disease. 2002 , 4, 181-192	
1567	End-stage Heart Failure: Surgical Therapy and Implantable Devices. 2002 , 4, 511-520	
1566	Cardiac resynchronization therapy. 2002 , 4, 371-8	10
1565	Hypertension, left ventricular hypertrophy, and sudden death. 2002 , 4, 449-57	41
1564	Endothelin antagonists and heart failure. 2002 , 4, 85-92	13
1563	Angiotensin II and progressive renal insufficiency. 2002 , 4, 403-7	14
1562	[ACE inhibitors in high risk heart patients. Primary analysis of the HOPE study]. 2002 , 43, 431-4	0
1561	Therapie der ischämischen und nichtischämischen Herzinsuffizienz Derzeitiger Stand und Perspektiven. 2002 , 43, S8-S18	0
1560	[Value of aldosterone receptor blockade in diuretic therapy of patients with chronic heart failure]. 2002 , 27, 135-49	2
1559	[Beta blockers in therapy of chronic heart failure]. 2002 , 27, 150-65	5

1558	Dilated cardiomyopathies as a cause of congestive heart failure. 2002 , 27, 113-34	21
1557	[Arrhythmias during remodeling after myocardial infarction]. 2002 , 27, 740-9	1
1556	Heart rate variability--a therapeutic target?. 2002 , 27, 85-92	100
1555	National sentinel clinical audit of evidence-based prescribing for older people: methodology and development. 2002 , 8, 189-98	12
1554	Asymptomatic versus symptomatic persistent atrial fibrillation: clinical and noninvasive characteristics (Journal of Internal Medicine 2002; 250: 390-7). 2002 , 251, 363-4; author reply 365	1
1553	Muscle strength, Na,K-pumps, magnesium and potassium in patients with alcoholic liver cirrhosis -- relation to spironolactone. 2002 , 252, 56-63	27
1552	Congestive heart failure due to systolic dysfunction: the Cinderella of cardiovascular management in dialysis patients. 2002 , 15, 135-40	24
1551	Determination of the clinical importance of study results. 2002 , 17, 469-76	109
1550	The development of outpatient Clinical Glidepaths. 2002 , 50, 1886-901	51
1549	Implantation techniques and chronic lead parameters of biventricular pacing dual-chamber defibrillators. 2002 , 13, 964-70	80
1548	Spironolactone therapy in older patients--the impact of renal dysfunction. 2002 , 35, 45-9	9
1547	Designing complex group sequential survival trials. 2002 , 21, 1969-89	36
1546	Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease. 2002 , 14, 178-88	25
1545	Drugs targeting the renin-angiotensin-aldosterone system. 2002 , 1, 621-36	326
1544	Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure. 2002 , 25, 247-9	13
1543	Management of heart failure in the elderly. 2002 , 7, 89-97	46
1542	Diastolic heart failure in the elderly. 2002 , 7, 17-27	77
1541	Age-related changes in ventricular-arterial coupling: pathophysiologic implications. 2002 , 7, 51-62	133

- 1540 Aldosterone receptor blockade in the management of heart failure. **2002**, 7, 205-19 5
- 1539 Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure. **2002**, 16, 53-9 31
- 1538 Angiotensin converting enzyme inhibition in heart failure: clinical trials and clinical practice. **2002**, 16, 67-74 6
- 1537 Arrhythmias associated with dilated cardiomyopathy. **2002**, 6, 18-25 9
- 1536 Significance and control of cardiac arrhythmias in patients with congestive cardiac failure. **2002**, 7, 285-300 14
- 1535 Prevalence and incidence of arrhythmias and sudden death in heart failure. **2002**, 7, 229-42 54
- 1534 New treatments for myocardial fibrosis. **2002**, 16, 181-2 4
- 1533 Effects of canrenone on myocardial reactive fibrosis in a rat model of postinfarction heart failure. **2002**, 16, 195-201 5
- 1532 Hibernation and congestive heart failure. **2003**, 8, 167-73 11
- 1531 Cardiomyocyte transplantation into the failing heart-new therapeutic approach for heart failure?. **2003**, 8, 201-11 26
- 1530 Outpatient management of heart failure. **2003**, 8, 345-8 3
- 1529 Pharmacological modulation of cardiovascular remodeling: a guide to heart failure therapy. **2003**, 17, 349-60 35
- 1528 Renin-angiotensin-aldosterone system: fundamental aspects and clinical implications in renal and cardiovascular disorders. **2003**, 10, 184-96 40
- 1527 Acute and chronic endothelial dysfunction: implications for the development of heart failure. **2003**, 8, 87-97 32
- 1526 Cost-effectiveness of spironolactone in patients with severe heart failure. **2003**, 172, 70-2 7
- 1525 The effects of spironolactone monotherapy on blood pressure and myocardial remodeling in spontaneously hypertensive rats: a stereological study. **2003**, 10, 50-7 8
- 1524 The management of patients with heart failure in a Slovenian community hospital: what has changed between 1997 and 2000?. **2003**, 115, 334-9 6
- 1523 Novel Pharmacologic Therapy of Heart Failure. **2003**, 5, 321-335

1522 Therapies for Preventing Heart Failure. **2003**, 5, 337-343

1521 Contemporary Medical, Surgical, and Device Therapies for End-stage Heart Failure. **2003**, 5, 487-499

7

1520 The renin-angiotensin-aldosterone system as a target in coronary disease. **2003**, 5, 124-30

11

1519 Sex differences in the causes and natural history of heart failure. **2003**, 5, 193-9

18

1518 The prognostic significance of renal dysfunction in patients with chronic systolic heart failure. **2003**, 5, 205-10

17

1517 Management issues for patients with coronary artery disease and heart failure. **2003**, 5, 216-22

1516 Regression of left ventricular hypertrophy is a key goal of hypertension management. **2003**, 5, 301-8

24

1515 Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease. **2003**, 5, 122-5

17

1514 RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. **2003**, 5, 408-17

54

1513 A neuroendocrine-immune interface. The immunostimulatory state of aldosteronism. **2003**, 28, 692-701

8

1512 [Current treatment of chronic heart failure]. **2003**, 52, 612-8

7

1511 [Diabetic cardiopathy: pathogenesis, diagnosis and therapy]. **2003**, 44, 806-12, 814-8

3

1510 Effects of education, self-care instruction and physical exercise on patients with chronic heart failure. **2003**, 92, 985-93

11

1509 Molekulare Mechanismen des plötzlichen Herztods und ihre klinische Bedeutung. **2003**, 14, 168-179

1508 Pathophysiological role of the mineralocorticoid receptor in heart: analysis of conditional transgenic models. **2003**, 445, 477-81

6

1507 Aldosterone action in the heart. **2003**, 446, 328-33

7

1506 Congenital heart disease in adults: management of advanced heart failure. **2003**, 17, 91-99

1505 Amiodarone versus Implantable Defibrillator (AMIOVIRT): background, rationale, design, methods, results and implications. **2003**, 7, 452-6

8

- 1504 Cardiac resynchronization therapy with or without an implantable defibrillator: only indicated when everything else has failed?. **2003**, 7, 421-9
- 1503 DEFibrillators In Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE). **2003**, 7, 457-62 11
- 1502 Aldosterone receptor antagonists: focus on eplerenone. **2003**, 18, 54-9 1
- 1501 Implementing guidelines in primary care: can population impact measures help?. **2003**, 3, 7 23
- 1500 The evolving role of nesiritide in advanced or decompensated heart failure. **2003**, 23, 1266-80 18
- 1499 Acute decompensated heart failure: a contemporary approach to pharmacotherapeutic management. **2003**, 23, 997-1020 25
- 1498 Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. **2003**, 91, 18F-40F 85
- 1497 Nonpharmacologic care of heart failure: counseling, dietary restriction, rehabilitation, treatment of sleep apnea, and ultrafiltration. **2003**, 91, 41F-50F 60
- 1496 Improving clinical outcomes with drug treatment in heart failure: what have trials taught?. **2003**, 91, 9D-14D 17
- 1495 Device therapy for heart failure. **2003**, 91, 53D-59D 59
- 1494 Effect of high-dose spironolactone on protein-losing enteropathy in patients with Fontan palliation of complex congenital heart disease. **2003**, 91, 1031-2, A9 56
- 1493 Comparison of the effects of dobutamine and nesiritide (B-type natriuretic peptide) on ventricular ectopy in acutely decompensated ischemic versus nonischemic cardiomyopathy. **2003**, 91, 1370-2 10
- 1492 A brief history of sudden cardiac death and its therapy. **2003**, 100, 89-99 14
- 1491 Aldosteronism revisited: perspectives on less well-recognized actions of aldosterone. **2003**, 142, 71-82 44
- 1490 Ventricular aneurysms, shock, and late follow-up in patients with heart failure. **2003**, 126, 323-5 6
- 1489 Heart failure: a hemodynamic disorder complicated by maladaptive proliferative responses. **2003**, 7, 1-10 37
- 1488 Controversies in the use of beta blockers in heart failure. **2003**, 9, 255-62 1
- 1487 Heart failure in the elderly. **2003**, 9, 311-21; discussion 309-10; quiz 322-3 16

1486	Prevalence, prognostic significance, and treatment of atrial fibrillation in congestive heart failure with particular reference to the DIAMOND-CHF study. 2003 , 9, 333-40	16
1485	Treatment of heart failure in older persons. Dilemmas with coexisting conditions: diabetes mellitus, chronic obstructive pulmonary disease, and arthritis. 2003 , 9, 142-7	17
1484	Is heart failure in African Americans a distinct entity?. 2003 , 9, 193-6	3
1483	Hyperkalemia, congestive heart failure, and aldosterone receptor antagonism. 2003 , 9, 224-9	25
1482	Discovery of selective CYP11B2 (aldosterone synthase) inhibitors for the therapy of congestive heart failure and myocardial fibrosis. 2003 , 38, 363-6	34
1481	Treatment of chronic heart failure in long-term care facilities: implications of recent heart failure guidelines recommendations. 2003 , 37, 131-7	5
1480	American College of Cardiology/American Heart Association Chronic Heart Failure Evaluation and Management guidelines: relevance to the geriatric practice. 2003 , 51, 123-6	49
1479	Extra-adrenal production of corticosteroids. 2003 , 30, 437-45	99
1478	Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats. 2003 , 30, 739-44	32
1477	Impact of smoking reduction on coronary heart disease mortality trends during 1981-2000 in England and Wales. 2003 , 1, 185	6
1476	The safety of spironolactone treatment in patients with heart failure. 2003 , 28, 285-7	18
1475	Improving ACE inhibitor use in patients hospitalized with systolic heart failure: a cluster randomized controlled trial of clinical practice guideline development and use. 2003 , 9, 373-82	10
1474	Sequential methods and group sequential designs for comparative clinical trials. 2003 , 17, 505-16	27
1473	Early aldosterone up-regulated genes: new pathways for renal disease?. 2003 , 64, 1199-207	25
1472	Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. 2003 , 63, 43-52	97
1471	Resynchronization therapy is an important advance in the management of congestive heart failure: view of an antagonist. 2003 , 14, S30-4	3
1470	Use of nonantiarrhythmic drugs for prevention of sudden cardiac death. 2003 , 14, S87-95	47
1469	Structural pathways and prevention of heart failure and sudden death. 2003 , 14, 764-75	18

1468	Risk stratification and management of sudden cardiac death: a new paradigm. 2003 , 14, 1113-9	10
1467	Antiarrhythmic drugs: past, present and future. 2003 , 14, 1389-96	20
1466	CHART: congestive cardiac failure in hospitals, an Australian review of treatment. 2003 , 12, 94-102	13
1465	Proportion of candidates for cardiac resynchronization therapy. 2003 , 26, 152-4	1
1464	The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. 2003 , 20, 607-21	60
1463	Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis. 2003 , 134, 151-8	49
1462	Growth hormone, acromegaly, and heart failure: an intricate triangulation. 2003 , 59, 660-71	71
1461	[Management of high blood pressure and cardiac insufficiency. New drugs and therapeutic concepts]. 2003 , 32, 54-9	
1460	[To what should we pay attention? Pharmaceutic care for patients with cardiac insufficiency]. 2003 , 32, 60-4	
1459	Treatment of congestive heart failure a neuroendocrine disorder. 2003 , 44, 154-60	5
1458	Optimal management of outpatients with heart failure using advanced practice nurses in a hospital-based heart failure center. 2003 , 15, 260-5	7
1457	Antiarrhythmic drugs: past, present, and future. 2003 , 26, 2340-9	1
1456	Eplerenone. 2003 , 2, 177-8	16
1455	La eplerenona, un antagonista selectivo de la aldosterona, reduce la morbilidad y la mortalidad en pacientes con disfunci3n ventricular o insuficiencia card3aca tras un infarto agudo de miocardio. 2003 , 10, 599	
1454	Tratamiento farmacol3gico de la hipertensi3n arterial. 2003 , 8, 6357-6372	
1453	[Combined cardiorenal failure: a rapidly expanding clinical entity]. 2003 , 121, 710-7	1
1452	Aldosterone as a target in congestive heart failure. 2003 , 87, 441-57	29
1451	Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics. 2003 , 87, 475-91	37

1450	Pharmacogenomics of congestive heart failure. 2003 , 87, 569-78, xiv	6
1449	Outcome studies in diabetic nephropathy. 2003 , 23, 255-71	16
1448	Pathophysiology of heart failure: identifying targets for pharmacotherapy. 2003 , 87, 303-16	20
1447	Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: what we know and current controversies. 2003 , 15, 423-37, vii-viii	
1446	Beta-blockers for heart failure: why, which, when, and where. 2003 , 87, 339-71	20
1445	Actualizaci3n (2003) de las Gu3as de Pr3ctica Cl3nica de la Sociedad Espa3ola de Cardiolog3a en hipertensi3n arterial. 2003 , 56, 487-497	2
1444	ACE inhibitors and ARBs in chronic heart failure: the established, the expected, and the pragmatic. 2003 , 87, 373-89	13
1443	Rational diuretic management in congestive heart failure: a case-based review. 2003 , 15, 453-60	2
1442	Heart failure. <i>New England Journal of Medicine</i> , 2003 , 348, 2007-18	59.2 1497
1441	The role of renin-angiotensin-aldosterone system inhibition in chronic kidney disease. 2003 , 1, 51-63	38
1440	Participation of the mineralocorticoid receptor in cardiac and vascular remodeling. 2003 , 94, p47-50	16
1439	Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. <i>New England Journal of Medicine</i> , 2003 , 348, 1309-21	59.2 3668
1438	Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. 2003 , 42, 2109-16	306
1437	Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. 2003 , 42, 1666-73	132
1436	Aldosterone antagonism and myocardial infarction: from animals to man and back. 2003 , 42, 1674-6	7
1435	Potassium and long QT syndrome: a new look at an old therapy. 2003 , 42, 1783-4	2
1434	A better survival for women with heart failure? It's not so simple. 2003 , 42, 2135-8	12
1433	Highlights of the year in JACC 2003. 2003 , 42, 2156-66	0

1432	Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. 2003 , 41, 211-4	173
1431	Spironolactone in chronic heart failure: all's well that ends well. 2003 , 41, 215-6	7
1430	The less familiar face of heart failure. 2003 , 41, 224-6	6
1429	Atriobiventricular pacing improves exercise capacity in patients with heart failure and intraventricular conduction delay. 2003 , 41, 582-8	20
1428	Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. 2003 , 41, 574-81	127
1427	Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. 2003 , 41, 997-1003	401
1426	Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. 2003 , 41, 1148-55	188
1425	Heart failure therapy at a crossroad: are there limits to the neurohormonal model?. 2003 , 41, 1606-10	58
1424	Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. 2003 , 41, 1707-12	413
1423	Use of spironolactone in heart failure patients receiving angiotensin-converting enzyme inhibitors and beta-blockers. 2003 , 41, 1851-2	1
1422	Reply. 2003 , 41, 1850-1851	
1421	Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. 2003 , 41, 2029-35	124
1420	Reply. 2003 , 42, 397-398	0
1419	Efficacy of simvastatin and ezetimibe in treating hypercholesterolemia. 2003 , 42, 398-9; author reply 399	5
1418	Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). 2003 , 42, 705-8	270
1417	Sparing a little may save a lot: lessons from the Studies of Left Ventricular Dysfunction (SOLVD). 2003 , 42, 709-11	2
1416	The effects of exercise training on sympathetic neural activation in advanced heart failure: a randomized controlled trial. 2003 , 42, 854-60	258
1415	Carvedilol: a review of its use in chronic heart failure. 2003 , 63, 1697-741	45

1414	Aldosterone receptor antagonists for hypertension: what do they offer?. 2003 , 63, 1963-72	9
1413	Antifibrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells. 2003 , 124, 504-20	42
1412	Cardiac size, autonomic function, and 5-year follow-up of chronic heart failure patients with severe prolongation of ventricular activation. 2003 , 9, 93-9	31
1411	A broader paradigm for understanding and treating heart failure. 2003 , 9, 147-52	12
1410	Effect of Valsartan on hospitalization: results from Val-HeFT. 2003 , 9, 164-71	47
1409	Prescription patterns of diuretics in chronic heart failure: a contemporary background as a clue to their role in treatment. 2003 , 9, 210-8	23
1408	Heart failure in diabetic patients: utility of beta-blockade. 2003 , 9, 333-44	19
1407	Late breaking heart failure trials from the 2003 ACC meeting: EPHESUS and COMPANION. 2003 , 9, 158-63	12
1406	Cardiac contractility modulation with nonexcitatory electric signals improves left ventricular function in dogs with chronic heart failure. 2003 , 9, 69-75	45
1405	The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. 2003 , 24, 464-74	501
1404	Aldosterone receptor antagonists: biology and novel therapeutical applications. 2003 , 26, 788-98	4
1403	The emerging role of pharmacogenomics in the treatment of patients with heart failure. 2003 , 76, S2246-53	4
1402	Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. 2003 , 146, 250-7	232
1401	Heart failure and the elderly: disease diversity, data, and delivery of care. 2003 , 146, 194-6	7
1400	Session. 2003 , 146, 25-26	
1399	Session. 2003 , 146, 26	1
1398	Decompensated heart failure: symptoms, patterns of onset, and contributing factors. 2003 , 114, 625-30	176
1397	The effects of cognitive impairment on mortality among hospitalized patients with heart failure. 2003 , 115, 97-103	262

1396	Update on therapy for heart failure. 2003 , 115, 480-8	16
1395	Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States. 2003 , 115, 467-72	55
1394	Blockade of the renin-angiotensin system in African Americans with hypertension and cardiovascular disease. 2003 , 5, 12-7	12
1393	ACE inhibitors reduce all-cause mortality in people with asymptomatic or symptomatic left ventricular dysfunction. 2003 , 7, 186-188	
1392	Magnesium and heart failure. 2003 , 24, 79-105	10
1391	Essential hypertension. 2003 , 361, 1629-41	347
1390	Demographics and concomitant disorders in heart failure. 2003 , 362, 147-58	118
1389	Patient selection for left ventricular assist device therapy. 2003 , 75, S29-35	90
1388	The role of coronary revascularization in the treatment of ischemic cardiomyopathy. 2003 , 75, S2-5	11
1387	[Cell therapy to treat heart failure]. 2003 , 24, 401-4	
1386	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. 2003 , 362, 759-66	1506
1385	The CHARM programme. 2003 , 362, 1676; author reply 1678-9	
1384	The CHARM programme. 2003 , 362, 1678-1679	3
1383	Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. 2003 , 25, 2388-404	62
1382	The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist. 2003 , 25, 2647-68	21
1381	New technologies and potential cost savings related to morbidity and mortality reduction in Class III/IV heart failure patients in Canada. 2003 , 88, 33-41	25
1380	Cilazapril treatment in a cohort of seven patients with congestive heart failure: a seven-year follow-up study. 2003 , 64, 167-75	
1379	Beta-blockers and reverse remodeling: what are the implications?. 2003 , 145, 200-2	15

- 1378 Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure. **2003**, 145, E14 18
- 1377 Hypertonic saline: a novel therapy for advanced heart failure?. **2003**, 145, 377-9 23
- 1376 Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. **2003**, 107, 1284-90 176
- 1375 Timing of cardiac transplantation in patients with heart failure receiving beta-adrenergic blockers. **2003**, 22, 1141-8 61
- 1374 Primary aldosteronism - treatment options. **2003**, 13 Suppl A, S102-8 22
- 1373 Aldosterone-induced cardiac damage: focus on blood pressure independent effects. **2003**, 16, 80-6 76
- 1372 Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. **2003**, 16, 781-8 85
- 1371 Efficacy of low-dose spironolactone in subjects with resistant hypertension. **2003**, 16, 925-30 383
- 1370 The clinical diagnosis of heart failure is predicted by neurohormonal and immune derangement. **2003**, 18, 207-211
- 1369 Aldosterone regulation of T-type calcium channels. **2003**, 85, 383-8 40
- 1368 Diuretic therapy in chronic heart failure: Implications for heart failure nurse specialists. **2003**, 16, 59-69 4
- 1367 Primary aldosteronism: from genesis to genetics. **2003**, 14, 310-7 44
- 1366 Tratamiento de la hipertensión arterial. **2003**, 120, 108-116
- 1365 Oportunidades clínicas del bloqueo aldosterónico en la hipertensión arterial. **2003**, 20, 335-339
- 1364 Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. **2003**, 88, 2489-94 86
- 1363 Pharmacogenomics of diuretic drugs: data on rare monogenic disorders and on polymorphisms and requirements for further research. **2003**, 4, 701-34 19
- 1362 Tratamiento farmacológico de la insuficiencia cardíaca. **2003**, 8, 6345-6356
- 1361 Specialist Nurse-Led Intervention in Outpatients with Congestive Heart Failure. **2003**, 11, 693-698 11

1360	Can antiarrhythmic drugs save lives in patients with congestive heart failure?. 2003 , 1, 191-202	0
1359	New developments in the pharmacological treatment of chronic heart failure. 2003 , 12, 751-7	8
1358	Oral contraceptives, CRP levels and cardiovascular risk. 2003 , 1, 5-6	
1357	Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. 2003 , 3, 389-94	48
1356	Potential beneficial as well as detrimental effects of chronic treatment with lisinopril and (or) spironolactone on isolated hearts following low-flow ischemia in normal and infarcted rats. 2003 , 81, 864-72	5
1355	Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 2003 , 42, 1206-52	10207
1354	Pharmacokinetics and metabolism of [¹⁴ C]eplerenone after oral administration to humans. 2003 , 31, 1448-55	66
1353	Selective aldosterone blockade with eplerenone in patients with congestive heart failure. 2003 , 12, 1423-7	5
1352	Aldosterone in chronic kidney and cardiac disease. 2003 , 14, 2395-401	106
1351	Potential of renin inhibition in cardiovascular disease. 2003 , 4, 6-10	57
1350	Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. 2003 , 93, 69-76	223
1349	Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. 2003 , 289, 730-40	523
1348	Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone. 2003 , 93, 1258-66	105
1347	Drug-drug interactions among elderly patients hospitalized for drug toxicity. 2003 , 289, 1652-8	480
1346	Interaction of beta-blockers and angiotensin receptor blockers/ACE inhibitors in heart failure. 2003 , 4, 137-9	5
1345	Drug therapy and heart failure prevention. 2003 , 107, 1234-6	15
1344	Gender differences in patients with heart failure. 2003 , 2, 7-18	108
1343	Combination of drugs acting on the natriuretic system and the renin-angiotensin system in heart failure. 2003 , 4, 140-8	2

1342	Aldosterone increases NHE-1 expression and induces NHE-1-dependent hypertrophy in neonatal rat ventricular myocytes. 2003 , 42, 1171-6	95
1341	Gender specific association of aldosterone synthase gene polymorphism with renal survival in patients with IgA nephropathy. 2003 , 40, 372-6	10
1340	Effectiveness of aldosterone blockade in patients with diabetic nephropathy. 2003 , 41, 64-8	369
1339	The Endocrine Society Meeting: topics in insulin sensitivity and hypertension. 2003 , 26, 2679-88	2
1338	Toward a broader understanding of aldosterone in congestive heart failure. 2003 , 4, 155-63	16
1337	Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. 2003 , 4, 164-8	43
1336	Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12 220 index admissions in Leicestershire 1993-2001. 2003 , 89, 615-20	104
1335	Mechanisms and management of diuretic resistance in congestive heart failure. 2003 , 79, 268-71	60
1334	Acid-base and electrolyte abnormalities observed in patients receiving cardiovascular drugs. 2003 , 8, 267-76	6
1333	Drug Treatment of Congestive Heart Failure. 2003 , 7, 13-17	1
1332	Single- and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats. 2003 , 33, 305-21	22
1331	The costs and outcomes of multifaceted interventions designed to improve the care of congestive heart failure in the inpatient setting: a review of the literature. 2003 , 60, 275-93	19
1330	Prevalence of impaired left ventricular systolic function and heart failure in a middle aged and elderly urban population segment of Copenhagen. 2003 , 89, 1422-9	35
1329	Aldosterone blockade in patients with acute myocardial infarction. 2003 , 107, 2525-7	11
1328	Angiotensin receptor blockers in heart failure. 2003 , 4, 171-5	4
1327	Determinants of spironolactone binding specificity in the mineralocorticoid receptor. 2003 , 31, 573-82	28
1326	Vasopressin receptor antagonists. Therapeutic potential in the management of acute and chronic heart failure. 2003 , 3, 13-20	11
1325	Aldosterone blockade in patients with systolic left ventricular dysfunction. 2003 , 108, 1790-4	43

1324	Demographics, treatment regimens and the use of angiotensin-receptor blockers in heart failure: findings from the Valsartan Heart Failure Trial. 2003 , 31, 351-61	2
1323	Drug therapy of heart failure in the elderly. 2003 , 12, 235-42	9
1322	Working heart function in diabetes is not improved by spironolactone treatment. 2003 , 81, 493-6	5
1321	A randomized trial of telenursing to reduce hospitalization for heart failure: patient-centered outcomes and nursing indicators. 2003 , 22, 1-20	80
1320	Drug development and the heart hospital. 2003 , 1, 188-91	
1319	Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. 2003 , 107, 2559-65	248
1318	Are implantable cardioverter-defibrillators always superior to amiodarone?. 2003 , 4, 2111-4	
1317	Corticosteroid receptors, 11 beta-hydroxysteroid dehydrogenase, and the heart. 2003 , 66, 77-112	20
1316	Should the aldosterone-receptor antagonist - eplerenone - be used after acute myocardial infarction with left ventricular dysfunction?. 2003 , 4, 1605-7	
1315	Plasma amino-terminal B-type natriuretic peptide measured by Elecsys 2010 assay in a trial of hormone-guided treatment for heart failure. 2003 , 49, 1212-5	13
1314	Effect of home-based intervention on hospital readmission and quality of life in middle-aged patients with severe congestive heart failure: a 12-month follow up study. 2003 , 2, 105-11	27
1313	NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. 2003 , 89, 150-4	137
1312	Survival advantage with cardiovascular drugs: are they real?. 2003 , 8, 249-51	
1311	Serum magnesium aberrations in furosemide (frusemide) treated patients with congestive heart failure: pathophysiological correlates and prognostic evaluation. 2003 , 89, 411-6	36
1310	Maternal glucocorticoid supplementation and S100B protein concentrations in cord blood and urine of preterm infants. 2003 , 49, 1215-8	28
1309	Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. 2003 , 93, e124-35	92
1308	Subclavian artery stenosis as a cause for recurrent angina after LIMA graft stenting. 2003 , 89, 1429	10
1307	50th anniversary of aldosterone. 2003 , 88, 2364-72	120

1306	Left ventricular assist devices: bridges to transplantation, recovery, and destination for whom?. 2003 , 108, 3059-63	88
1305	Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. 2003 , 108, 2517-23	85
1304	Aldosterone stimulates epidermal growth factor receptor expression. 2003 , 278, 43060-6	84
1303	A prognostic index to predict long-term mortality in patients with mild to moderate chronic heart failure stabilised on angiotensin converting enzyme inhibitors. 2003 , 5, 489-97	48
1302	Drug therapy in chronic heart failure. 2003 , 79, 634-42	11
1301	The diagnosis of heart failure in general practice: implications for the UK National Service Framework. 2003 , 5, 349-54	20
1300	Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. 2003 , 5, 261-70	98
1299	Congenital heart disease: the original heart failure syndrome. 2003 , 24, 970-6	84
1298	Update of clinical trials from the American College of Cardiology 2003. EPHEUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans. 2003 , 5, 391-8	21
1297	Difficulties of introducing the National Service Framework for heart failure into general practice in the UK. 2003 , 5, 355-61	10
1296	Patterns of pharmacotherapy in patients hospitalised for congestive heart failure. 2003 , 5, 195-200	21
1295	Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. 2003 , 5, 669-77	53
1294	Differences between general practitioners and cardiologists in diagnosis and management of heart failure: a survey in every-day practice. 2003 , 5, 337-44	102
1293	Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels. 2003 , 107, 889-95	64
1292	Management of chronic heart failure due to systolic left ventricular dysfunction by cardiologist and non-cardiologist physicians. 2003 , 5, 549-55	31
1291	Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone. 2003 , 18, 1814-9	48
1290	Portable Echocardiography: An Innovative Tool in Screening for Cardiac Abnormalities in the Community. 2003 , 4, 119-127	30
1289	Clinical use of diuretics. 2003 , 3, 517-20	3

1288	Expression and modulation of steroidogenic acute regulatory protein messenger ribonucleic acid in rat cardiocytes and after myocardial infarction. 2003 , 144, 1861-8	27
1287	Estrogen regulates adrenal angiotensin type 1 receptors by modulating adrenal angiotensin levels. 2003 , 144, 1350-6	26
1286	Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. 2003 , 18, 1984-92	39
1285	Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. 2003 , 327, 147-9	77
1284	Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. 2003 , 327, 1141-2	53
1283	Nongenomic steroid action: controversies, questions, and answers. 2003 , 83, 965-1016	461
1282	The role of angiotensin II receptor blockers in the treatment of heart failure patients. 2003 , 9, 29-34	5
1281	Is spironolactone safe for dialysis patients?. 2003 , 18, 2364-8	35
1280	Living and dying with congestive heart failure: addressing the needs of older congestive heart failure patients. 2003 , 32, 566-8	27
1279	Diuretika sind ein muss!. 2003 , 32, 82-89	
1278	[Primary prevention of sudden cardiac death]. 2003 , 128, 2547-52	0
1277	Eplerenone: cardiovascular protection. 2003 , 107, 2512-8	118
1276	Cardiovascular endocrinology 1: aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease. 2003 , 88, 516-23	54
1275	Aldosterone resurgens--letter from EPHESUS. 2003 , 88, 2373-5	4
1274	Eplerenone in patients with left ventricular dysfunction. <i>New England Journal of Medicine</i> , 2003 , 349, 88-9; author reply 88-9	59.2 6
1273	Aldosterone blockade and heart failure. <i>New England Journal of Medicine</i> , 2003 , 348, 1380-2	59.2 29
1272	Minireview: primary aldosteronism--changing concepts in diagnosis and treatment. 2003 , 144, 2208-13	293
1271	Different inactivating mutations of the mineralocorticoid receptor in fourteen families affected by type I pseudohypoaldosteronism. 2003 , 88, 2508-17	72

1270	Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1. 2003 , 88, 3867-73	31
1269	Aldosterone inhibits inducible nitric oxide synthase in neonatal rat cardiomyocytes. 2003 , 144, 1712-7	43
1268	Aldosterone: direct effects on and production by the heart. 2003 , 88, 2376-83	70
1267	Pacing in heart failure: patient and pacing mode selection. 2003 , 24, 977-86	7
1266	Neurohormonal inhibition in heart failure, is there no limit?. 2003 , 24, 1705-6	1
1265	Lack of clinically significant interference by spironolactone with the AxSym Digoxin II assay. 2003 , 25, 112-3	10
1264	Combined effects of enalapril and spironolactone in hamsters with dilated cardiomyopathy. 2003 , 41, 49-59	12
1263	The pharmacological management of heart failure: too many treatments?. 2003 , 5, 5-8	5
1262	Combined effects of low-dose oral spironolactone and captopril therapy in a rat model of spontaneous hypertension and heart failure. 2003 , 41, 830-7	31
1261	Sudden cardiac death: implantable cardioverter defibrillators and pharmacological treatments. 2003 , 26, 45-9	3
1260	Role for aldosterone in cardiovascular injury. 2003 , 10, 191-196	
1259	2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. 2003 , 21, 1011-53	2526
1258	High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. 2003 , 21, 2149-57	191
1257	Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. 2003 , 41, 955-63	110
1256	Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). 2003 , 42, 719-26	35
1255	Aldo is back: recent advances and unresolved controversies in hyperaldosteronism. 2003 , 12, 153-8	12
1254	Aldosterone in renal disease. 2003 , 12, 159-64	30
1253	Activating and inactivating mutations of the human mineralocorticoid receptor. 2003 , 10, 186-190	

1252	An evidence-based national quality measurement and reporting system. 2003 , 41, 18-15	18
1251	Aldactone therapy in a peritoneal dialysis patient. 2003 , 18, 1232; author reply 1232-3	3
1250	Reply. 2003 , 18, 1232-1233	4
1249	Safety of low-dose spironolactone administration in chronic haemodialysis patients. 2003 , 18, 2359-63	53
1248	Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. 2003 , 17 Suppl 1, S96-122	25
1247	2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. 2003 , 21, 1983-92	1808
1246	Revascularization and ventricular restoration in patients with ischemic heart failure: the STICH trial. 2003 , 18, 454-7	31
1245	Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine. 2003 , 42 Suppl 1, S71-4	16
1244	Value of N-Terminal proBNP in the Diagnosis of Left Ventricular Systolic Dysfunction in Primary Care Patients Referred for Echocardiography. 2003 , 3, 141-146	19
1243	Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra). 2003 , 5, 102-18	29
1242	Skeletal Mineralization: Understood as the Integration of Proximate and Ultimate Causation. 2003 , 13, 381-393	
1241	Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure in elderly patients. 2003 , 5, 279-94	21
1240	Cardiac resynchronization therapy: overcoming ventricular dyssynchrony in dilated heart failure. 2003 , 11, 221-39	9
1239	Aldosterone: its receptor, target genes, and actions. 2003 , 66, 29-76	62
1238	Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling. 2003 , 284, H176-84	124
1237	Pathogenesis of hypertension. 2003 , 139, 761-76	381
1236	Neurohormonal effects of furosemide withdrawal in elderly heart failure patients with normal systolic function. 2003 , 5, 47-53	25
1235	The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. 2003 , 326, 15-24	191

1234	Pharmacotherapy for heart failure in patients with renal insufficiency. 2003 , 138, 917-24	112
1233	References. 601-868	
1232	Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure. 2003 , 5, 354-63	24
1231	Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. 2003 , 67, 384-90	49
1230	Studies on the interactions between drug and estrogen. II. On the inhibitory effect of 29 drugs reported to induce gynecomastia on the oxidation of estradiol at C-2 or C-17. 2003 , 26, 695-700	29
1229	Evaluation and management of a patient with congestive heart failure. 2003 , 124, 728-31	3
1228	Update on therapy for acute and chronic heart failure. Applying advances in outpatient management. 2003 , 113, 36-8, 41-4, 47-8	
1227	. 2003 ,	
1226	Variabilität der Mechanismen und des arrhythmogenen Substrats von Herzrhythmusstörungen. 2003 ,	
1225	Effects of spironolactone and metoprolol on QT dispersion in heart failure. 2003 , 44, 681-92	23
1224	Why Cardiovascular Endocrinology?. 2003 , 144, 2178-2178-ii	
1223	New pacing technologies for heart failure. 2003 , 326, 1073-7	15
1222	Heart Failure Guidelines and Disease Management. 21-38	
1221	ProBNP for stratifying patients with heart failure. 2003 , 81, 239-8	2
1220	Cardiovascular Disease. 2003 , 509-543	3
1219	Treatment options for acute decompensated heart failure. 2003 , 60 Suppl 4, S7-15	11
1218	Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition. 2003 , 89, 1024-1030	49
1217	Heart failure and the brain: new perspectives. 2003 , 284, R259-76	104

1216	Central mineralocorticoid receptor blockade decreases plasma TNF-alpha after coronary artery ligation in rats. 2003 , 284, R328-35	51
1215	Carvedilol and metoprolol European trial: do the results merit challenge?. 2004 , 61, 1289-93	
1214	Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. 2004 , 27, 303-10	76
1213	Integrating traditional and emerging treatment options in heart failure. 2004 , 61 Suppl 2, S14-22	8
1212	Development of educational materials for congestive-heart-failure patients. 2004 , 61, 386-9	3
1211	Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist. 2004 , 27, 781-9	39
1210	Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure. 2004 , 61 Suppl 2, S4-13	36
1209	[Heart failure: preventing rehospitalizations by disease management programs]. 2004 , 62, 86-96	
1208	Role of aldosterone blockade in managing heart failure: new and emerging treatment options. Introduction. 2004 , 61 Suppl 2, S2-3	
1207	The Role of Aldosterone Antagonists in Systolic Heart Failure. 2004 , 39, 944-953	
1206	What is Heart Failure and What are the Treatment Options? Complex Questions. 1-38	1
1205	Misprogram a PCA Pump? It's Easier than you Think: Ratio Expression for Epinephrine Injection Again Leads to Error: Tetanus Toxoid Vaccines Used for PPD: Current Nonproprietary Drug Names under Consideration by United States Adopted Names Council. 2004 , 39, 932-953	2
1204	. 2004 ,	5
1203	[Cardiac failure in Chilean hospitals: results of the National Registry of Heart Failure, ICARO]. 2004 , 132, 655-62	8
1202	The syndromes of low-renin hypertension: "separating the wheat from the chaff". 2004 , 48, 674-81	11
1201	ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. 2004 , 110,	59
1200	Drug-drug interactions: where do we go from here?. 2004 , 44, 128, 131-2, 134	6
1199	Update in cardiology. 2004 , 141, 628-34	

1198	Aldosterone upregulates connective tissue growth factor gene expression via p38 MAPK pathway and mineralocorticoid receptor in ventricular myocytes. 2004 , 19, 805-11	26
1197	Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy-1 irreversible nephritis. 2004 , 27, 971-8	25
1196	Facts and principles learned at the 31st Annual Williamsburg Conference on Heart Disease. 2004 , 17, 106-15	
1195	Pediatric Hypertension. 2004 ,	1
1194	Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. 2004 , 25, 1920-6	37
1193	Novel antihypertensive agents. 2004 , 13, 987-98	
1192	Elevated resting and exercise-induced cortisol levels after mineralocorticoid receptor blockade with canrenoate in healthy humans. 2004 , 89, 5048-52	41
1191	Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data. 2004 , 34, 215-28	36
1190	Role of aldosterone blockade in the management of hypertension and cardiovascular disease. 2004 , 143, 90-104	3
1189	Handbook of Clinical Nutrition and Aging. 2004 ,	4
1188	Eplerenone in hypertension. 2004 , 5, 2573-81	7
1187	Direct and indirect effects of aldosterone on cyclooxygenase-2 and interleukin-6 expression in rat cardiac cells in culture and after myocardial infarction. 2004 , 145, 3135-42	24
1186	Drug development and the importance of ethnicity: lessons from heart failure management and implications for hypertension. 2004 , 10, 3569-77	3
1185	Aldosterone revisited. <i>New England Journal of Medicine</i> , 2004 , 351, 2131-3; author reply 2131-3	59.2 1
1184	Hyperkalemia after the publication of RALES. <i>New England Journal of Medicine</i> , 2004 , 351, 2448-50; author reply 2448-50	59.2 10
1183	Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. <i>New England Journal of Medicine</i> , 2004 , 350, 2151-8	59.2 1488
1182	Treatment of heart failure with spironolactone--trial and tribulations. <i>New England Journal of Medicine</i> , 2004 , 351, 526-8	59.2 57
1181	[Old and new drugs to block aldosterone and ameliorate cardiovascular disease]. 2004 , 129, 2491-6	0

1180	Origin of aldosterone in the rat heart. 2004 , 145, 4796-802	114
1179	Hypertensive therapy: Part II. 2004 , 109, 3081-8	28
1178	Cardiac synthesis of aldosterone: going, going, gone...?. 2004 , 145, 4793-5	32
1177	Pharmacological modulations of the renin-angiotensin-aldosterone system in human congestive heart failure: effects on peripheral vascular endothelial function. 2004 , 2, 65-70	2
1176	Association of -344/T/C aldosterone synthase polymorphism (CYP11B2) with left ventricular structure and humoral parameters in young normotensive men. 2004 , 13, 158-63	11
1175	Mode of death from congestive heart failure: implications for clinical management. 2004 , 13, 299-304; quiz 305-6	18
1174	Impact of appropriate pharmaceutical therapy for chronic conditions on direct medical costs and workplace productivity: a review of the literature. 2004 , 7, 61-75	18
1173	References. 2004 , 355-397	
1172	Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. 2004 , 43, 352-7	83
1171	Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. 2004 , 109, 1680-5	94
1170	Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. 2004 , 110, 2180-3	203
1169	Role of the selective aldosterone receptor blockers in arterial hypertension. 2004 , 5, 23-5	4
1168	Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. 2004 , 109, 2492-9	165
1167	Aldosterone blockade in heart failure. 2004 , 5 Suppl 1, S23-7	7
1166	Will changes in primary care improve health outcomes? Modelling the impact of financial incentives introduced to improve quality of care in the UK. 2004 , 13, 191-7	39
1165	Review of aldosterone- and angiotensin II-induced target organ damage and prevention. 2004 , 61, 663-70	194
1164	Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart. 2004 , 164, 1737-48	81
1163	Heart transplantation. 2004 , 19, 3-12	19

1162	What causes sudden death in heart failure?. 2004 , 95, 754-63	416
1161	Hypertension and the vascular patient. 2004 , 38, 103-19	3
1160	Treatment of acne vulgaris. 2004 , 292, 726-35	158
1159	Aldosterone and cardiovascular remodelling: focus on myocardial failure. 2004 , 5, 3-13	12
1158	Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?. 2004 , 110, 3281-8	58
1157	Digitalis therapy for patients in clinical heart failure. 2004 , 109, 2942-6	68
1156	Reassessing guidelines for heart failure. 2004 , 5 Suppl 1, S28-33	
1155	Glucocorticoid treatment and cardiovascular disease. 2004 , 90, 829-30	40
1154	Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. 2004 , 43, 957-62	115
1153	Current guidelines in the pharmacological management of chronic heart failure. 2004 , 5 Suppl 1, S11-6	2
1152	Adrenal aldosterone biosynthesis is elevated in a model of chronic renal failure--role of local adrenal renin-angiotensin system. 2004 , 97, p37-44	11
1151	Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. 2004 , 109, 2857-61	153
1150	ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). 2004 , 110, 588-636	1550
1149	Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. 2004 , 43, 841-8	241
1148	Primary aldosteronism: Diagnosis and differential diagnosis / Primärer Hyperaldosteronismus: Diagnose und Differentialdiagnose. 2004 , 28, 135-143	
1147	Aortic valve endocarditis causing fatal myocardial infarction caused by ostial coronary artery obliteration. 2004 , 90, 303	5
1146	The complex world of prescribing behavior. 2004 , 291, 104-6	18
1145	Use of angiotensin-converting enzyme inhibitors in elderly people with heart failure: prevalence and outcomes. 2004 , 59, 716-21	9

1144	Pathophysiology of hypertensive renal damage: implications for therapy. 2004 , 44, 595-601	243
1143	Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. 2004 , 90, 765-70	111
1142	Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. 2004 , 42, 627-36	79
1141	Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. 2004 , 90, 297-303	160
1140	Valsartan. 2004 , 2, 67-101	
1139	Treatment of the patient with diabetes mellitus and risk of nephropathy: what do we know, and what do we need to learn?. 2004 , 164, 125-30	13
1138	Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model. 2004 , 24, 242-9	61
1137	Effects of eplerenone on heart and kidney in two-kidney, one-clip rats. 2004 , 24, 54-60	26
1136	Age and quality of in-hospital care of patients with heart failure. 2004 , 14, 123-7	7
1135	Diagnosis and management of chronic heart failure: how to reestablish a key role for the primary care physician?. 2004 , 59, 300-3	
1134	Current implementation of proven therapy in heart failure. 2004 , 6, h43-h48	1
1133	Tranilast and hypertensive heart disease: further insights into mechanisms of an anti-inflammatory and anti-fibrotic drug. 2004 , 22, 883-6	12
1132	Heart failure clinics and outpatient management: review of the evidence and call for quality assurance. 2004 , 25, 1596-604	70
1131	The role of exercise training in patients with chronic heart failure. 2004 , 13, 452-6	2
1130	Candesartan prevents myocardial fibrosis during progression of congestive heart failure. 2004 , 43, 860-7	5
1129	The many targets of aldosterone. 2004 , 43, 938-40	16
1128	Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure). 2004 , 110, 975-81	168
1127	Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. 2004 , 109, 2792-800	193

1126	Is the female heart more sensitive to aldosterone for early remodeling?. 2004 , 43, 936-7	10
1125	Angiotensin inhibition in heart failure. 2004 , 5 Suppl 1, S17-22	12
1124	Endothelin expression and the progression of heart failure: exemplifying the vagaries of therapeutic development. 2004 , 109, 143-5	13
1123	Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. 2004 , 109, 120-4	454
1122	Candesartan for the treatment of hypertension and heart failure. 2004 , 5, 1589-97	11
1121	Advanced heart failure: a practical management algorithm and therapeutic options. 2004 , 2, 142-8	1
1120	Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. 2004 , 110, 2618-26	282
1119	The clinical implications of aldosterone escape in congestive heart failure. 2004 , 6, 539-45	81
1118	Heart failure--the importance of ethnicity. 2004 , 6, 831-43	19
1117	Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. 2004 , 109, 1284-91	198
1116	Midterm benefits of left univentricular pacing in patients with congestive heart failure. 2004 , 109, 1741-4	89
1115	Hypertension and heart failure: role of neurohormonal mechanisms. 2004 , 26, 603-10	7
1114	Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats. 2004 , 64, 437-47	36
1113	Specialist care of heart failure improves appropriate pharmacotherapy at the expense of greater polypharmacy and drug-interactions. 2004 , 6, 235-43	29
1112	Aldosterone blockade in cardiovascular disease. 2004 , 90, 1229-34	36
1111	Combined angiotensin receptor blocker and ACE inhibitor on myocardial fibrosis and left ventricular stiffness in dogs with heart failure. 2004 , 287, H2487-92	18
1110	Austrian survey of treating heart failure--AUSTRIA. 2004 , 6, 947-52	5
1109	Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. 2004 , 110, 1819-25	92

1108	The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. 2004 , 25, 292-9	262
1107	Treatment of coronary heart disease with folic acid: is there a future?. 2004 , 287, H1-7	24
1106	NT-proBNP and BNP: biomarkers for heart failure management. 2004 , 6, 359-63	55
1105	Chronic hyperaldosteronism in a transgenic mouse model fails to induce cardiac remodeling and fibrosis under a normal-salt diet. 2004 , 286, F1178-84	44
1104	Aldosterone directly induces myocyte apoptosis through calcineurin-dependent pathways. 2004 , 110, 317-23	84
1103	Pharmacogenomics of heart failure -- focus on drug disposition and action. 2004 , 64, 32-9	17
1102	Diabetic renal disease: from recent studies to improved clinical practice. 2004 , 21, 4-17	35
1101	The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. 2004 , 21, 471-5	116
1100	Understanding the aging cardiovascular system. 2004 , 4, S298-S303	5
1099	Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor. 2004 , 31, 704-9	36
1098	Spironolactone use in patients with heart failure. 2004 , 29, 165-70	3
1097	Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message. 2004 , 58, 554-7	24
1096	Aldosterone antagonism in heart failure: improvement of cardiac remodelling, endothelial dysfunction and platelet activation. 2004 , 34, 649-52	11
1095	Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients. 2004 , 66, 1647-53	19
1094	Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. 2004 , 82, 661-87	329
1093	Metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure. 2004 , 17, 455-65	122
1092	Pharmacogenomics and heart failure: tailor-made therapy?. 2004 , 10, 273, 288	1
1091	Pharmacotherapy in congestive heart failure: aldosterone receptor antagonism: interface with hyperkalemia in heart failure. 2004 , 10, 259-64	20

1090	Statin Therapy Is Associated With Improved Survival in Ischemic and Non-Ischemic Heart Failure. 2004 , 10, 313-315	
1089	BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. 2004 , 10, 1-30	230
1088	Right ventricular function: a stepchild in the management of congestive heart failure. 2004 , 10, 152-3	
1087	Is it important to examine gender differences in the epidemiology and outcome of severe heart failure?. 2004 , 127, 1247-52	47
1086	Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. 2004 , 102, 223-41	117
1085	References. 2004 , 43, 268-290	
1084	Assessing the impact of heart failure specialist services on patient populations. 2004 , 4, 10	3
1083	Audit of therapeutic interventions in inpatient children using two scores: are they evidence-based in developing countries?. 2004 , 4, 40	3
1082	Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure. 2004 , 24, 750-6	15
1081	Anemia management in heart failure: a thick review of thin data. 2004 , 24, 757-67	7
1080	Quality of heart failure care in managed Medicare and Medicaid patients in North Carolina. 2004 , 93, 714-8	14
1079	Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy. 2004 , 93, 1564-6	40
1078	Usefulness of spironolactone in a specialized heart failure clinic. 2004 , 94, 443-7	26
1077	Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). 2004 , 94, 595-601	96
1076	Importance of in-hospital initiation of evidence-based medical therapies for heart failure-a review. 2004 , 94, 1155-60	41
1075	Comparative effects of ventricular resynchronization therapy in heart failure patients with or without coronary artery disease. 2004 , 53, 171-6	3
1074	A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET). 2004 , 18, 139-52	9
1073	Increasing awareness and perception of heart failure in Europe and improving care--rationale and design of the SHAPE Study. 2004 , 18, 153-9	13

1072	RAAS inhibitors in the cardiovascular continuum: what is still missing?. 2004 , 18, 311-20	2
1071	Sex-related differences in heart failure and beta-blockers. 2004 , 9, 149-59	9
1070	Cardiac resynchronization therapy in patients with heart failure and conduction abnormalities other than left bundle-branch block: analysis of the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). 2004 , 27, 678-82	48
1069	Distinction between Liddle syndrome and apparent mineralocorticoid excess. 2004 , 19, 118-9	4
1068	Therapie der Herzinsuffizienz. 2004 , 41, 451-464	3
1067	Medikamentöse Therapie der Herzinsuffizienz. 2004 , 15, i74-i80	
1066	New pharmacological strategies in chronic heart failure. 2004 , 18, 491-501	4
1065	Cardioprotective action of perindopril versus candesartan in renovascular hypertensive rats. 2004 , 18, 353-62	20
1064	[Significance of aldosterone antagonist therapy]. 2004 , 45, 347-54	3
1063	[Modern differential therapy with diuretics]. 2004 , 45, 598-605	4
1062	[Heart insufficiency: therapy with selective aldosterone antagonists. EPHEsus study]. 2004 , 45, 476-7; discussion 477-8	
1061	Renal function in relation to three candidate genes in a Chinese population. 2004 , 82, 715-22	5
1060	Medikamentöse Therapie der Herzinsuffizienz im Kindesalter. 2004 , 152, 659-665	
1059	Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. 2004 , 47, 1687-94	89
1058	Structure and function of coagulogen, a clottable protein in horseshoe crabs. 2004 , 61, 1257-65	47
1057	[Potassium in renal disease]. 2004 , 99, 355-61	1
1056	[The patient with edema of the legs]. 2004 , 99, 383-9; quiz 390	
1055	Is too much neurohormonal blockade harmful?. 2004 , 6, 169-75	4

1054	Is heart failure different on the two continents (North America and Europe)?. 2004 , 6, 182-8	1
1053	Evolving concepts in left ventricular systolic and diastolic remodeling: implications for therapy. 2004 , 6, 200-4	1
1052	Primary prevention of sudden cardiac death. 2004 , 6, 339-47	2
1051	Current concepts for the neurohormonal management of left ventricular dysfunction after myocardial infarction. 2004 , 1, 161-7	1
1050	Aldosterone in heart failure: pathophysiology and treatment. 2004 , 1, 171-5	13
1049	Anemia and heart failure. 2004 , 1, 176-82	26
1048	Pharmacologic effects on cardiac remodeling. 2004 , 1, 9-13	5
1047	The changing epidemiology of sudden death in heart failure. 2004 , 1, 93-7	9
1046	Current role of device therapy to reduce sudden cardiac death in heart failure. 2004 , 1, 104-10	1
1045	Cardiorenal syndrome in decompensated heart failure: prognostic and therapeutic implications. 2004 , 1, 113-20	24
1044	Interactions between the sympathetic nervous system and the RAAS in heart failure. 2004 , 1, 45-50	60
1043	Efficacy of aldosterone receptor antagonism in heart failure: potential mechanisms. 2004 , 1, 51-6	3
1042	Inhibition of RAAS--when is it too much?. 2004 , 1, 57-64	0
1041	Beta-blockers in heart failure: is more better?. 2004 , 1, 77-81	
1040	Primary aldosteronism: a needle in a haystack or a yellow cab on Fifth Avenue?. 2004 , 6, 1-4	33
1039	Mineralocorticoid receptor antagonists and hypertension: is there a rationale?. 2004 , 6, 279-87	11
1038	The use of selective aldosterone antagonists. 2004 , 6, 342-5	5
1037	Diastolic heart failure: the forgotten manifestation of hypertensive heart disease. 2004 , 6, 164-70	7

1036	Clinical trials report. 2004 , 6, 211-214	7
1035	Adrenocortical hypertension. 2004 , 6, 224-9	4
1034	Hypertensive renal damage: insights from animal models and clinical relevance. 2004 , 6, 145-53	38
1033	Peripartum Cardiomyopathy: Current Therapeutic Perspectives. 2004 , 6, 481-488	20
1032	Neurohormonal Therapy for Congestive Heart Failure. 2004 , 6, 499-507	1
1031	Treatment of Arrhythmias in Patients with Congestive Heart Failure. 2004 , 6, 519-529	0
1030	Antiarrhythmic Drugs. 2004 , 6, 357-364	12
1029	Management of Chronic Congestive Heart Failure in Children. 2004 , 6, 407-416	3
1028	Prevention and Reversal of LV Remodeling with Neurohormonal Inhibitors. 2004 , 6, 313-325	5
1027	Aldosterone Receptor Blockers in the Treatment of Heart Failure. 2004 , 6, 327-334	5
1026	Biventricular pacing and left ventricular pacing in heart failure: similar hemodynamic improvement despite marked electromechanical differences. 2004 , 15, 1342-7	45
1025	Should we be screening for myocardial hibernation in heart failure?. 2004 , 11, 114-7	3
1024	Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells. 2004 , 91, 87-91	43
1023	Drug interactions in primary care: impact of a new algorithm on risk determination. 2004 , 76, 85-96	49
1022	Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. <i>New England Journal of Medicine</i> , 2004 , 351, 585-92	59.2 402
1021	Hyperkalaemia: again. 2004 , 19, 2163-6	8
1020	Evidence-Based Indications in Hypertensive Patients. 2004 , 11, 1-7	2
1019	Angiotensin Receptor Blockers and Target-Organ Protection Beyond Blood Pressure Control. 2004 , 11, 65-73	4

1018	Carnitine palmitoyltransferase-I, a new target for the treatment of heart failure: perspectives on a shift in myocardial metabolism as a therapeutic intervention. 2004 , 4, 201-9	14
1017	Angiotensin antagonism in patients with heart failure: ACE inhibitors, angiotensin receptor antagonists or both?. 2004 , 4, 345-53	6
1016	Use of diuretics in cardiovascular diseases: (1) heart failure. 2004 , 80, 201-5	12
1015	Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. 2004 , 89, 1045-50	745
1014	Mechanisms of hypertension: the expanding role of aldosterone. 2004 , 15, 1993-2001	86
1013	Medical therapy for sudden death. 2004 , 51, 1379-87	3
1012	Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction. 2004 , 172, 1590-4	51
1011	Reading tarot cards. 2004 , 84, 323-31, xii-xiii	
1010	Avances en el tratamiento de la insuficiencia cardíaca. 2004 , 123, 149-155	
1009	Impacto de los fármacos antihipertensivos sobre la enfermedad renal. 2004 , 21, 127-138	
1008	The prevention of heart failure in minority communities and discrepancies in health care delivery systems. 2004 , 88, 1347-68, xii-xiii	17
1007	Ischemic heart disease and congestive heart failure in diabetic patients. 2004 , 88, 1037-61, xi-xii	18
1006	Spironolactone and its main metabolite canrenoic acid, block human ether-a-go-go-related gene channels. 2004 , 16, 83-84	
1005	Coronary artery disease and prevention of heart failure. 2004 , 88, 1209-35	17
1004	Coronary revascularization in ischemic cardiomyopathy. 2004 , 84, 179-99, x	17
1003	Heart failure in women. 2004 , 88, 1321-45, xii	63
1002	Utilidad clínica de los marcadores neurohormonales en la insuficiencia cardíaca. 2004 , 57, 347-356	9
1001	Estudio europeo del tratamiento ambulatorio de la insuficiencia cardíaca realizado por cardiólogos. 2004 , 57, 1170-1178	4

1000	Antiarrhythmic drugs: past, present, and future. 2004 , 1, 57C-66C	0
999	Bases y evidencias clínicas de los efectos de los nuevos tratamientos farmacológicos en la insuficiencia cardíaca. 2004 , 57, 447-464	5
998	Hiperaldosteronismo primario. 2004 , 51, 295-302	0
997	Activación neurohormonal en la insuficiencia cardíaca congestiva: ¿se normaliza después del trasplante cardíaco?. 2004 , 57, 725-731	1
996	Clinical Use of Markers of Neurohormonal Activation in Heart Failure. 2004 , 57, 347-356	
995	Rationale and Clinical Evidence for the Effects of New Pharmacological Treatments for Heart Failure. 2004 , 57, 447-464	1
994	European Study of Ambulatory Management of Heart Failure by Cardiologists. 2004 , 57, 1170-1178	
993	Neurohormonal Activation in Congestive Heart Failure: Does it Normalize After Heart Transplantation?. 2004 , 57, 725-731	
992	Risk Stratification and Prevention of Sudden Death in Patients With Heart Failure. 2004 , 57, 768-782	
991	Effect of nolomirole on monocrotaline-induced heart failure. 2004 , 49, 1-5	8
990	Role of a selective aldosterone blocker in mice with chronic heart failure. 2004 , 10, 67-73	32
989	The role of G-protein-coupled receptors in heart failure. 2004 , 1, 37-43	1
988	Therapy interactions in chronic heart failure: synergies and asynergies of medication and device interventions. 2004 , 1, 135-141	
987	What is the optimal serum potassium level in cardiovascular patients?. 2004 , 43, 155-61	239
986	Association between aldosterone synthase (CYP11B2) polymorphism and left ventricular mass in human essential hypertension. 2004 , 43, 265-70	48
985	Intra-left ventricular electromechanical asynchrony. A new independent predictor of severe cardiac events in heart failure patients. 2004 , 43, 248-56	380
984	Selection of patients for heart transplantation in the current era of heart failure therapy. 2004 , 43, 787-93	75
983	Frequency and impact of delayed decisions regarding heart transplantation on long-term outcomes in patients with advanced heart failure. 2004 , 43, 794-802	11

982	Acute aldosterone antagonism improves cardiac vagal control in humans. 2004 , 43, 1270-5	14
981	Long-term retention of cardiac resynchronization therapy. 2004 , 44, 72-7	115
980	Generic drugs in cardiology: will they reduce health care costs?. 2004 , 44, 10-3	10
979	Furosemide and the progression of left ventricular dysfunction in experimental heart failure. 2004 , 44, 1301-7	119
978	Furosemide in the long-term management of heart failure: the good, the bad, and the uncertain. 2004 , 44, 1308-10	18
977	Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial. 2004 , 44, 1181-6	41
976	ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). 2004 , 44, E1-E211	830
975	Surgical ventricular restoration in the treatment of congestive heart failure due to post-infarction ventricular dilation. 2004 , 44, 1439-45	344
974	The diagnosis of heart failure in the community. Comparative validation of four sets of criteria in unselected older adults: the ICARE Dicomano Study. 2004 , 44, 1601-8	75
973	Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. 2004 , 10, 115-9	62
972	Searching for evidence: Refractory questions in advanced heart failure. 2004 , 10, 210-8	12
971	How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?. 2004 , 10, 297-303	95
970	Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. 2004 , 10, 155-64	55
969	2003: The year in heart failure. 2004 , 10, 1-3	
968	Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. 2004 , 10, 403-11	87
967	Key issues in trial design for ventricular assist devices: a position statement of the Heart Failure Society of America. 2004 , 10, 91-100	2
966	Eplerenone, a selective aldosterone blocker, improves diastolic function in aged rats with small-to-moderate myocardial infarction. 2004 , 10, 433-41	18
965	Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study. 2004 , 10, 490-5	60

964	New therapeutic strategies for heart failure: left ventricular remodeling as a target. 2004 , 10, S200-1	23
963	Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction. 2004 , 64, 2689-707	8
962	Digitalis for treatment of congestive heart failure in patients in sinus rhythm. 2004 , CD002901	15
961	Blood pressure-lowering drugs: essential therapy for some patients with normal blood pressure. 2004 , 2, 771-5	12
960	Cardiovascular Pharmacogenetics. 2004 ,	
959	Angiotensin Vol. II. 2004 ,	1
958	Estratificaci3n del riesgo y prevenci3n de la muerte s3bita en pacientes con insuficiencia card3aca. 2004 , 57, 768-782	5
957	Clinical practice. Diastolic heart failure. <i>New England Journal of Medicine</i> , 2004 , 351, 1097-105	59.2 412
956	Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. <i>New England Journal of Medicine</i> , 2004 , 351, 543-51	59.2 1275
955	Eplerenone in the treatment of chronic heart failure. 2004 , 2, 315-20	2
954	Recent advances in the secondary prevention of coronary heart disease. 2004 , 2, 877-89	5
953	Evaluation and management of breast pain. 2004 , 79, 353-72	117
952	Management of heart failure: crossing boundary over to the surgical country. 2004 , 84, 1-25	2
951	The potential role of ventricular compressive therapy. 2004 , 84, 45-59	11
950	Involvement of oxidative stress in the profibrotic action of aldosterone: Interaction with the renin-angiotensin system. 2004 , 17, 597-603	84
949	Dilated cardiomyopathy: an update. 2004 , 34, 1187-207	55
948	International Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in children. 2004 , 23, 1313-33	179
947	Digitalis may reduce hospitalisation and improve clinical status in heart failure, but has no effect on mortality. 2004 , 8, 245; discussion 246-7	

946 Th apeutique diur ique. **2004**, 1, 73-111

945 Rapid effects of aldosterone on vascular cells: clinical implications. **2004**, 69, 575-8

28

944 Aldosterone and DNA: the 50th anniversary. **2004**, 15, 143-6

3

943 Is aldosterone bad for the heart?. **2004**, 15, 139-42

80

942 Mineralocorticoid resistance. **2004**, 15, 264-70

63

941 Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker). **2004**, 93, 105-11

33

940 From CONSENSUS to CHARM--how do ACEI and ARB produce clinical benefits in CHF?. **2004**, 94, 137-41

13

939 Reduction of morbidity by immunoabsorption therapy in patients with dilated cardiomyopathy. **2004**, 97, 517-20

42

938 Fiftieth anniversary of aldosterone: from discovery to cardiovascular therapy. **2004**, 96, 321-33

21

937 Towards defining heart failure in adults with congenital heart disease. **2004**, 97 Suppl 1, 15-23

44

936 Additive effects of combined valsartan and spironolactone on cardiac aldosterone escape in spontaneously hypertensive rats. **2004**, 75, 1871-8

7

935 The discovery, isolation and identification of aldosterone: reflections on emerging regulation and function. **2004**, 217, 1-21

30

934 The evolution of aldosterone antagonists. **2004**, 217, 27-31

121

933 Primary aldosteronism--careful investigation is essential and rewarding. **2004**, 217, 33-9

145

932 The 45-year story of the development of an anti-aldosterone more specific than spironolactone. **2004**, 217, 45-52

72

931 Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. **2004**, 217, 53-8

84

930 A quick glance at rapid aldosterone action. **2004**, 217, 137-41

25

929 Aldosterone-synthase overexpression in heart: a tool to explore aldosterone's effects. **2004**, 217, 213-9

15

928	The myosin binding protein is a novel mineralocorticoid receptor binding partner. 2004 , 217, 221-7	7
927	The impact of polymorphisms in the gene encoding aldosterone synthase (CYP11B2) on steroid synthesis and blood pressure regulation. 2004 , 217, 243-7	40
926	Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension. 2004 , 217, 249-54	38
925	Towards selectively modulating mineralocorticoid receptor function: lessons from other systems. 2004 , 217, 151-65	29
924	Expression and function of the human mineralocorticoid receptor: lessons from transgenic mouse models. 2004 , 217, 127-36	32
923	Aldosterone target organ protection by eplerenone. 2004 , 217, 229-38	50
922	Role of voltage-gated calcium channels in potassium-stimulated aldosterone secretion from rat adrenal zona glomerulosa cells. 2004 , 92, 209-18	15
921	Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data. 2004 , 147, 564-72	16
920	Relationship of myocardial perfusion imaging findings to outcome of patients with heart failure and suspected ischemic heart disease. 2004 , 147, 714-20	8
919	Time trends in the use of beta-blockers and other pharmacotherapies in older adults with congestive heart failure. 2004 , 148, 710-7	37
918	Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. 2004 , 148, 971-8	79
917	Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion. 2004 , 17, 188-93	58
916	Involvement of oxidative stress in the profibrotic action of aldosteroneInteraction with the renin-angiotensin system. 2004 , 17, 597-603	7
915	Managing the patient with diabetes mellitus and heart failure: issues and considerations. 2004 , 116 Suppl 5A, 76S-88S	15
914	Effects of ACE gene insertion/deletion polymorphism on response to spironolactone in patients with chronic heart failure. 2004 , 116, 657-61	35
913	The use of aldosterone receptor blockers in the treatment of hypertension. 2004 , 6, 632-5	2
912	Effect of drug therapy for heart failure on quality of life. 2004 , 6, 256-61	3
911	Gynecomastia and antihypertensive therapy. 2004 , 6, 469-70	19

910	[Diagnostic and therapeutic progress. Venous thromboembolism, cardiac insufficiency and radio contrast agents]. 2004 , 33, 623-30	1
909	[Features of the treatment of heart failure in the elderly]. 2004 , 33, 1086-8	
908	Aldosterone and anti-aldosterone effects in cardiovascular diseases and diabetic nephropathy. 2004 , 30, 311-8	11
907	ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). 2004 , 44, 671-719	940
906	Methodology of an ongoing, randomized, controlled trial to improve drug use for elderly patients with chronic heart failure. 2004 , 2, 53-65	46
905	Recipient selection and management. 2004 , 16, 358-63	16
904	The -344T>C promoter variant of the gene for aldosterone synthase (CYP11B2) is not associated with cardiovascular risk in a prospective study of UK healthy men. 2004 , 174, 81-6	9
903	Tratamiento farmacológico de la hipertensión arterial. 2004 , 9, 1481-1493	
902	Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. 2004 , 26, 694-703	17
901	Physician opinions on the implementation of the SIGN guideline for heart failure. 2004 , 49, 10-3	4
900	Biventricular pacing in heart failure. 2004 , 65, 149-52	
899	Sudden death. 2004 , 328, E275	
898	Valsartan. 2004 , 2, 67-101	2
897	Eplerenone: selective aldosterone antagonism in management of cardiovascular and renal disease. 2004 , 44, 604-10; quiz 610-1	6
896	Guidelines for the diagnosis and management of heart failure. 2004 , 11, 467-72	11
895	Hypertensive heart disease and fibrosis. 2004 , 19, 326-31	13
894	Osteonecrosis of the femoral head resulting from excessive corticosteroid nasal spray use. 2004 , 10, 45-7	4
893	The coincidence of ankylosing spondylitis and gouty arthritis. 2004 , 10, 47-50	1

892	Progression of coronary artery disease in non-ischemic dilated cardiomyopathy. 2004 , 15, 291-7	13
891	Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. 2004 , 43, 518-24	214
890	Aldosterone antagonism and congestive heart failure: a new look at an old therapy. 2004 , 19, 301-8	11
889	The pharmacologic treatment of heart failure. 2004 , 11, 480-8	3
888	Successful use of etanercept in a patient with pyoderma gangrenosum complicating rheumatoid arthritis. 2004 , 10, 50-2	19
887	The Aldosterone???Renin Ratio in Screening for Primary Aldosteronism. 2004 , 14, 267-276	26
886	Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension. 2004 , 13, 451-8	94
885	Computed tomography does not support sacroiliitis as a feature of Behçet disease: a metaanalytic review. 2004 , 10, 42-5	7
884	Review: Aldosterone the future challenge in cardiovascular disease?. 2004 , 4, 370-376	2
883	Hypertension: A Clinical Pharmacist's Synopsis of JNC 7. 2004 , 68, 71	
882	Synergistic stimulation of aldosterone production in human adrenocortical carcinoma NCI-H295R cells by endothelin-1 and angiotensin II. 2004 , 44 Suppl 1, S289-92	4
881	The role of bridge to transplantation: should LVAD patients be transplanted?. 2004 , 19, 148-53	62
880	Epidemiology and economic burden of chronic heart failure. 2004 , 6, D57-D60	49
879	Atrial remodelling in persistent atrial fibrillation: the potential role of aldosterone: Reply. 2004 , 25, 1087	
878	Gynecomastia. 2004 , 104, 72AA-72GG	
877	Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats. 2004 , 22, 1017-23	20
876	New treatment option for heart failure patients: eplerenone. 2004 , 19, 390-5	
875	Cardiac defibrillation and resynchronization therapies: principles, therapies, and management implications. 2004 , 15, 340-61	2

874	Life-threatening hyperkalemia in the intraoperative period. 2004 , 16, 263	
873	Advances in the management of acute and chronic decompensated heart failure. 2004 , 9, 4-18; quiz 19-20	1
872	Advances in the management of acute and chronic decompensated heart failure. 2004 , 9, S1-15; quiz S16-7	4
871	Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. 2004 , 22, 2217-26	196
870	Ventricular dysrhythmias in heart failure. 2004 , 19, S11-26	2
869	Overview. 2004 , 15, 77-79	
868	Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease. 2004 , 13, 191-6	51
867	2003: The year in heart failure*1. 2004 , 10, 1-3	23
866	Brain natriuretic peptide in the management of heart failure: the versatile neurohormone. 2004 , 125, 652-68	74
865	Importance of CHARM in relation to other heart failure trials with ARBs. 2004 , 6, h55-h60	
864	Acute and Chronic Endothelial Dysfunction: Implications for the Development of Heart Failure. 2004 , 101-111	
863	Potential candidates for cardiac resynchronization therapy in Japanese patients with idiopathic dilated cardiomyopathy--a Niigata multicenter study of DCM--. 2004 , 68, 1104-9	5
862	Additive improvement of left ventricular remodeling by aldosterone receptor blockade with eplerenone and angiotensin II type 1 receptor antagonist in rats with myocardial infarction. 2004 , 124, 83-9	4
861	Mineralocorticoid receptor antagonist spironolactone improves left ventricular remodeling in patients with congestive heart failure and acute myocardial infarction. 2004 , 124, 90-100	2
860	Electropharmacological effects of a spironolactone derivative, potassium canrenoate, assessed in the halothane-anesthetized canine model. 2004 , 96, 436-43	8
859	[Clinical trials of beta-blockers in heart failure: history, overview and future prospects]. 2004 , 59, 517-26	1
858	A practical and evidence-based approach to cardiovascular disease risk reduction. 2004 , 164, 1490-500	40
857	2003 European Society of Hypertension-European Society of Cardiology Guidelines for the Management of Arterial Hypertension. 2004 , 4, 6-51	

856	Furosemide in the long-term management of heart failureThe good, the bad, and the uncertain*. 2004 , 44, 1308-1310	59
855	Effects of a novel immune modulation therapy in patients with advanced chronic heart failureResults of a randomized, controlled, phase II trial. 2004 , 44, 1181-1186	39
854	The proinflammatory heart failure phenotype: a case of integrative physiology. 2005 , 330, 219-26	12
853	Can drospirenone with 17-beta estradiol safely reduce blood pressure in hypertensive postmenopausal women?. 2005 , 1, 72-3	1
852	The role of aldosterone blockers in the management of chronic heart failure. 2005 , 330, 176-83	6
851	Alternative therapies for orthotopic heart transplantation. 2005 , 330, 88-101	3
850	Endocrine and Metabolic Agents. 2005 , 1037-1103	
849	Current guidelines in the management of chronic heart failure: practical issues in their application to the community population. 2005 , 7, 317-21	10
848	Bone loss in rats with aldosteronism. 2005 , 330, 1-7	26
847	Angiotensin receptor blockers in congestive heart failure: evidence, concerns, and controversies. 2005 , 13, 297-303	10
846	Interactions of high salt intake and the response of the cardiovascular system to aldosterone. 2005 , 13, 118-24	11
845	Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure. 2005 , 11, 435-55	36
844	Cardiac synthesis of aldosterone: con. 2005 , 12, 215-218	3
843	Natriuretic peptides: novel therapeutic targets in heart failure. 2005 , 53, 378-84	11
842	Strategies to reduce hospitalization in the management of heart failure. 2005 , 10, S1-15; quiz S16-7	14
841	Assessment of Prescriber Compliance with Established Heart Failure Guidelines at a Major Medical Center. 2005 , 40, 680-686	
840	Recent advances in hypertension, stroke, and cardiorenal disease. 2005 , 20, 258-63	7
839	Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. 2005 , 45, 810-21	35

838	Angiotensin-converting enzyme inhibitors, AG receptor blockers, and aldosterone receptor antagonists. 2005 , 43, 23-37	4
837	Correlation between left ventricular mass and urinary sodium excretion in specific genotypes of CYP11B2. 2005 , 23, 1149-57	22
836	Cardiac and vascular synthesis of aldosterone: yes, but???. 2005 , 12, 211-214	
835	Aldosterone and end-organ damage. 2005 , 14, 235-41	114
834	New directions in the assessment and treatment of hypertensive heart disease. 2005 , 14, 428-34	12
833	Update on acute coronary syndromes and ST-elevation myocardial infarction. 2005 , 11, 401-5	1
832	Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers in the management of congestive heart failure patients: what have we learned from recent clinical trials?. 2005 , 20, 250-5	10
831	Pathway for the management of acute heart failure. 2005 , 4, 37-42	14
830	Cardio-renal insufficiency: the search for management strategies. 2005 , 14, 442-7	14
829	Life-saving or life-prolonging? Interpreting trial data and survival curves for patients with congestive heart failure. 2005 , 7, 143-8	7
828	Improving outcomes in heart failure in the community: long-term survival benefit of a disease-management program. 2005 , 127, 2042-8	21
827	Aldosterone and end-organ damage. 2005 , 4, 381-387	1
826	Ga-67 citrate and F-18 FDG uptake in spironolactone-induced gynecomastia. 2005 , 30, 105-6	5
825	The neurohormonal axis and biochemical markers of heart failure. 2005 , 15, 333-44	8
824	Reshaping our perception of the typical hospitalized heart failure patient: a gender analysis of data from the ADHERE Heart Failure Registry. 2005 , 20, 442-50	17
823	Long-term effect of spironolactone on cardiac structure as assessed by analysis of ultrasonic radio-frequency signals in patients with ventricular hypertrophy. 2005 , 69, 1394-400	5
822	Prevention of sudden cardiac death: lessons from recent controlled trials. 2005 , 69, 625-9	18
821	[Aldosterone in heart failure]. 2005 , 126, 377-80	1

820	3,3-Bisaryloxindoles as mineralocorticoid receptor antagonists. 2005 , 15, 2553-7	43
819	Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress. 2005 , 28, 447-55	52
818	Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats. 2005 , 28, 925-36	66
817	Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. 2005 , 111, 1106-13	60
816	Rationale for the use of angiotensin II receptor blockers in patients with left ventricular dysfunction (part I of II). 2005 , 28, 215-8	
815	Heart failure after acute ST-segment elevation myocardial infarction: what should we do about it?. 2005 , 28, 360-1	1
814	Prescriptions for chronic high-dose cyclooxygenase-2 inhibitors are often inappropriate and potentially dangerous. 2005 , 20, 879-83	20
813	Chronic kidney disease in patients with cardiac disease: a review of evidence-based treatment. 2005 , 68, 1419-26	9
812	Beneficial impact of spironolactone in diabetic nephropathy. 2005 , 68, 2829-36	164
811	Therapeutic measures in proteinuric nephropathy. 2005 , S137-41	18
810	Cardiac resynchronization therapy (CRT) in heart failure--a model to assess the economic value of this new medical technology. 2005 , 8, 128-39	19
809	A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure. 2005 , 59, 571-8	12
808	Cautionary tales in the clinical interpretation of therapeutic trial reports. 2005 , 35, 611-21	4
807	Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients. 2005 , 59, 520-3	33
806	Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil. 2005 , 30, 603-10	14
805	Mineralocorticoid resistance. 2005 , 62, 513-20	58
804	Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?. 2005 , 145, 664-71	36
803	Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1 + minK channels. 2005 , 146, 146-61	24

802	Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan. 2005 , 19, 173-83	20
801	Three year outcome of cardiac resynchronization therapy: a single center evaluation. 2005 , 28, 1013-7	11
800	A direct relationship between plasma aldosterone and cardiac L-type Ca ²⁺ current in mice. 2005 , 569, 153-62	49
799	CD4CD25 regulatory T cells: a new treatment option in glomerulonephritis. 2005 , 68, 1898-9	5
798	Aldosterone-mediated endothelial remodeling and oxidative stress. 2005 , 68, 1899	2
797	Screening for microalbuminuria. 2005 , 68, 1899-901; author reply 1901-2	
796	Determinants of mortality in patients undergoing cardiac resynchronization therapy: baseline clinical, echocardiographic, and angioscintigraphic evaluation prior to resynchronization. 2005 , 28, 1260-70	24
795	Cardiac resynchronization--a heart failure perspective. 2005 , 10, 16-23	7
794	Congestive heart failure: understanding the pathophysiology and management. 2001 , 13, 249-57	5
793	Broad modulation of tissue responses (immune activation) by celastrol may favorably influence pathologic processes associated with heart failure progression. 2005 , 95, 30C-37C; discussion 38C-40C	12
792	Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure. 2005 , 96, 867-71	39
791	An approach to heart failure and diabetes mellitus. 2005 , 96, 47E-52E	24
790	Heart failure in African Americans. 2005 , 96, 3i-12i	77
789	Neurohormonal inhibition in heart failure: insights from recent clinical trials. 2005 , 96, 3L-9L	204
788	Drugs for left ventricular remodeling in heart failure. 2005 , 96, 10L-18L	105
787	[Cardiac resynchronisation therapy: what kind of equipment to use?]. 2005 , 54, 12-6	2
786	[A new look at adult chronic heart failure in Africa in the age of the Doppler echocardiography: experience of the medicine department at Yaounde General Hospital]. 2005 , 54, 276-83	53
785	The cardiovascular implications of hypokalemia. 2005 , 45, 233-47	39

784	Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. 2005 , 46, 94-101	86
783	Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. 2005 , 46, 45-51	108
782	Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure. 2005 , 11, 12-6	47
781	A review of the renal and neurohormonal effects of B-type natriuretic peptide. 2005 , 11, 30-8	30
780	Novel therapies for heart failure: vasopressin and selective aldosterone antagonists. 2005 , 11, 21-9	5
779	Neurohumoral pathways in heart failure with preserved systolic function. 2005 , 47, 357-66	58
778	New antiarrhythmic drugs for prevention of atrial fibrillation. 2005 , 48, 193-208	32
777	Heart failure guidelines and prescribing in primary care across Europe. 2005 , 5, 57	11
776	Aldosterone receptor antagonism in heart failure. 2005 , 25, 1126-33	4
775	Protective effects of angiotensin II interruption: evidence for antiinflammatory actions. 2005 , 25, 1213-29	72
774	[Successful resuscitation of a patient with hyperkalemic cardiac arrest by emergency hemodiafiltration]. 2005 , 54, 1100-4	4
773	[Effects of the RALE study. Hyperkalemia following spironolactone treatment]. 2005 , 46, 466, 468	
772	[Blood pressure independent effects of antihypertensive agents]. 2005 , 46, 548-56	2
771	The human mineralocorticoid receptor only partially differentiates between different ligands after expression in fission yeast. 2005 , 5, 627-33	12
770	[Effect of CRT on morbidity and mortality]. 2005 , 16, 32-7	2
769	Therapies to prevent heart failure post-myocardial infarction. 2005 , 2, 174-82	15
768	Current Treatment Options for CHF Management: Focus on the Renin-Angiotensin-Aldosterone System. 2005 , 7, 3-13	2
767	Heart Failure with Preserved Systolic Function. 2005 , 7, 55-59	2

766	Aldosterone antagonists in the treatment and prevention of heart failure. 2005 , 7, 431-6	1
765	Treatment of the African-American patient with congestive heart failure. 2005 , 7, 307-15	4
764	Treatment of heart failure with a normal ejection fraction. 2005 , 7, 317-25	2
763	Heart failure and shock complicating acute coronary syndromes. 2005 , 7, 276-82	
762	Clinical trials report. 2005 , 7, 155-158	
761	Advanced heart failure and transplantation in women. 2005 , 7, 184-9	
760	Nonsustained ventricular tachycardia in dilated cardiomyopathy. 2005 , 7, 368-75	1
759	ACE inhibitors and mineralocorticoid receptor blockade in patients with congestive heart failure. 2005 , 5, 36-40	3
758	The addition of angiotensin receptor blockers to angiotensin-converting enzyme inhibitors--what has time told us?. 2005 , 2, 59-64	1
757	The risks and benefits of aldosterone antagonists. 2005 , 2, 65-71	15
756	Combination pharmacologic therapies for heart failure: what next after angiotensin-converting enzyme inhibitors and beta-blockers?. 2005 , 2, 89-93	2
755	When to initiate beta-blockers in heart failure: is it ever too early?. 2005 , 2, 94-9	3
754	Aldosterone receptor antagonists: biology and novel therapeutic applications. 2005 , 7, 206-11	6
753	Cardiorenal disease: a clinical intersection. 2005 , 37, 175-84	2
752	Aldosterone and heart failure: the rest of the story. 2005 , 10, 5-6	6
751	Mineralocorticoid receptors: distribution and activation. 2005 , 10, 15-22	165
750	Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. 2005 , 10, 23-9	135
749	Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. 2005 , 10, 31-7	91

- 748 Effect of aldosterone and MR blockade on the brain and the kidney. **2005**, 10, 53-62 20
- 747 Autonomic effects of spironolactone and MR blockers in heart failure. **2005**, 10, 63-9 6
- 746 Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure. **2005**, 10, 71-8 60
- 745 The role of aldosterone blockade in patients with heart failure. **2005**, 10, 79-83 7
- 744 Heart failure following anterior myocardial infarction: an indication for ventricular restoration, a surgical method to reverse post-infarction remodeling. **2004**, 9, 241-54 7
- 743 Surgical ventricular restoration: the RESTORE Group experience. **2004**, 9, 287-97 65
- 742 Neurohormonal intervention to reduce sudden cardiac death in heart failure: what is the optimal pharmacologic strategy?. **2004**, 9, 337-45; discussion 347-51 7
- 741 Back to Earth: "Common Sense" in the Management of Heart Failure. **2013**, 119-125
- 740 Pharmacologic Treatment of Childhood Hypertension. **2013**, 539-555 1
- 739 Medical Practice Variations in Heart Failure. **2013**, 1-28
- 738 Diuretika. **2013**, 587-600
- 737 The Role of Growth Differentiation Factor 5 in Cardiac Repair Post-Myocardial Infarction. **2013**, 365-382 1
- 736 Trends in the medical management of patients with heart failure. **2013**, 5, 194-204 9
- 735 Diuretics. **2013**, 72, 254-255
- 734 Pathophysiology of Heart Failure: Back to Basics. **2013**, 3-23
- 733 4. Registry Based Comparative Effectiveness Research. **2013**, 44, 335-337
- 732 Algorithm for Treatment of Advanced Heart Failure. **2013**, 9-34
- 731 Non-antiarrhythmic Drugs in Sudden Death Prevention. **2013**, 525-541

730 Adrenal Gland Hormones and the Vascular System. **2013**, 1-13

729 Heart Transplantation. 813-826

728 Priorities for choosing diuretics in the treatment of hypertensive disease: Evidence-based medicine, recommendation documents, and real clinical practice. **2013**, 10, 62-65

1

727 RAAS?????(??????). **2013**, 21, 9-16

726 La prise en charge thérapeutique de l'insuffisance cardiaque. **2013**, 58, 29-34

725 Diagnosis and Management of Acute Heart Failure. **2014**, 238-254

0

724 Chronic and End-Stage Heart Failure. **2014**, 255-270

723 Long-Term Cardiac Conditions. 178-197

722 Cardiovascular Disease in Women. **2014**, 255-266

1

721 Congestive Heart Failure. **2014**, 2045-2062

720 Pharmacotherapy Considerations in Cardiovascular Disease in Women: Therapeutic Implications for Cardiovascular Disease. **2014**, 427-447

719 Heart Failure and Pulmonary Hypertension in Women. **2014**, 155-173

718 Herzinsuffizienz. **2014**, 645-655

717 Hypertension in the Kidney Transplant Recipient. **2014**, 205-224

716 Herzinsuffizienz. **2014**, 535-549

715 Aldosterone and Cardiovascular Diseases. **2014**, 155-196

714 Prevention of Cardiovascular Disease in Older Adults. **2014**, 1-28

713 The RAAS in Heart Failure: An Update on Clinical Trials and Opportunities for Therapy. **2014**, 165-182

712 Treatment of arterial hypertension in the light of new guidelines. **2014**, 33, 241-245

711 Acute heart failure. **2014**, 271-288.e5

710 Biomarkers of Necrosis and Myocardial Remodeling. **2014**, 1-24

709 Pharmacological Treatment of Patients with Chronic Systolic Heart Failure. **2014**, 9, 43-48

o

708 Effects of adriamycin and candesartan on the collagen and elastin of the aorta in rats. **2014**, 20, 8

707 Management of multimorbidity in the edarly. **2014**, 57, 743

2

706 Combined Effects of Blood Pressure and Aldosterone on Cardiac Left Ventricular Mass Index—Ethnic Differences between Kazakh, Uygur and Han Subjects. **2014**, 04, 99-105

705 Aging and Optimal Therapy of Systolic Heart Failure in the Elderly. **2014**, 47-63

704 Non-pharmacological Measures: Complementary and Crucial. **1999**, 39-52

703 Renal Adverse Drug Reactions. 567-575

702 Pharmacoepidemiological study of recommendations of diuretics for the treatment of hypertension in the outpatient setting. **2014**, 11, 48-52

701 Current State and Future Improvement of the Elderly Participation in Clinical Trials. **2014**, 18, 122-135

1

700 MRA Inhibition in CKD: More Than Salt and Water. **2015**, 41-50

699 How to Use Inhibitors of the Renin-Angiotensin-Aldosterone System in Patients with CKD and Heart Failure. **2015**, 163-170

698 Hallmark Clinical Trials. **2015**, 675-727

697 Chronic Heart Failure. **2015**, 215-236

696 Diuretics. **2015**, 167-198

695 ACE Inhibitor ARB Controversies. **2015**, 129-137

694 Heart Failure. **2015**, 369-421

693 Renal Denervation for Congestive Heart Failure. **2015**, 163-173

692 Refractory Edema with Congestive Heart Failure Stepwise Approaches Nephrology Perspectives. **2014**, 1,

691 Acute Decompensated Cardiac Failure. **2015**, 445-470

690 Conventional Radionuclide Imaging of Autonomic Function in Heart Failure. **2015**, 263-288

689 Electrophysiology and Pathophysiology of the Autonomic Nervous System of the Heart. **2015**, 13-60

688 Neurohormonal Blockade in Heart Failure. **2015**, 77-111

687 Medicatie bij hartfalen. **2015**, 53-83

686 Congestive Heart Failure in Nigerians: A Review. **2015**, 319-328

685 Biomarkers of Necrosis and Myocardial Remodeling. **2015**, 659-688

684 Dissemination of Comparative Effectiveness Research. **2015**, 1-11

683 Diuretika. **2015**, 661-674

682 [Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015]. **2015**, 87, 77-83

681 Principles of Primary and Secondary Prevention of Cardiovascular Disease. **2015**, 1627-1664

680 Heart Failure. **2015**, 173-187

679 Risk for Sudden Cardiac Death in Heart Failure: Underlying Mechanisms and Therapeutic Modalities. **2015**, 129-149

678 Cardiac Hypertrophy and Hypertrophic Cardiomyopathy: Introduction and Management. **2015**, 291-324

677 Adding T1 Mapping and Extracellular Volume Fraction for Myocardial Fibrosis Assessment: Implications for Cardiovascular Risk Assessment. **2015**, 137-151

- 676 1. Clinical Pharmacology in Heart Failure. **2015**, 46, 83-88 1
- 675 Spezifische Aspekte der Arzneimitteltherapie in der Palliativmedizin. **2015**, 1-63
- 674 Epidemiology of Heart Failure. **2015**, 1-12
- 673 Heart Failure in South Asian Population. **2015**, 305-317
- 672 Adjunct Therapy and Calcium Channel Blockers. **2015**, 303-321
- 671 Cardio Renal Syndromes 2015: Is there a Silver Lining to the Dark Clouds?. **2015**, 8, 45-52
- 670 Current and Future Therapies for Management of Systolic Heart Failure. **2015**, 3,
- 669 Volume Assessment and Management: Medical and Device Therapies. **2016**, 125-163
- 668 Elevated Heart Rate is Associated with Cardiac Denervation in Patients with Heart Failure: A 123-Iodine-MIBG Myocardial Scintigraphy Study. **2016**, 107, 455-459 1
- 667 A ceiling dose with furosemide in systolic heart failure: A myth or a pertinent clinical consideration?. **2016**, 3, 1-7
- 666 Diuretika. **2016**, 471-479
- 665 Plasma 8-Isoprostane as a Biomarker and Applications to Cardiovascular Disease. **2016**, 467-488 1
- 664 Management of Heart Failure After CABG. **2016**, 615-622 1
- 663 Mitral Regurgitation. 329-363
- 662 Outpatient Medication Titration in Acute Heart Failure. **2017**, 243-258
- 661 Acute Decompensated Heart Failure: Treatment Specific Therapies. **2017**, 219-284
- 660 Clinical Features and Diagnosis. **2017**, 11-24 1
- 659 Literatur. **2017**, 305

658 Pharmacologic Treatment of Pediatric Hypertension. **2017**, 1-25

657 Inhibition of the Renin-Angiotensin-Aldosterone System. **2017**, 85-96

656 Tissue ACE/Angiotensin/AT1 Receptor Axis and Repair in the Heart. **2017**, 497-504

655 Mechanical Circulatory Support as a Bridge to Heart Transplantation. **2017**, 639-663

654 Diuretika. **2017**, 477-485

653 Heart Failure in Women: Is There a Typical Female Type?. **2017**, 107-116

652 A Historical Overview of Cardiovascular Medicine and Heart Failure. **2017**, 3-19

651 Kardiale Erkrankungen. **2017**, 139-200

650 Cardiorenal Syndrome (CRS). **2017**, 371-401

649 Dual inhibition in the treatment of heart failure. **2017**, 19, 29-32

648 PharmacotherapyFirst: A Multimedia Learning Resource. **2017**,

647 Chronic Heart Failure. **2017**,

646 Cardiovascular complications in patients with primary hyperaldosteronism. **2017**, 23, 203-211

645 Kardiovaskuläres System. **2018**, 121-218

644 OBSOLETE: Heart Failure in the Elderly. **2018**,

643 Inherited Cardiac Muscle Disorders: Hypertrophic and Restrictive Cardiomyopathies. **2018**, 259-317

642 Spezifische Aspekte der Arzneimitteltherapie in der Palliativmedizin. **2018**, 1-81

641 Sacubitril/valsartan improves ejection fraction in heart failure with reduced ejection fraction: A retrospective study. **2018**, 3, 119

640 Gender Differences in Cardiovascular Drugs. **2018**, 287-302

639 Management of Advanced Heart Failure: An Overview. **2018**, 1-14

638 Diuretika. **2018**, 525-534

637 Pharmacologic Treatment of Pediatric Hypertension. **2018**, 767-790

636 Traitement de l'insuffisance cardiaque. **2018**, 141-166.e2

635 Acute and Chronic Heart Failure. **2018**, 237-252

634 OBSOLETE: Echocardiography in Heart Failure. **2018**,

633 Sex-Based Differences in Risk Determinants and Management of Heart Failure. **2018**, 49-61

632 Cardiac Disease in Older Adults. **2018**, 1-21

631 Effects of mineralocorticoid receptor antagonists on responses to hemorrhagic shock in rats. **2018**, 7, 1-8

630 Prevalence of mineralocorticoid antagonist prescription after ST-elevation myocardial infarction with impaired left ventricular function: a single centre experience. (Preprint).

629 II. Clinical Practice of Primary Aldosteronism: an Update. **2018**, 107, 667-673

628 Possibilities of treatment of patients with resistant arterial hypertension. **2018**, 15, 14-22

627 Spironolactone in the treatment of hypertension: a neglected molecule. **2018**, 64, 815-820

626 [A novel agent in the treatment of heart failure with depressed systolic function]. **2018**, 88, 287-297

625 Randomized Trials. **2019**, 79-111

624 [The relationship between death from renal insufficiency and diuretic therapy among older adults at two nursing homes catering atomic bomb survivors]. **2018**, 55, 640-649

623 Key Considerations For Integrating Sacubitril/Valsartan Into Chronic Heart Failure Management. **2018**, 2, 34-43

- 622 Correlation between the cytokine profile and anticongestive medication in patients with chronic chagasic cardiopathy. **2019**, 52, e20190386
- 621 Pharmacological Targets of Hypertension. **2019**, 179-191
- 620 Complications cardiovasculaires macro-angiopathiques et insuffisance cardiaque chez le diabétique. **2019**, 377-390
- 619 Diuretika. **2019**, 683-694
- 618 Current Management and Treatment. **2019**, 199-215
- 617 [The 'Dangerous' ECG]. **2019**, 108, 45-52
- 616 Recently Approved Pharmacologic Agents to Improve Outcomes in Heart Failure. **2019**, 105-115
- 615 Heart Failure in Older Patients. **2019**,
- 614 Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality. **2020**, 23, 160-168 2
- 613 The Art of the 5-Minute Talk. **2019**, 167-176
- 612 Novel role of spironolactone in the therapy of resistant hypertension: Spironolactone and resistant hypertension. **2019**, 41, 157-166
- 611 Mineralocorticoid Receptor Antagonists. **2019**, 674-680
- 610 Therapie der chronischen Herzinsuffizienz. **2019**, 40,
- 609 Fat tissue and adrenal function: mechanisms of mutual influence. **2019**, 70-77 2
- 608 7. Diabetes and Heart Failure: How to Treat Doubles Dangers. **2019**, 108, 1902-1911
- 607 Aspectos diferenciales en la insuficiencia cardiaca en la mujer. **2019**, 54, 253-261 1
- 606 Mineralocorticoid Receptor Antagonist Eplerenone in Cardiovascular Disease. **2019**, 14, 263-269
- 605 The modern paradigm of pathophysiology, prevention and treatment of heart failure in type 2 diabetes mellitus. **2019**, 98-111 3

- 604 Heart failure disease management program, its contribution to established pharmacotherapy and long-term prognosis in real clinical practice - retrospective data analysis. **2019**, 163, 318-323 1
- 603 Encyclopedia of Gerontology and Population Aging. **2020**, 1-8
- 602 Drug-Nutrient Interactions. **2020**, 213-220
- 601 Reducing All-cause 30-day Hospital Readmissions for Patients Presenting with Acute Heart Failure Exacerbations: A Quality Improvement Initiative. **2020**, 12, e7420 1
- 600 Correlations between parameters of calcium metabolism and renin-angiotensin-aldosterone system in patients with primary hyperparathyroidism in the pre- and early postoperative periods. **2020**, 25, 630-638 1
- 599 Triple neurohormonal blockade in de novo heart failure with reduced ejection fraction during index hospitalization. **2020**, 55, 79-85
- 598 Management of the heart failure patient in the primary care setting. **2020**, 61, 225-229 1
- 597 TRIF/miR-34a mediates aldosterone-induced cardiac inflammation and remodeling. **2020**, 134, 1319-1331 1
- 596 Renin-Angiotensin-Aldosterone System Inhibitors in Patients with COVID-19: General Considerations and Clinical Implications. **2020**, 33, 1-5
- 595 Why We Fail at Heart Failure: Lymphatic Insufficiency Is Disregarded. **2020**, 12, e8930 1
- 594 Pharmacological Treatment of Chronic Heart Failure. **2020**, 79, 209-215
- 593 Clinical stability in heart failure. Myth or reality. **2020**, 220, 356-358
- 592 Management of proteinuria: blockade of the renin-angiotensin-aldosterone system. **2020**, 43, 121-125 0
- 591 The Utilization of Spironolactone in Heart Failure Patients at a Tertiary Hospital in Saudi Arabia. **2020**, 12, e10032 0
- 590 Cost to Save a Life in Heart Failure: Health Disparity Costs Lives. **2020**, 12, e10081
- 589 Etiology of Sudden Death. **2021**, 17-35
- 588 EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020). **2020**, 6-76 3
- 587 ICD in primary prevention: the ugly duckling of Spain. **2021**, 75, 2-2

- 586 Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function. **2021**, 16, e0258949
- 585 Harnessing the Potential of Primary Care Pharmacists to Improve Heart Failure Management. **2021**, 48, 25-25
- 584 Signal Transduction of Mineralocorticoid and Angiotensin II Receptors in the Central Control of Sodium Appetite: A Narrative Review. **2021**, 22,
- 583 Cardiovascular Prognosis in Drug-Resistant Hypertension Stratified by 24-Hour Ambulatory Blood Pressure: The JAMP Study. **2021**, 78, 1781-1790 6
- 582 Pharmacology of Antihypertensive Drugs. **2020**, 267-313
- 581 Exercise in Specific Diseases: Heart Failure with Reduced Ejection Fraction. **2020**, 957-976
- 580 Pharmacologic Support of the Failing Heart. **2020**, 597-605
- 579 Antihypertensive Therapy in Patients Receiving Maintenance Hemodialysis: A Narrative Review of the Available Clinical-Trial Evidence. **2021**, 19, 12-20 o
- 578 Heart failure medication after a first hospital admission and risk of heart failure readmission, focus on beta-blockers and renin-angiotensin-aldosterone system medication: A retrospective cohort study in linked databases. **2020**, 15, e0244231 1
- 577 Prevention of Heart Failure. **2021**, 489-512
- 576 Neurohormonal and metabolic profile of heart failure in obese versus non-obese patients. **2020**, 4, 16-21 o
- 575 Metabolic and nutritional responses to acidemia and alkalemia. **2022**, 127-145
- 574 A Unified Survey of Treatment Effect Heterogeneity Modelling and Uplift Modelling. **2022**, 54, 1-36 o
- 573 Diuretika. **2020**, 537-547
- 572 Classification of heart failure: A farewell to ejection fraction?. **2021**, 25, 2-6
- 571 Cardiac Disease in Older Adults. **2020**, 229-249
- 570 Chronic heart failure: actual aspects of treatment in real clinical practice. **2019**, 50-58
- 569 Hypertension in Cushing's Syndrome. **2020**, 127-139

568 Antiarrhythmic Properties of Non-Antiarrhythmic Drugs in Atrial Fibrillation: Upstream Therapy. **2020**, 307-377

567 Cardiorenal syndrome. **2020**, 63, 20

566 Heart Failure. **2020**, 529-544

565 Secondary Prevention of Coronary Artery Disease. **2020**, 75-82

564 Chronic Heart Failure. **2020**, 137-154

563 The expanding class of mineralocorticoid receptor modulators: New ligands for kidney, cardiac, vascular, systemic and behavioral selective actions. **2020**, 16, 487-496 2

562 [Pharmacological profile, clinical efficacy, and safety of esaxerenone (Minnebro tablets 1.25 mg, 2.5 mg, 5 mg)]. **2020**, 155, 340-350

561 Contemporary therapies for chronic heart failure with reduced ejection fraction. **2020**, 1, 146-150

560 Heart Failure Pathophysiology and Current Therapeutic Implications. **2020**, 33, 439-446

559 Edema. **2020**, 39-46

558 Use of disease-modifying drugs in diabetic patients with heart failure with reduced ejection fraction. **2021**, 1 1

557 Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction.. **2022**, 9, 712-720 2

556 Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: A retrospective study. **2021**, 16, e0259485 0

555 Spironolactone to improve exercise tolerance in people with permanent atrial fibrillation and preserved ejection fraction: the IMPRESS-AF RCT. **2020**, 7, 1-42 0

554 Acute decompensation of chronic heart failure and renal dysfunction. Diagnosis and treatment. **2020**, 35, 35-43

553 Advanced Heart Failure Management and Selection for Advanced Therapies. 216-235

552 Kardiovaskuläre Pharmaka und körperliche Belastung. **2007**, 95-117

551 Heart-Failure Management: Focus on Heart-Failure Practice Guidelines. **2007**, 101-115

550 Cardiac Aldosterone Production: A Vascular Problem?. **2006**, 191-199

549 Use of Antioxidants in Patients with Congestive Heart Failure. **2006**, 451-476

548 Heart Failure. **2005**, 199-207

547 Kardiomyopathien. **2005**, 34-61

546 Herzinsuffizienz. **2005**, 1096-1109

545 Definition und Epidemiologie. **2005**, 1-14

544 Therapie der chronischen Herzinsuffizienz. **2005**, 149-268

543 Virale Herzerkrankungen. **2006**, 619-640

542 Rhythmusstörungen des Herzens. **2006**, 143-204

541 Neue Arzneimittel. 37-107

540 Diuretika. 607-622

539 Herzinsuffizienz. **2006**, 393-400

538 Herzinsuffizienz. **2004**, 239-258

537 Neuropeptide Y and the heart: implication for myocardial infarction and heart failure. **2006**, 113-22

2

536 Herzinsuffizienz. **2005**, 75-85

535 Herzinsuffizienz. **2006**, 355-374

534 Kardiovaskuläre Pharmakologie. **2006**, 1-30

533 New Markers of Sudden Cardiac Death: Genetic Variables. **2006**, 373-383

532 Value of Non-antiarrhythmic Drugs in Preventing Sudden Cardiac Death: Aldosterone Antagonists. **2006**, 415-423

531 Cardiac Resynchronization for Heart Failure: Do We Need More Trials?. **2008**, 105-122

530 Treatment of Congestive Heart Failure. **2005**, 371-390

529 Heart Disease in the Elderly. **2005**, 705-727

528 Management of Hypertension. **2006**, 93-112

527 Management of Heart Failure. **2007**, 211-240

526 Heart Failure Controversies. **2007**, 241-248

525 Hallmark Clinical Trials. **2007**, 381-394

524 ACE Inhibitor Controversies. **2007**, 63-66

523 Diuretics. **2007**, 85-101

522 New Directions in Pulmonary Hypertension Therapy. **2008**, 405-430

521 Pharmacotherapy in Prevention and Rehabilitation. **2007**, 439-453

520 Clinical Role of Antiarrhythmic Drugs in the Prevention of Sudden Death. **2008**, 733-759

519 Nonantiarrhythmic Drugs in Sudden Death Prevention. **2008**, 760-771

518 Diastolic Versus Systolic Heart Failure. **2008**, 119-133

517 Resynchronisation cardiaque dans l'insuffisance cardiaque sŕve aiguŕ et chronique. **2006**, 261-274

516 Interaction rein et cŕr. **2007**, 153-175

515 Kardiale Erkrankungen. **2006**, 209-279

514 Herzinsuffizienz. **2007**, 241-257

513 Therapie von Ödemen. **2007**, 57-65

512 Diuretika. **2007**, 602-618

511 Herzinsuffizienz. **2007**, 1225-1239

510 Herzinsuffizienz. **2008**, 405-413

509 Diuretika. **2008**, 563-578

508 Setting- und Kontexteinflüsse in evidenzbasierten Leitlinien. **2008**, 281-314

507 Diagnosis and Management of Acute Heart Failure. **2021**, 497-515

506 Chronic and End-Stage Heart Failure. **2021**, 517-533

505 Stable Ischemic Heart Disease. **2021**, 125-154

504 Pharmacoepidemiology in Cardiorenal Medicine. **2021**, 315-331

503 Type 2 Cardiorenal Syndrome. **2021**, 75-94

502 Impact of Endocrine Disorders on Vasculature. **2021**, 97-122

501 Anticoagulation in Patients with Heart Failure and Sinus Rhythm. **2020**, 61, 1204-1211

0

500 Maximal Oxygen Uptake and Ventilation Improvement Following Sacubitril-Valsartan Therapy. **2020**, 115, 821-827

0

499 Emerging Topics in Heart Failure: New Era of Pharmacological Treatment. **2020**, 115, 956-960

1

498 Nocturnal hypoxemia severity influences the effect of CPAP therapy on renal renin-angiotensin-aldosterone system activity in humans with obstructive sleep apnea. **2021**, 44,

3

497 Health-Related Quality of Life in the Spironolactone to Reduce ICD Therapy (SPIRIT) Trial.

496	Congestive heart failure: what can we offer our patients?. 2001 , 165, 1053-5	1
495	Accelerated publication versus usual publication in 2 leading medical journals. 2002 , 166, 1137-43	3
494	Aldosterone blockade after myocardial infarction. 2003 , 169, 444	
493	Role of spironolactone in heart failure should be emphasised. 2000 , 321, 706-7	1
492	1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension. 1999 , 161 Suppl 12, S1-17	38
491	Clinical problem solving based on the 1999 Canadian recommendations for the management of hypertension. 1999 , 161 Suppl 12, S18-22	2
490	Hyperkalemia associated with spironolactone therapy. 2005 , 51, 357-60	5
489	Approach to managing patients with sulfa allergy: use of antibiotic and nonantibiotic sulfonamides. 2006 , 52, 1434-8	11
488	Cardiac resynchronization therapy: can we make our heart failure patients smarter?. 2007 , 118, 153-64	19
487	Contemporary management of heart failure in clinical practice. 2002 , 88 Suppl 2, ii5-8	2
486	Heart failure in 10 years time: focus on pharmacological treatment. 2002 , 88 Suppl 2, ii40-6	2
485	Just the berries. Management of heart failure. 2001 , 47, 499-501	
484	Don't keep that ACE (inhibitor) up your sleeve! Is ramipril effective for secondary prevention of cardiovascular disease and stroke?. 2000 , 46, 821-3	
483	Aldosterone antagonism in heart failure. 2007 , 3, 605-9	5
482	Macro- and micronutrients in patients with congestive heart failure, particularly African-Americans. 2007 , 3, 743-7	3
481	Bisoprolol in the treatment of chronic heart failure. 2007 , 3, 431-9	6
480	What's old is new again. Spironolactone and heart failure. 1999 , 45, 2621-2	
479	Management of hyperkalaemia in adults. 2005 , 74, 75-7	1

478	Cost-effectiveness of eplerenone plus standard treatment compared with standard treatment in patients with myocardial infarction complicated by left ventricular systolic dysfunction and heart failure in the Netherlands. 2005 , 13, 393-400	7
477	Heart failure: chapter 6. Pharmacological treatment of chronic heart failure. 2004 , 12, 512-515	
476	Beta blockers in heart failure haemodynamics, clinical effects and modes of action. 2001 , 9, 334-342	1
475	Turning 65 in Ontario: the impact of public drug benefit coverage on hospitalizations for acute and chronic disease. 2006 , 1, 87-98	2
474	Male gynecomastia. 2009 , 84, 672	5
473	Acute decompensated heart failure: contemporary medical management. 2009 , 36, 510-20	66
472	Heart failure. 2010 , 2010,	1
471	DEFEAT - Heart Failure: a guide to management of geriatric heart failure by generalist physicians. 2009 , 100, 39-50	11
470	Fractional excretion of sodium predicts worsening renal function in acute decompensated heart failure. 2010 , 15, e65-9	5
469	Mineralocorticoid receptor antagonists and endothelial function. 2008 , 9, 963-9	11
468	Targeting success in heart failure: evidence-based management. 2010 , 56, 1313-7	2
467	Hypokalemia and sudden cardiac death. 2010 , 15, e96-9	67
466	Congestive heart failure in Indians: how do we improve diagnosis & management?. 2010 , 132, 549-60	8
465	Progress toward genetic tailoring of heart failure therapy. 2010 , 12, 294-304	3
464	Clinical evidence review: best practice heart failure. 2007 , 11, 55-64	
463	Advanced heart failure and management strategies. 2009 , 9, 227-33	1
462	More help for patients with less severe heart failure. 2011 , 60, 482-4	
461	Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases. 2011 , 52, 1219-25	7

- 460 The predicted impact of heart disease prevention and treatment initiatives on mortality in Lithuania, a middle-income country. **2011**, 8, A139 2
- 459 Aldosterone and aldosterone antagonists in cardiac disease: what is known, what is new. **2012**, 2, 50-7 11
- 458 Heart failure. **2011**, 2011, 1
- 457 Eplerenone: the evidence for its place in the treatment of heart failure after myocardial infarction. **2005**, 1, 125-41
- 456 Pharmacological management of chronic heart failure in adults: a review of the literature. **2004**, 16, 22-6
- 455 Aldosterone induces p21-regulated apoptosis via increased synthesis and secretion of tumour necrosis factor- α in human proximal tubular cells. **2012**, 39, 858-63 7
- 454 Challenges and scientific considerations in hypertension management reflected in the 2012 recommendations of the Canadian Hypertension Education Program. **2012**, 6, e127-33 1
- 453 Heart failure in elderly: progress in clinical evaluation and therapeutic approach. **2013**, 10, 165-77 9
- 452 Management of Diabetic Nephropathy in the Elderly: Special Considerations. **2012**, 2,
- 451 Patient Medication Adherence and Physician Prescribing among Congestive Heart Failure Patients of Yemen. **2013**, 75, 557-62 6
- 450 Heart failure with preserved ejection fraction. **2013**, 10, 369-76 14
- 449 Aldosterone antagonists in systolic heart failure. **2014**, 60, e104 2
- 448 A randomised, controlled, double-blind, cross-over pilot study assessing the effects of spironolactone, losartan and their combination on heart rate variability and QT dispersion in patients with chronic heart failure. **2008**, 19, 292-6 11
- 447 Three ways to die suddenly: do they all require calcium calmodulin-dependent protein kinase II?. **2014**, 125, 173-85
- 446 Glucocorticoids Induce Cardiac Fibrosis via Mineralocorticoid Receptor in Oxidative Stress: Contribution of Elongation Factor Eleven-Nineteen Lysine-Rich Leukemia (ELL). **2014**, 57, 109-16 7
- 445 Effects of low-dose spironolactone combined with irbesartan on cardiac hypertrophy induced by pressure overload in rats. **2014**, 6, 809-19 3
- 444 Roles of oxidative stress and the mineralocorticoid receptor in cardiac pathology in a rat model of metabolic syndrome. **2015**, 77, 275-89 5
- 443 Management of Patients Admitted with Acute Decompensated Heart Failure. **2015**, 15, 284-9 3

442	Pharmacology of Aldosterone and the Effects of Mineralocorticoid Receptor Blockade on Cardiovascular Systems. 2013 , 29, 201-7	2
441	Cardioprotective mechanisms of lifestyle modifications and pharmacotherapies on cardiac remodeling and dysfunction in hypertensive heart disease: an overview. 2011 , 73, 91-105	4
440	An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice. 2016 , 8, 1339-54	18
439	TSOC-HFrEF Registry: A Registry of Hospitalized Patients with Decompensated Systolic Heart Failure: Description of Population and Management. 2016 , 32, 400-11	40
438	Effect of Spironolactone on Plasma Apelin-12 Levels in Patients with Chronic Systolic Heart Failure. 2016 , 32, 690-697	2
437	Renin Angiotensin Blocker Pre-treatment and Recurrence After Pulmonary Vein Isolation in Patients with Paroxysmal and Persistent Atrial Fibrillation. 2013 , 6, 898	0
436	Enhancing Cardiac Resynchronization Therapy for Patients with Atrial Fibrillation: The Role of AV Node Ablation. 2012 , 4, 438	
435	One-Year Outcomes of Acute Decompensated Systolic Heart Failure in Taiwan: Lessons from TSOC-HFrEF Registry. 2017 , 33, 127-138	21
434	Heart Failure: A Class Review of Pharmacotherapy. 2017 , 42, 464-472	6
433	Heart Failure with Mid-Range Ejection Fraction - a New Category of Heart Failure or Still a Gray Zone. 2016 , 11, 320-324	9
432	Heart Failure in Older Adults: A Geriatrician Call for Action. 2018 , 35, S23-S29	
431	Novel paradigms in the therapeutic management of heart failure with preserved ejection fraction: clinical perspectives. 2019 , 9, 91-108	6
430	Pharmacist- or Nurse Practitioner-Led Assessment and Titration of Sacubitril/Valsartan in a Heart Failure Clinic: A Cohort Study. 2020 , 73, 186-192	1
429	Latest British Society of Echocardiography recommendations for left ventricular ejection fraction categorisation: potential implications and relevance to contemporary heart failure management. 2020 , 7, L1-L4	1
428	Reply to Letter to the Editor regarding reference limits for echocardiography. 2020 ,	
427	Effect of spironolactone on cardiovascular morbidity and mortality in patients with hypertension and glucose metabolism disorders (ESCAM): a study protocol for a pragmatic randomised controlled trial. 2020 , 10, e038694	
426	The Characteristics and Outcomes of Patients with Heart Failure and Reduced Ejection Fraction: The Eligibility of Novel Heart Failure Medications. 2021 , 37, 394-403	
425	Encyclopedia of Gerontology and Population Aging. 2021 , 2365-2372	

424	SGLT-2 Inhibitors on Top of Current Pharmacological Treatments for Heart Failure: A Comparative Review on Outcomes and Cost Effectiveness. 2021 , 1	0
423	Novel Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiorenal Disease. 2021 ,	10
422	Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. 2021 ,	0
421	Optimization of RAASi Therapy with New Potassium Binders for Patients with Heart Failure and Hyperkalemia: Rapid Review and Meta-Analysis. 2021 , 10,	2
420	Trends in survival of Swedish men and women with heart failure from 1987 to 2014: a population-based case-control study. 2021 ,	1
419	Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease.. 2021 , 40, 555-565	2
418	Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post-hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. 2021 ,	3
417	Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics. 2021 , 1-17	3
416	Diagnosis and treatment of primary aldosteronism. 2021 , 9, 876-892	7
415	Was tun, wenn die Luft wegbleibt? Herzschwäche nach Herzinfarkt. 2021 , 147-157	
414	Encyclopedia of Molecular Pharmacology. 2021 , 768-775	
413	Diuretic Agents. 2021 ,	
412	Diuretika. 2021 , 443-453	
411	THE EFFECT OF SPIRONOLACTONE ON SERUM ELECTROLYTES AND RENAL FUNCTION TESTS IN PATIENTS WITH SEVERE CHRONIC HEART FAILURE. 2021 , 74, 2460-2462	
410	Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus.. 2021 , 17, 84-87	0
409	Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies.. 2022 , CIRCHEARTFAILURE121008594	2
408	Clinical Determinants and Prognosis of Left Ventricular Reverse Remodelling in Non-Ischemic Dilated Cardiomyopathy.. 2022 , 9,	0
407	Cardiovascular therapeutics: A new potential for anxiety treatment?. 2022 ,	0

- 406 Screening-Guided Spironolactone Treatment of Subclinical Left Ventricular Dysfunction for Heart Failure Prevention in At-risk Patients.. **2022**, 0
- 405 Latest British Society of Echocardiography recommendations for left ventricular ejection fraction categorisation: potential implications and relevance to contemporary heart failure management. **2020**, 7, L1-L4 1
- 404 Response to Latest British Society of Echocardiography recommendations for left ventricular ejection fraction categorisation: potential implications and relevance to contemporary heart failure management. **2020**, 7, L5-L7
- 403 Effect of spironolactone on cardiovascular morbidity and mortality in patients with hypertension and glucose metabolism disorders (ESCAM): a study protocol for a pragmatic randomised controlled trial. **2020**, 10, e038694
- 402 Has the profile of heart transplantation recipients changed within the last three decades?. **2021**, 152, 0
- 401 Diuretics and Clinical Management of Congestion in Heart Failure: A Review. **2021**, 1, 55-62
- 400 Mineralocorticoid Receptor Antagonists-Evidence for Kidney Protection, Trials With Novel Agents.. **2021**, 28, 371-377 0
- 399 Endpoints in Heart Failure Drug Development.. **2022**, 8, e01 0
- 398 Heart Failure. **2022**, 103-155
- 397 Mineralocorticoid receptor antagonists for cardioprotection in chronic kidney disease: a step into the future.. **2022**,
- 396 SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis.. **2022**, 4
- 395 Density Functional Theoretical Study, Spectroscopic characterization and Molecular Docking of the diuretic drug, Spironolactone, adsorbed on AuNPs surface and in-vitro studies based on anticancer activity studies against A549 lung cancer cell line. **2022**, 128255
- 394 JCS 2018 Guideline on Revascularization of Stable Coronary Artery Disease.. **2022**, 86, 3
- 393 Evoluțiã de la leziãã orgãnicã mediada por hipertensiãã en pacientes con hipertensiãã arterial resistente tras aãdir espironolactona. **2022**,
- 392 Putting it All Together: Practical Approach to the Patient with Diabetic Kidney Disease. **2022**, 637-659
- 391 Real world comparison of spironolactone and eplerenone in patients with heart failure.. **2022**, 0
- 390 Myocardial strain to identify benefit from beta-blockers in patients with heart failure with reduced ejection fraction.. **2022**, 1
- 389 Racial Differences in Trends and Prognosis of Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction: the Atherosclerosis Risk in Communities (ARIC) Surveillance Study.. **2022**,

388	Mineralocorticoid Receptor Antagonist Treatment of Established Pulmonary Arterial Hypertension Improves Interventricular Dependence in SU5416-Hypoxia Rat Model.. 2022 ,	0
387	Therapeutic Advances in Diabetic Nephropathy.. 2022 , 11,	6
386	Cure and Long-Term Remission Strategies.. 2022 , 2407, 391-428	1
385	Characterizing a Clinical Trial - Representative, Real-World Population with Heart Failure with Reduced Ejection Fraction.. 2022 , 14, 39-49	1
384	Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: A nationwide study in Denmark from 2003-2017.. 2021 ,	3
383	Treatment of heart failure with reduced ejection fraction. 2022 , 65, 9-17	
382	El DAI en la prevención primaria: el patito feo de nuestro país. 2022 , 75, 2-4	
381	Impact of Loop Diuretic on Outcomes in Patients with Heart Failure and Reduced Ejection Fraction.. 2022 , 19, 15	0
380	Rationale and Design of the Efficacy and Safety of Esaxerenone in Hypertensive Patients With Left Ventricular Hypertrophy (ESES-LVH) Study - Protocol for a Multicenter, Open-Label, Exploratory Interventional Study.. 2022 , 4, 99-104	0
379	Clinical Characteristics and Outcome of Immediate-Release Versus SLOW-Release Carvedilol in Heart Failure Patient (SLOW-HF): a Prospective Randomized, Open-Label, Multicenter Study.. 2022 , 1	
378	Primary Aldosteronism: Where Are We Now? Where to From Here?. 2022 , HYPERTENSIONAHA12118761	4
377	Drug Treatment of Heart Failure in Children: Gaps and Opportunities.. 2022 , 24, 121	0
376	Heart failure: a 70 year Odyssey. 2022 ,	1
375	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC.. 2022 , 24, 4-131	50
374	Cardiovascular Events and Long-Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE-IT.. 2022 , e022733	1
373	Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction.. 2022 , 82, 375	2
372	The cardiovascular outcomes of finerenone in patients with chronic kidney disease and type 2 diabetes: A meta-analysis of randomized clinical trials.. 2022 , 11, 31-33	0
371	Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors, and vericiguat for congestive heart failure therapy.. 2022 ,	0

370	Myocardial oedema: pathophysiological basis and implications for the failing heart.. 2022 ,	1
369	An updated systematic review on heart failure treatments for patients with renal impairment: the tide is not turning.. 2022 , 1	1
368	Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases.. 2022 , 84, 585-610	3
367	Mineralocorticoid receptor in non-alcoholic fatty liver disease.. 2021 ,	1
366	Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. 2021 ,	26
365	Adding low-dose spironolactone to multidrug regimens for resistant hypertension. 2004 , 6, 211-2	2
364	Unique populations: different outcomes. 2005 , 7, 155-6; discussion 156-8	
363	Atherosclerosis and depression. Obvious and non-obvious relationships. Part I. 2021 , 16, 26	1
362	Mechanisms for the development of heart failure and improvement of cardiac function by angiotensin-converting enzyme inhibitors. 2022 , 53, 51-76	1
361	Medical Management of Patients With Heart Failure and Reduced Ejection Fraction.. 2022 , 52, 173-197	2
360	EplerenoneA novel Mineralocorticoid receptor antagonist for the clinical application. 2022 , 7, 1	
359	Capillaries as a Therapeutic Target for Heart Failure.. 2022 ,	1
358	Heart Failure Management for the Inpatient Provider. 2022 , 59-69	
357	Heart Failure with Reduced Ejection Fraction. 2022 , 251-266	
356	Spezifische Aspekte der Arzneimitteltherapie in der Palliativmedizin. 2022 , 1-108	
355	Cardiovascular benefits of digoxin and empagliflozin in patients with chronic heart failure: the DIG trial revisited.. 2022 ,	
354	Diagnosis and Treatment of Acute Coronary Syndromes: A Review.. 2022 , 327, 662-675	10
353	Clinical Pharmacokinetics and Pharmacodynamics of Esaxerenone, a Novel Mineralocorticoid Receptor Antagonist: A Review.. 2022 , 1	0

352	Lysine-specific demethylase 1 as a corepressor of mineralocorticoid receptor.. 2022,	0
351	The Prescription Characteristics, Efficacy and Safety of Spironolactone in Real-World Patients With Acute Heart Failure Syndrome: A Prospective Nationwide Cohort Study.. 2022, 9, 791446	2
350	Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium-glucose co-transporter-2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase 3 studies.. 2022,	0
349	(Pharmacotherapy of chronic heart failure from the viewpoint of the new ESC 2021 guidelines). 2022, 64, 61-65	
348	Emerging fields for therapeutic targeting of the aldosterone-mineralocorticoid receptor signaling pathway.. 2022,	1
347	Heart Failure Subtypes and Cardiomyopathies in Women.. 2022, 130, 436-454	0
346	A retrospective cohort review of prescribing in hospitalised patients with heart failure using Beers criteria and STOPP recommendations.	0
345	Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease.. 2022, 145, 693-712	6
344	Opportunistic screening for asymptomatic left ventricular dysfunction in type 2 diabetes mellitus.. 2022,	
343	Renal effects of guideline directed medical therapies in heart failure - a consensus document from the Heart Failure Association of the European Society of Cardiology.. 2022,	3
342	Reconsidering the ejection fraction centric view of pharmacologic treatment for heart failure.. 2022,	2
341	Therapeutic targets for cardiac fibrosis: from old school to next-gen.. 2022, 132,	4
340	Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations.. 2022, 18, 315-322	2
339	Sex Differences in Therapies for Heart Failure.. 2022,	
338	Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes.. 2022,	0
337	Optimizing Foundational Therapies in Patients With HFrEF. 2022,	6
336	Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care.. 2022,	3
335	Optimal effectiveness of heart failure management - an umbrella review of meta-analyses examining the effectiveness of interventions to reduce (re)hospitalizations in heart failure.. 2022, 1	2

334	Efficacy and safety of a low-sodium diet and spironolactone in patients with stage 1-3a chronic kidney disease: a pilot study.. 2022 , 23, 95	
333	Effects of mokuboito, a Japanese Kampo medicine, on long-term clinical outcomes in patients with heart failure. 2022 , 9, 49-56	
332	Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.. 2022 , 79, 1129-1137	1
331	Baseline characteristics of outpatients with heart failure according to phenotype: preliminary analysis from SMYRNA-HF registry. 2022 , 8, 266-274	
330	Erhalt von Leistungsfähigkeit und Lebensqualität bei chronischer Herzinsuffizienz. 2022 , 16, 185-196	0
329	Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update.. 2022 , 1-8	0
328	[SEMERGEN positioning on approaching chronic heart failure in primary care].. 2021 ,	0
327	Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.. 2022 ,	1
326	Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.. 2022 , 12, 27-35	4
325	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. 2022 ,	1
324	Prevalence and Prognostic Implications of Left Ventricular Systolic Dysfunction in Adults With Congenital Heart Disease.. 2022 , 79, 1356-1365	2
323	Aldosterone and cardiovascular diseases.. 2022 ,	0
322	Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction.. 2022 ,	2
321	Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms.. 2022 , 12, 19-26	3
320	Sudden cardiac death in heart failure with preserved ejection fraction: an updated review. 2022 , 23,	0
319	Acute but not Chronic Heart Failure is Associated with Higher Mortality among Patients Hospitalized with Pneumonia: An Analysis of a Nationwide Database. 2022 , 100013	
318	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. 2022 ,	15
317	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. 2022 , 101161CIR0000000000001063	35

316	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. 2022 , 101161CIR0000000000001062	6
315	Role of Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease. 2022 , 2, 163-182	0
314	Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF. 2022 ,	0
313	Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism.. 2022 , 23,	6
312	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. 2022 ,	49
311	Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines.. 2022 , 108185	0
310	Risk factor control among heart failure patients in the United States: Results from the NHANES 1999-2018.. 2022 , 13, 200128	0
309	Osteoblast MR deficiency protects against adverse ventricular remodeling after myocardial infarction.. 2022 ,	0
308	New insights of cardiovascular and renal protection in diabetic chronic kidney disease with finerenone.. 2022 , 118, e36-e37	1
307	Heart failure and its treatment from the perspective of sympathetic nerve activity.. 2021 ,	1
306	Primary and Secondary Prevention of CAD: A Review.. 2022 , 31, 16-26	
305	The role of the mineralocorticoid receptor in immune cells in in cardiovascular disease.. 2021 ,	2
304	Consideration regarding the Analysis of Randomized Controlled Trials in the era of Evidence-Based Medicine.. 2021 ,	0
303	Bortezomib-Induced Reversible Cardiomyopathy: Recovered With Guideline-Directed Medical Therapy.. 2021 , 13, e20295	
302	Spironolactone and chlorthalidone-old drugs, new uses-but approach with caution. 2021 ,	1
301	New Perspectives in the Treatment of Acute and Chronic Heart Failure with Reduced Ejection Fraction. 2021 , 7, 88-99	
300	Can we cure diabetic kidney disease? Present and future perspectives from a nephrologist's point of view.. 2021 ,	3
299	Drug interaction (52. Drug interaction with diuretics). 2021 , 133, 189-194	

- 298 Milestones in Heart Failure: How Far We Have Come and How Far We Have Left to Go.. **2021**, 13, e20359 0
- 297 Drug-induced gynecomastia: A systematic review and meta-analysis of randomized clinical trials.. **2021**, 93, 489-496 1
- 296 Clinical and Economic Effectiveness of the Drug Sakubitril/ Valsartan in Treatment of Patients with Chronic Heart Failure with the Reduced Ejection Fraction in Conditions of Healthcare System of the Republic of Belarus. **2020**, 439-448
- 295 Diuretics in Treatment of Heart Failure. **2022**, 2, 86-93
- 294 Rational drug therapy of chronic heart failure: the role of mineralocorticoid receptor antagonists: review. **2022**, 24, 28-35
- 293 Pharmacological Treatment in Patients with Advanced Heart Failure: Recommendations and Challenges. **2022**, 2, 109-115
- 292 Treatment of Heart Failure with reduced Ejection Fraction in 2022: The Essential Pillars. **2022**, 2, 15-23
- 291 Pharmacological Treatment Sequencing for Heart Failure with Reduced Ejection Fraction. **2022**, 2, 31-35
- 290 SGLT2 Inhibitors and Sacubitril-Valsartan: How Trial Results will Revolutionize the Treatment of Heart Failure with Mildly Reduced Ejection Fraction. **2022**, 2, 67-71
- 289 Sequencing of Pharmacotherapy for Heart Failure with Reduced Ejection Fraction: A Clinical Profile-Based Approach. **2022**, 2, 36-40
- 288 Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists.. **2022**, 22, 213 1
- 287 Hyperkalemia as a limiting factor of neurohormonal blockade/modulation in everyday clinical practice. **2022**,
- 286 Conventional medical therapy in heart failure patients eligible for the PARADIGM-HF, DAPA-HF, and SHIFT trials.. **2022**,
- 285 Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. **2022**, 1
- 284 Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica. **2022**, 1
- 283 The prognosis and therapeutic management of patients hospitalized for heart failure in 2010-2020.. **2022**, 0
- 282 Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration.. **2022**, 5, e227958 3
- 281 Uptitrating vs Adding HFrEF Medications: Bring More Players to the Game.. **2022**,

280 Sex and Gender-Related Issues in Heart Failure.. **2022**, 40, 259-268

279 DataSheet1.pdf. **2017**,

278 Image_1.tif. **2019**,

277 Image_2.tif. **2019**,

276 Image_3.tif. **2019**,

275 Image_4.tif. **2019**,

274 Image_5.tif. **2019**,

273 Table_1.docx. **2019**,

272 Table_2.docx. **2019**,

271 Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology.. **2022**,

0

270 Signaling cascades in the failing heart and emerging therapeutic strategies.. **2022**, 7, 134

1

269 Spironolactone prevents dietary-induced metabolic syndrome by inhibiting PI3-K/Akt and p38MAPK signaling pathways. **2013**, 36, 923-30

4

268 Medication management for heart failure with reduced ejection fraction: Clinical pearls for optimizing evidenced-informed therapy.. **2021**, 67, 915-922

267 . **2021**, 67, e329-e336

266 Acute coronary syndrome without persistent elevation of the ST segment: New recommendations. **2022**, 1, 105-110

265 The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers.. **2022**, 1

1

264 Controversy: Critical Review of the Stich Trial and Assessment of Viability. Back to the Future? Or Maybe Not. **2022**, 49, 63-68

263 Evidence-based Therapy in Older Patients with Heart Failure with Reduced Ejection Fraction.. **2022**, 8, e16

1

262	Cardiac Remodelling Part 2: Clinical, Imaging and Laboratory Findings A review from the Biomarkers Working Group of the Heart Failure Association of the ESC.. 2022 ,	2
261	Medical Treatment of Heart Failure with Reduced Ejection Fraction in the Elderly. 8,	
260	Aldosteronantagonisten Revisited1	
259	The Mineralocorticoid receptor signal could be a new molecular target for the treatment of diabetic retinal complication.. 2022 ,	1
258	Daily Ambulatory Remote Monitoring System for Drug Escalation in Chronic Heart Failure with Reduced Ejection Fraction: Pilot Phase of DAVID-HF Study.	0
257	Quantification and treatment of congestion in heart failure: A clinical and pathophysiological overview. 2022 ,	
256	Inhibitors of the renin-angiotensin-aldosterone system. 2013 , 119-168	6
255	Antihypertensive therapies. 2013 , 224-271	
254	Which therapy for which condition?. 2013 , 463-541	
253	Diuretics. 2013 , 93-118	
252	Heart failure. 2013 , 169-223	5
251	Chronische Herzinsuffizienz: Der Langzeitverlauf in der allgemeinfztlichen Praxis. 2022 , 03, 157-175	
250	Cardiac Structure and Function Across the Spectrum of Aldosteronism: the Atherosclerosis Risk in Communities Study.. 2022 , 101161HYPERTENSIONAHA12219134	0
249	Mineralocorticoid Receptor Antagonists Cause Natriuresis in the Absence of Aldosterone.. 2022 , 101161HYPERTENSION	
248	Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta-analysis.	0
247	Association of Mineralocorticoid Receptor Antagonists With the Mortality and Cardiovascular Effects in Dialysis Patients: A Meta-analysis. 2022 , 13,	0
246	Prognostic Impact of Cardiovascular versus Noncardiovascular Hospitalizations in Heart Failure with Preserved Ejection Fraction: Insights from TOPCAT. 2022 ,	0
245	Potassium and disease-modifying therapy for heart failure with reduced ejection fraction: The beginning of a beautiful friendship?. 2022 ,	

- 244 The impact of medical therapy on left ventricular strain: Current state and future perspectives. 1
- 243 Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist. 0
- 242 Procedural results and in-hospital outcomes of percutaneous coronary intervention for chronic total occlusion in patients with reduced left ventricular ejection fraction: Sub-analysis of the Japanese CTO-PCI Expert Registry. 0
- 241 Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonists for Renal Outcomes: A Systematic Review and Meta-Analysis.
- 240 A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL/6 Mice. **2022**, 1
- 239 Four aces of heart failure therapy: systematic review of established and emerging therapies for heart failure with reduced ejection fraction. **2022**, 7, 20-28
- 238 Blood Pressure Assessment and Treatment in the Observation Unit.
- 237 Therapie der Herzinsuffizienz mit reduzierter Auswurfraction: Was ist neu in den Leitlinien 2021?. **2022**, 111, 445-456
- 236 Increased glucocorticoid metabolism in diabetic kidney disease. **2022**, 17, e0269920 0
- 235 A multidisciplinary approach to heart failure care in the hospital: improving the patient journey.
- 234 Hyperkalaemia in Heart Failure: Consequences for Outcome and Sequencing of Therapy. 0
- 233 Cardiorenal Crosstalk in Patients with Heart Failure. **2022**, 2, 369-385
- 232 Chinese expert consensus on the diagnosis and treatment of chronic heart failure in elderly patients (2021). 0
- 231 Pharmacological Anti-Remodelling Effects of Disease-Modifying Drugs in Heart Failure with Reduced Ejection Fraction. 1
- 230 Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. 0
- 229 Optimal cardiovascular medical therapy: current guidelines and new developments. 1-7
- 228 Role of Implantable Cardioverter Defibrillator in Heart Failure With Contemporary Medical Therapy.
- 227 Biglycan Is a Novel Mineralocorticoid Receptor Target Involved in Aldosterone/Salt-Induced Glomerular Injury. **2022**, 23, 6680

- 226 Clinical effect of nonsteroidal mineralocorticoid receptor (MR) antagonists in the treatment of diabetic kidney disease: expectations as a new therapeutic strategy. O
- 225 Treatment and prescribing trends of antihypertensive drugs in 2.7 million UK primary care patients over 31 years: a population-based cohort study. **2022**, 12, e057510 1
- 224 Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure. **2022**, 79, 2516-2525 1
- 223 Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist. O
- 222 Can we stop reflexively discontinuing mineralocorticoid antagonists for patients with heart failure and hyperkalemia?. **2022**,
- 221 Association of Age with Optimal Medical Therapy in Patients with Chronic Heart Failure. **2022**, 2, 138-145
- 220 The place of diuretics in hfref therapy according to the guidelines of European associations for the treatment of acute and chronic heart failure. **2022**, 1, 90-94
- 219 Is There Room for Sacubitril-Valsartan in the Treatment of Advanced Heart Failure?. **2022**, 2, 192-194
- 218 Managing persistent hyperkalaemia with next-generation potassium binders. **2022**, 7, S1-S18
- 217 Managing heart failure with reduced ejection fraction in patients with chronic kidney disease: a case-based approach and contemporary review. **2022**,
- 216 New strategies and therapies for the prevention of heart failure in high-risk patients. **2022**, 45,
- 215 Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction. **2022**, 45, O
- 214 New Perspectives on Sex Steroid and Mineralocorticoid Receptor Signaling in Cardiac Ischemic Injury. 13, 1
- 213 In-hospital Initiation and Up-titration of Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction. 8, 2
- 212 Insights into foundational therapies for heart failure with reduced ejection fraction. **2022**, 45, O
- 211 Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?. 1
- 210 Diagnosis and Management of Heart Disease. **2022**, 139-172
- 209 Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction. 1

208 The FIFTY SHADOWS of the RALES Trial: Lessons about the Potential Risk of Dietary Potassium Supplementation in Patients with Chronic Kidney Disease. **2022**, 11, 3970

207 Positionspapier Herzinsuffizienz und Diabetes.

0

206 Targeted potassium levels to decrease arrhythmia burden in high risk patients with cardiovascular diseases (POTCAST): Study protocol for a randomized controlled trial. **2022**,

205 Multimodal Strategies for the Diagnosis and Management of Refractory Congestion. An Integrated Cardioresenal Approach. 13,

0

204 Human induced pluripotent stem cells for studying mitochondrial diseases in the heart.

1

203 Reduction of heart failure guideline-directed medication during hospitalization: prevalence, risk factors, and outcomes.

0

202 Advantages of long-term combination pharmacotherapy with a beta-blocker and eplerenone in patients with ST-segment elevation acute coronary syndrome. **2022**, 21, 3269

201 Optimizing Therapies in Heart Failure: The Role of Potassium Binders. **2022**, 10, 1721

1

200 Positionspapier Herzinsuffizienz und Diabetes.

199 MANP Activation Of The cGMP Inhibits Aldosterone Via PDE2 And CYP11B2 In H295R Cells And In Mice. **2022**, 79, 1702-1712

1

198 Progress in the management of patients with diabetes and chronic kidney disease. **2022**, 31, 456-463

197 Guideline Directed Medical Therapy in Newly Diagnosed Heart Failure with Reduced Ejection Fraction in the Community. **2022**,

0

196 Targeting Myocardial Fibrosis A Magic Pill in Cardiovascular Medicine?. **2022**, 14, 1599

2

195 Three ages of spironolactone. Evolution of views on spironolactone capabilities in the treatment of patients with heart failure.. **2022**, 62, 3-11

194 Mineralocorticoid receptor-antagonism prevents COVID-19-dependent glycocalyx damage.

193 Role of sex on the efficacy of pharmacological and non-pharmacological treatment of heart failure with reduced ejection fraction: A systematic review. 9,

0

192 Utility of PREDICT-HF score in high-risk Asian heart failure patients receiving sacubitril/valsartan. 9,

0

191 New Strategies for Volume Control in Patients with Diabetes Mellitus, a Narrative Review. **2022**, 14, 1569

- 190 Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives. Volume 18, 753-760 o
- 189 Management of Heart Failure in Patients with Chronic Kidney Disease. 17, o
- 188 Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. 2
- 187 Potassium binders for patients with heart failure? The real enlightenment of the DIAMOND trial. o
- 186 Clinically unrecognized plasma volume expansion predicts long-term all-cause-mortality in chronic heart failure.
- 185 Use of Guideline-directed Medical Therapy in patients 5 years after the Diagnosis of Heart Failure: A Canadian Population-based Study. 2022, 2
- 184 Cost-effectiveness of a centrifugal-flow pump for patients with advanced heart failure in Argentina. 2022, 17, e0271519
- 183 Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry. 2
- 182 Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care. 1
- 181 Mineralocorticoid Receptor Activation in Vascular Insulin Resistance and Dysfunction. 2022, 23, 8954 1
- 180 Activation of an accessory pathway of glucose metabolism to treat dilated cardiomyopathy. o
- 179 Management of heart failure with reduced ejection fraction. heartjnl-2020-318811 o
- 178 Translation of Immunomodulatory Therapy to Treat Chronic Heart Failure: Preclinical Studies to First in Human.
- 177 Aldosterone breakthrough as a clue to the physiological importance of paracrine regulation of aldosterone secretion. o
- 176 Hyperkalemia in Chronic Kidney Disease: Links, Risks and Management. Volume 15, 215-228 o
- 175 Herzinsuffizienz bei Menschen mit Diabetes mellitus. 2022, 20, 229-236
- 174 Evaluation of arterial stiffness and serum endocan levels in patients with primary aldosteronism with new-onset hypertension and long-term hypertension.
- 173 Guideline-Directed Medical Therapy Before and After Primary Prevention Implantable Cardioverter Defibrillator Implantation in New Zealand (ANZACS-QI 66). 2022,

172	The design of the Dashboard Activated Services and Telehealth for Heart Failure (DASH-HF) study: A pragmatic quality improvement randomized implementation trial for patients with heart failure with reduced ejection fraction. 2022 , 106895	
171	Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial.	
170	Aldosterone as a Mediator of Cardiovascular Damage. 2022 , 79, 1899-1911	4
169	Outcomes After Transcatheter Edge-to-Edge Mitral Valve Repair According to Mitral Regurgitation Etiology and Cardiac Remodeling. 2022 , 15, 1711-1722	1
168	Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction. 2022 , 155, 113701	0
167	The role of a multidisciplinary heart failure clinic in optimization of guideline-directed medical therapy: HF-optimize. 2023 , 57, 95-101	0
166	NEUROHORMONAL FACTORS IN HEART FAILURE. 2000 , 35, 841-853	0
165	Pharmacologic Treatment of Pediatric Hypertension. 2022 , 1-25	0
164	Corticosteroid Receptors in Cardiac Health and Disease. 2022 , 109-122	0
163	Evaluating the Application of Chronic Heart Failure Therapies and Developing Treatments in Individuals With Recent Myocardial Infarction.	1
162	Finerenone, a Novel and Safer Approach toward Management of Diabetic Kidney Disease with Heart Failure. 17, 12	0
161	Edema formation in congestive heart failure and the underlying mechanisms. 9,	1
160	Regulation of mineralocorticoid receptor activation by circadian protein TIMELESS. 2022 ,	1
159	(Optimizing Foundational Therapies in Patients With HFrEF. How Do We Translate These Findings Into Clinical Care? Translation of the document prepared by the Czech Society of Cardiology). 2022 , 64, 441-454	0
158	Steroidal MRA Across the Spectrum of Renal Function. 2022 ,	0
157	Motives, frequency, predictors and outcomes of MRA discontinuation in a real-world heart failure population. 2022 , 9, e002022	0
156	How Do I Optimize Heart Failure Medications for Patients with Hypotension or Chronic Kidney Disease?. 2022 , 1,	0
155	Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure.	0

- 154 Patiromer use in patients with heart failure: lessons and clinical considerations from the DIAMOND trial. ○
- 153 Impact of Socioeconomic Status on Mortality and Readmission in Patients With Heart Failure With Reduced Ejection Fraction: The ARIC Study. **2022**, 11, ○
- 152 Different Doses of Empagliflozin in Patients with Heart Failure with Reduced Ejection Fraction. **2022**, 63, 852-856 ○
- 151 Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure. ○
- 150 Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure. **2022**, 23, 11336 1
- 149 Mineralocorticoid Receptor Antagonists Mitigate Mitral Regurgitation-Induced Myocardial Dysfunction. **2022**, 11, 2750 ○
- 148 Therapie der chronischen Herzinsuffizienz | State of the Art nach den europäischen Leitlinien von 2021. ○
- 147 Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms. **2022**, 1
- 146 Congestive Heart Failure: Insight on Pharmacotherapy. **2022**, 25-37 ○
- 145 Finerenone in diabetic kidney disease: A systematic review and critical appraisal. **2022**, 102638 ○
- 144 Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective. 1-10 ○
- 143 Higher plasma aldosterone is associated with increased risk of cardiovascular events in hypertensive patients with suspected OSA: UROSAH data. 13, 1
- 142 Hospital Variation of Spironolactone Use in Patients Hospitalized for Heart Failure in China | The China PEACE Retrospective Heart Failure Study. **2022**, 11, ○
- 141 Sex-specific differences in the efficacy of heart failure therapies: a meta-analysis of 84,818 patients. 1
- 140 Optimization of Drug Therapy for Heart Failure With Reduced Ejection Fraction Based on Gender. ○
- 139 Finerenone: A New Era for Mineralocorticoid Receptor Antagonism and Cardiorenal Protection. **2022**, 47, 101386 ○
- 138 Eurasian guidelines for the prevention and treatment of cardiovascular diseases in patients with obesity (2022). **2022**, 6-56 ○
- 137 Baroreflex activation therapy in advanced heart failure therapy: insights from a real-world scenario. ○

136	The Role of the Non-Steroidal Mineralocorticoid Antagonist Finerenone in Cardiorenal Management.	0
135	Importance of Micromilieu for Pathophysiologic Mineralocorticoid Receptor ActivityWhen the Mineralocorticoid Receptor Resides in the Wrong Neighborhood. 2022 , 23, 12592	0
134	Comparison of Patients with Reduced and Mildly Reduced Left Ventricular Ejection Fraction: Intermediate Data from the FAR NHL Registry. 2022 , 12, 10827	0
133	Mechanisms of mineralocorticoid receptor-associated hypertension in diabetes mellitus: the role of O-GlcNAc modification.	0
132	Soluble Guanylate Cyclase Stimulators in Patients with Heart Failure with Reduced Ejection Fraction Across the Risk Spectrum.	3
131	How can we improve the diagnosis of heart failure?. 175573802211289	0
130	Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy.	1
129	Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial Infarction. 2022 , 15,	0
128	Is esaxerenone the ultimate mineralocorticoid receptor antagonist?.	0
127	The association between beta-blockers and outcomes in patients with heart failure and concurrent Alzheimer's disease and related dementias.	0
126	History of clinical care and research in cardiac sarcoidosis. 2022 , 42, 1-7	0
125	An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook. 2022 , 23, 1737-1751	0
124	Heart Failure Medical Therapy: A Review for Structural/Interventional Cardiologists. 2022 , 100082	0
123	KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. 2022 , 102, S1-S127	8
122	Reducing the Risk of Financial Toxicity in the Real-World Setting for Heart Failure Care. 2022 , 10, 885	0
121	A case of venous stasis colitis possibly caused by eplerenone.	0
120	Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence. 2022 , 102, 990-999	1
119	CURRENT TRENDS IN THE MANAGEMENT OF HEART FAILURE. 2000 , 35, 855-875	1

- 118 New Paradigms in Heart Failure: RAAS Inhibition and the Management of Hyperkalaemia. 53-61 o
- 117 Optimising Renin-Angiotensin-Aldosterone System Inhibitor Therapy in Heart Failure and Resistant Hypertension: Challenges and Solutions. 19-26 o
- 116 Sequencing of medical therapy in heart failure with a reduced ejection fraction. heartjnl-2022-321497 o
- 115 Social Determinants of Health and Heart Failure: Clinical Takeaways From 5 Pivotal Analyses of the GWTG-HF Registry. **2022**, 15, o
- 114 Primary Aldosteronism and the Role of Mineralocorticoid Receptor Antagonists for the Heart and Kidneys. **2023**, 74, o
- 113 Guías de práctica clínica: imprescindibles, pero insuficientes. **2022**, o
- 112 The non-steroidal MRA finerenone in cardiorenal medicine: a state-of-the-art review of the literature. o
- 111 Secondary Diseases of the Kidney. **2022**, 366-399 o
- 110 Apparent Mineralocorticoid Excess. **2022**, 1-34 o
- 109 Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists for renal outcomes: A systematic review and meta-analysis. **2023**, 195, 110210 o
- 108 Meta-Analysis on Drug and Device Therapy of New York Heart Association Functional Class IV Heart Failure With Reduced Ejection Fraction. **2023**, 188, 52-60 o
- 107 Evaluation of Pulmonary Arterial Catheter Parameters Utilizing Intermittent Pneumatic Compression Boots in Congestive Heart Failure. **2002**, 68, 286-290 o
- 106 Eurasian guidelines for the prevention and treatment of cardiovascular diseases in patients with obesity (2022). **2022**, 6-56 o
- 105 Angina in 2022: Current Perspectives. **2022**, 11, 6891 o
- 104 Exploring the cardiac ECM during fibrosis: A new era with next-gen proteomics. 9, 1
- 103 Frequency and predictors of hyperkalemia in the heart failure outpatient clinic. o
- 102 C-reactive protein and statins in heart failure with reduced and preserved ejection fraction. 9, o
- 101 Mechanisms of current therapeutic strategies for heart failure: more questions than answers?. o

100	Heart Failure is Associated with Early Medical and Surgery-Related Complications Following Total Hip Arthroplasty: A Propensity-Scored Analysis. 2022 ,	0
99	Heart failure with reduced ejection fraction and the intersection of cardio-renal-metabolic medicine #CaReMe. 2022 , 24, L29-L37	0
98	Sudden Cardiac Death in Heart Failure: A 20-Year Perspective from a Mediterranean Cohort. 2022 ,	0
97	Hypertensive mediated organ damage evolution in resistant hypertension patients after adding spironolactone. 2022 ,	0
96	The effects of mineralocorticoid receptor antagonists on cardiovascular outcomes in patients with end-stage renal disease and heart failure.	2
95	Hyperkalemia: Prevalence, Predictors and Emerging Treatments.	0
94	Prognostic Value of Left Ventricular Global Longitudinal Strain in Patients With Congenital Heart Disease. 2022 , 15,	0
93	Aldosterone as a Possible Contributor to Eye Diseases. 2022 , 164,	0
92	Reflecting on the advancements of HFrEF therapies over the last two decades and predicting what is yet to come. 2022 , 24, L2-L9	0
91	Getting ahead of the game: in-hospital initiation of HFrEF therapies. 2022 , 24, L38-L44	1
90	The need for new clinical trials of old cardiovascular drugs.	0
89	Efficacy and Safety of Sacubitril/Valsartan Compared With ACEI/ARB on Health-Related Quality of Life in Heart Failure Patients: A Meta-Analysis. 106002802211405	0
88	The impact of sacubitril/valsartan on outcome in patients suffering from heart failure with a concomitant diabetes mellitus.	1
87	The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?. 2022 , 24, L10-L19	0
86	Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. 2022 , 9, e002069	0
85	Phosphorylation of CaMK and CREB-Mediated Cardiac Aldosterone Synthesis Induced by Arginine Vasopressin in Rats with Myocardial Infarction. 2022 , 23, 15061	0
84	Diuretics in pediatrics.	0
83	Research Progress of Mineralocorticoid Receptor Antagonists on Diabetic Kidney Disease. 2023 , 13, 427-435	0

- 82 Pharmacologic Treatment of Pediatric Hypertension. **2023**, 857-881 ○
- 81 Use of Guideline-Directed Medical Therapy in Patients Aged 80 Years or Older with Heart Failure with Reduced Ejection Fraction. **2023**, ○
- 80 Heart Failure: A Problem of Our Age. **2011**, 40, 392-393 4
- 79 Blood Pressure Control in Patients with Diabetic Kidney Disease. **2022**, 20, 39 ○
- 78 Renal Mechanisms of Diuretic Resistance in Congestive Heart Failure. **2023**, 3, 56-72 ○
- 77 Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. ○
- 76 Renin-Angiotensin-Aldosterone System as an Old New Target in Heart Failure Therapy. **2023**, 307-330 ○
- 75 Hypertension in Patients Receiving Dialysis: A Review of the Current Clinical Approach. ○
- 74 Choice of Antihypertensive Drugs and Antihypertensive Drug Combination in Diabetes. **2023**, 389-403 ○
- 73 Outcomes in Patients with Cardiometabolic Disease Who Develop Hyperkalemia While Treated with a RAAS Inhibitor. **2023**, ○
- 72 Effect of eplerenone on clinical stability of Japanese patients with acute heart failure. **2022**, ○
- 71 Acute Severe Heart Failure Reduces Heart Rate Variability: An Experimental Study in a Porcine Model. **2023**, 24, 493 ○
- 70 Renin-Angiotensin-Aldosterone system and blood pressure regulation. **2023**, 63-75 ○
- 69 Association between dosing of spironolactone and outcomes in heart failure with preserved ejection fraction patients combined with chronic kidney disease-----Balance of efficacy and risk. 14, ○
- 68 Potential Impact of Non-Steroidal Mineralocorticoid Receptor Antagonists in Cardiovascular Disease. **2023**, 24, 1922 ○
- 67 Systematic approach to the diagnosis and management of endocrine hypertension. **2023**, 331-368 ○
- 66 Medications for When the Heart Fails. **2023**, ○
- 65 Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. **2023**, 47, 10-26 ○

64	Representativeness in randomised clinical trials supporting acute coronary syndrome guidelines.	0
63	Controls of Central and Peripheral Blood Pressure and Hemorrhagic/Hypovolemic Shock. 2023 , 12, 1108	0
62	Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care. 2023 , 10, 205435812211505	1
61	Finerenone, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Reduces Vascular Injury and Increases Regulatory T-Cells: Studies in Rodents with Diabetic and Neovascular Retinopathy. 2023 , 24, 2334	0
60	Management of Heart Failure with Reduced Ejection Fraction. 2023 , 101596	0
59	Cardiovascular Disease in Obstructive Sleep Apnea: Putative Contributions of Mineralocorticoid Receptors. 2023 , 24, 2245	0
58	Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. 2023 , 5, 1	2
57	Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients.	0
56	Dosing of basic pharmacotherapy and its effect on the prognosis of patients hospitalized for heart failure. 2023 , 69, 109-118	0
55	Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials.	0
54	A Computable Algorithm for Medication Optimization in Heart Failure With Reduced Ejection Fraction. 2023 , 100289	0
53	Heart failure and diabetes: Clinical significance and epidemiology of this two-way association.	0
52	Cardiopulmonary Exercise Testing in Heart Failure With Preserved Ejection Fraction: Technique Principles, Current Evidence, and Future Perspectives. Publish Ahead of Print,	0
51	Medication-Attributable Adverse Events in Heart Failure Trials. 2023 , 11, 425-436	0
50	Diuretika. 2022 , 651-660	0
49	Chronic Kidney Disease as a Comorbidity in Heart Failure. 2023 , 24, 2988	0
48	Fat mass as an important predictor of persistent hypertension in patients with primary aldosteronism after adrenalectomy.	0
47	Effects of Spironolactone on Arrhythmias in Hemodialysis Patients: Secondary Results of the SPin-D Randomized Controlled Trial. 2023 , Publish Ahead of Print,	0

- 46 Mineralocorticoid Receptor on T Cells Contributes to Injury and Remodelling of Ischemic Myocardium. **2023**, ○
- 45 Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus. 14, ○
- 44 Use of and association between heart failure pharmacological treatments and outcomes in obese versus non-obese patients with heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry. ○
- 43 Association of Aldosterone with Mortality in the General Population. ○
- 42 Spironolactone as a Potential New Treatment to Prevent Arrhythmias in Arrhythmogenic Cardiomyopathy Cell Model. **2023**, 13, 335 ○
- 41 Nationwide Temporal Trends in Clinical Characteristics and Treatment of Dilated Cardiomyopathy From 2003 to 2013 in Japan [A Report From Clinical Personal Records] **2023**, 87, 500-507 ○
- 40 Transcatheter interventions for heart failure. **2023**, 18, 1135-1149 ○
- 39 Consistency Breeds Confidence: The Continuing Story of SGLT2 Inhibitors. **2023**, 147, 635-637 ○
- 38 Diffuse Myocardial Fibrosis on Cardiac Magnetic Resonance Imaging Is Related to Galectin-3 and Predicts Outcome in Heart Failure. **2023**, 13, 410 ○
- 37 Breakthrough: a first-in-class virtual simulator for dose optimization of ACE inhibitors in translational cardiovascular medicine. **2023**, 13, ○
- 36 Declining Risk of Sudden Cardiac Death in Heart Failure: Fact or Myth?. **2023**, 147, 759-767 ○
- 35 Fluid homeostasis induced by sodium-glucose cotransporter 2 inhibitors: novel insight for better cardio-renal outcomes in chronic kidney disease. ○
- 34 Cardiorenal syndrome in the pediatric population: A systematic review. **2022**, 15, 493 ○
- 33 THE ACUTE CORONARY SYNDROME: THE POSSIBILITY OF THE MODERN THERAPY (REFERENCES REVIEW. PART I). **2009**, 12-18 ○
- 32 Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease. **2023**, 38, 43-55 ○
- 31 Cost-Effectiveness of Comprehensive Quadruple Therapy for Heart Failure With Reduced Ejection Fraction. **2023**, ○
- 30 Challenges and Opportunities in Titrating Disease-Modifying Therapies in Heart Failure with Reduced Ejection Fraction and Chronic Kidney Disease. **2023**, 20, 101-112 ○
- 29 Practical Pharmacological Treatment of Heart Failure: Does Ejection Fraction Matter Anymore?. **2023**, 10, 114 ○

- 28 Leveraging Biomarkers for Precision Medicine in Heart Failure. **2023**, 29, 459-462 ○
- 27 Relationship Between Medical Therapy, Long-Term Care Insurance, and Comorbidity in Elderly Patients With Heart Failure With Systolic Dysfunction. **2023**, ○
- 26 Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced Chronic Kidney Disease. 25-32 ○
- 25 Heart failure with reduced ejection fraction and atrial fibrillation: a Sub-Saharan African perspective. ○
- 24 Beyond Stage C: Considerations in the Management of Patients with Heart Failure Progression and Gaps in Evidence. **2023**, ○
- 23 Finerenone: Efficacy of a New Nonsteroidal Mineralocorticoid Receptor Antagonist in Treatment of Patients With Chronic Kidney Disease and Type 2 Diabetes. Publish Ahead of Print, ○
- 22 Cardiorenal Syndrome, Chronic Kidney Disease, Anemia, and Heart Failure. **2023**, 157-175 ○
- 21 Limiting Factors in Implementing Pharmacovigilance Principles in the Elderly. **2023**, ○
- 20 Implantable cardioverter-defibrillator implantation in non-ischaemic cardiomyopathy: towards individualized risk stratification. ○
- 19 The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials. **2023**, 15, 1092 ○
- 18 Aldosterone: Renal Action and Physiological Effects. 4409-4491 ○
- 17 Effect on cardiac function among patients with type 2 diabetes following high-dose mineralocorticoid receptor antagonist using echocardiography; data from the MIRAD randomized clinical trial. **2023**, 23, ○
- 16 Heart failure: pathophysiology and the emergence of novel therapies. **2023**, 441-458 ○
- 15 Evaluation of early left-sided cardiac reverse remodeling under combined therapy of sacubitril-valsartan and spironolactone compared with angiotensin-converting enzyme inhibitors and spironolactone. 10, ○
- 14 A randomized study to compare oral potassium binders in the treatment of acute hyperkalemia. **2023**, 24, ○
- 13 An IL-6/STAT3/MR/FGF21 axis mediates heart-liver cross-talk after myocardial infarction. **2023**, 9, ○
- 12 Translation of immunomodulatory therapy to treat chronic heart failure: Preclinical studies to first in human. **2023**, 18, e0273138 ○
- 11 Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA. **2023**, ○

- 10 Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment. 53, ○
- 9 Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Treatment. 5, ○
- 8 The Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and Therapy. **2023**, 132, 902-914 ○
- 7 STRONG-HF and Implementing Heart Failure Therapies: Godspeed ¶With Care. **2023**, 147, 1189-1191 ○
- 6 The role of the renin-angiotensin-aldosterone system in the development of cardiovascular complications in COVID-19. **2023**, 14, 98-118 ○
- 5 Cardiac Microvascular Endothelial Cells and Pressure Overload-Induced Cardiac Fibrosis. **2023**, 229-264 ○
- 4 Effects of a low-sodium diet in patients with idiopathic hyperaldosteronism: a randomized controlled trial. 14, ○
- 3 Congestion and Use of Diuretics in Heart Failure and Cardiomyopathies: a Practical Guide. ○
- 2 Sex-specific analysis of the rapid up-titration of guideline-directed medical therapies after a hospitalisation for acute heart failure: insights from the STRONG-HF trial. ○
- 1 Hallmarks of cardiovascular ageing. ○